US20220340544A1 - Substituted heterocyclic derivatives as pi3k inhibitors - Google Patents
Substituted heterocyclic derivatives as pi3k inhibitors Download PDFInfo
- Publication number
- US20220340544A1 US20220340544A1 US17/846,799 US202217846799A US2022340544A1 US 20220340544 A1 US20220340544 A1 US 20220340544A1 US 202217846799 A US202217846799 A US 202217846799A US 2022340544 A1 US2022340544 A1 US 2022340544A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- cycloalkyl
- membered heteroaryl
- membered heterocycloalkyl
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 208000035475 disorder Diseases 0.000 claims abstract description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 5
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 1750
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 758
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 707
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 518
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 516
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 359
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 344
- 125000001424 substituent group Chemical group 0.000 claims description 327
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims description 315
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 314
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 285
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 275
- 229910020008 S(O) Inorganic materials 0.000 claims description 249
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 178
- 229910052805 deuterium Inorganic materials 0.000 claims description 157
- 229910052739 hydrogen Inorganic materials 0.000 claims description 157
- 125000005843 halogen group Chemical group 0.000 claims description 147
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 146
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 136
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 119
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 98
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 96
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 95
- -1 aminocarbonyloxy Chemical group 0.000 claims description 78
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 37
- 229910004749 OS(O)2 Inorganic materials 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 26
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 125000006601 (C1-C3) alkylcarbamyl group Chemical group 0.000 claims description 23
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims description 23
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 claims description 23
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 22
- 125000004043 oxo group Chemical group O=* 0.000 claims description 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 13
- 125000006599 (C1-C3) alkylaminocarbonylamino group Chemical group 0.000 claims description 12
- 125000006596 (C1-C3) alkylcarbonyloxy group Chemical group 0.000 claims description 12
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 12
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 claims description 12
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 12
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 11
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 claims description 11
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims description 11
- 125000006602 (C1-C3) alkylsulfonylamino group Chemical group 0.000 claims description 11
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims description 11
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 11
- 125000006603 (C1-C3) alkylaminosulfonyl group Chemical group 0.000 claims description 10
- 125000006595 (C1-C3) alkylsulfinyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- HTDJMMGADYFBCS-GMHXGFMTSA-N nrc-11 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(C)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 HTDJMMGADYFBCS-GMHXGFMTSA-N 0.000 claims description 8
- 108091000080 Phosphotransferase Proteins 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- 102000020233 phosphotransferase Human genes 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 6
- 102000001253 Protein Kinase Human genes 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 108060006633 protein kinase Proteins 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 10
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 6
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 6
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 5
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 5
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 206010047115 Vasculitis Diseases 0.000 claims 4
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 4
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 4
- 201000003076 Angiosarcoma Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 229940124639 Selective inhibitor Drugs 0.000 claims 2
- 208000025317 T-cell and NK-cell neoplasm Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 210000001102 germinal center b cell Anatomy 0.000 claims 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 2
- ZKUQORLDQGFVSV-LBPRGKRZSA-N 2-[(1S)-1-cyclopropylethyl]-5-[2-(5-methyl-1H-1,2,4-triazol-3-yl)pyridin-4-yl]-3H-isoindol-1-one Chemical compound C1(CC1)[C@H](C)N1C(C2=CC=C(C=C2C1)C1=CC(=NC=C1)C1=NN=C(N1)C)=O ZKUQORLDQGFVSV-LBPRGKRZSA-N 0.000 claims 1
- VWFUOBXPYHOAJU-AWEZNQCLSA-N 2-[(1S)-1-cyclopropylethyl]-5-[2-(5-methyl-1H-pyrazol-3-yl)pyridin-4-yl]-7-methylsulfonyl-3H-isoindol-1-one Chemical compound C1(CC1)[C@H](C)N1C(C2=C(C=C(C=C2C1)C1=CC(=NC=C1)C1=CC(=NN1)C)S(=O)(=O)C)=O VWFUOBXPYHOAJU-AWEZNQCLSA-N 0.000 claims 1
- URVHTJNZTFBDKB-ZDUSSCGKSA-N 2-[(1S)-1-cyclopropylethyl]-5-[6-(5-methyl-1H-pyrazol-3-yl)pyridazin-4-yl]-3H-isoindol-1-one Chemical compound C1(CC1)[C@H](C)N1C(C2=CC=C(C=C2C1)C1=CN=NC(=C1)C1=CC(=NN1)C)=O URVHTJNZTFBDKB-ZDUSSCGKSA-N 0.000 claims 1
- FDQWDYKZBRNJOG-ZDUSSCGKSA-N 2-[(1S)-1-cyclopropylethyl]-5-[6-(5-methyl-1H-pyrazol-3-yl)pyridazin-4-yl]-7-methylsulfonyl-3H-isoindol-1-one Chemical compound C1(CC1)[C@H](C)N1C(C2=C(C=C(C=C2C1)C1=CN=NC(=C1)C1=CC(=NN1)C)S(=O)(=O)C)=O FDQWDYKZBRNJOG-ZDUSSCGKSA-N 0.000 claims 1
- FZMFCHMHOZJWDA-LBPRGKRZSA-N 2-[(1S)-1-cyclopropylethyl]-7-methylsulfonyl-5-[2-(5-methyl-1H-1,2,4-triazol-3-yl)pyridin-4-yl]-3H-isoindol-1-one Chemical compound C1(CC1)[C@H](C)N1C(C2=C(C=C(C=C2C1)C1=CC(=NC=C1)C1=NN=C(N1)C)S(=O)(=O)C)=O FZMFCHMHOZJWDA-LBPRGKRZSA-N 0.000 claims 1
- NEHFHBFFKMQIRM-LBPRGKRZSA-N 2-[(1S)-1-cyclopropylethyl]-7-methylsulfonyl-5-[6-(1H-pyrazol-5-yl)pyridazin-4-yl]-3H-isoindol-1-one Chemical compound N1N=CC=C1C1=CC(=CN=N1)C=1C=C2CN(C(C2=C(C=1)S(=O)(=O)C)=O)[C@@H](C)C1CC1 NEHFHBFFKMQIRM-LBPRGKRZSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
- 208000017925 Askin tumor Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000010007 Cogan syndrome Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 claims 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims 1
- 206010059352 Desmoid tumour Diseases 0.000 claims 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 claims 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 claims 1
- 206010015848 Extraskeletal osteosarcomas Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000006050 Hemangiopericytoma Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010073144 Peripheral primitive neuroectodermal tumour of soft tissue Diseases 0.000 claims 1
- 208000002163 Phyllodes Tumor Diseases 0.000 claims 1
- 206010071776 Phyllodes tumour Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 201000006827 desmoid tumor Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 201000008815 extraosseous osteosarcoma Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000025036 lymphosarcoma Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 230000025185 skeletal muscle atrophy Effects 0.000 claims 1
- 230000025175 skeletal muscle hypertrophy Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 125000004429 atom Chemical group 0.000 description 52
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 23
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 229910052799 carbon Inorganic materials 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 10
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 108091007960 PI3Ks Proteins 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 125000002393 azetidinyl group Chemical group 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101100079340 Rattus norvegicus Nalcn gene Proteins 0.000 description 2
- 101100495923 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr2 gene Proteins 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 150000003906 phosphoinositides Chemical class 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 102100021723 Arginase-1 Human genes 0.000 description 1
- 101710129000 Arginase-1 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108091007958 Class I PI3Ks Proteins 0.000 description 1
- 208000018458 Colitis-Associated Neoplasms Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108700016256 Dihydropteroate synthases Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000668250 Human herpesvirus 8 type P (isolate GK18) viral G-protein coupled receptor Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001056 activated astrocyte Anatomy 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- the present disclosure provides compounds that modulate the activity of phosphoinositide 3-kinases-gamma (PI3K ⁇ ) and are useful in the treatment of diseases related to the activity of PI3K ⁇ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
- diseases related to the activity of PI3K ⁇ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
- PI3Ks The phosphoinositide 3-kinases (PI3Ks) belong to a large family of lipid signaling kinases that phosphorylate phosphoinositides at the D3 position of the inositol ring (Cantley, Science, 2002, 296(5573):1655-7). PI3Ks are divided into three classes (class I, II, and III) according to their structure, regulation and substrate specificity.
- Class I PI3Ks which include PI3K ⁇ , PI3K ⁇ , PI3K ⁇ , and PI3K ⁇ , are a family of dual specificity lipid and protein kinases that catalyze the phosphorylation of phosphatidylinosito-4,5-bisphosphate (PIP2) giving rise to phosphatidylinosito-3,4,5-trisphosphate (PIP3).
- PIP3 functions as a second messenger that controls a number of cellular processes, including growth, survival, adhesion and migration. All four class I PI3K isoforms exist as heterodimers composed of a catalytic subunit (p110) and a tightly associated regulatory subunit that controls their expression, activation, and subcellular localization.
- PI3K ⁇ , PI3K ⁇ , and PI3K ⁇ associate with a regulatory subunit known as p85 and are activated by growth factors and cytokines through a tyrosine kinase-dependent mechanism (Jimenez, et al., J Biol Chem., 2002, 277(44):41556-62) whereas PI3K ⁇ associates with two regulatory subunits (p101 and p84) and its activation is driven by the activation of G-protein-coupled receptors (Brock, et al., J Cell Biol., 2003, 160(1):89-99).
- PI3K ⁇ and PI3K ⁇ are ubiquitously expressed. In contrast, PI3K ⁇ and PI3K ⁇ are predominantly expressed in leukocytes (Vanhaesebroeck, et al., Trends Biochem Sci., 2005, 30(4):194-204).
- PI3K ⁇ is mainly restricted to hematopoietic system, although it can be also detected at lower level in endothelium, heart and brain.
- PI3K ⁇ knock-out or kinase dead knock in mice are normal and fertile and do not present any overt adverse phenotypes. Analysis at the cellular level indicates that PI3K ⁇ is required for GPCR ligand-induced PtdINs (3,4,5)P3 production, chemotaxis and respiratory burst in neutrophils.
- PI3K ⁇ -null macrophages and dendritic cell exhibit reduced migration towards various chemoattractants. T-cells deficient in PI3K ⁇ show impaired cytokine production in response to anti-CD3 or Con A stimulation.
- PI3K ⁇ working downstream of adenosine A3A receptor is critical for sustained degranulation of mast cells induced by FC ⁇ RI cross-linking with IgE.
- PI3K ⁇ is also essential for survival of eosinophils (Ruckle et al., Nat. Rev. Drug Discovery, 2006, 5, 903-918)
- PI3K ⁇ was shown to be important for recruitment of neutrophils and eosinopohils to airways and degranulation of mast cells (see e.g. Laffargue et al., Immunity, 2002, 16, 441-451; Prete et al., The EMBO Journal, 2004, 23, 3505-3515; Pinho et al., L.
- PI3K ⁇ ⁇ / ⁇ mice were largely protected in four different models of rheumatoid arthritis (CIA, ⁇ -CII-IA, K/BxN serum transfer and TNF transgenic) and PI3K ⁇ inhibition suppressed the progression of joint inflammation and damage in the CIA and ⁇ -CII-IA models (see e.g., Camps et al., Nat.
- AD Alzheimer's disease
- PI3K ⁇ inhibition was shown to attenuate A ⁇ (1-40)-induced accumulation of activated astrocytes and microglia in the hippocampus and prevent the peptide-induced congnitive deficits and synaptic dysfunction in a mouse model of AD (Passos et al., Brain Behay. Immun.
- PI3K ⁇ deficiency or inhibition also was shown to delay onset and alleviate symptoms in experimental autoimmune encephalomyelitis in mice, a mouse model of human multiple sclerosis, which is another form of neurodegeneration disease (see e.g., Rodrigues et al., I Neuroimmunol. 2010, 222, 90-94; Berod et al., Euro. I Immunol. 2011, 41, 833-844; Comerford et al., PLOS one, 2012, 7, e45095; Li et al., Neuroscience, 2013, 253, 89-99).
- PI3K ⁇ is reported to mediate various inflammatory processes, its role as an immune oncology target has also been investigated.
- a recent study reported that PI3K ⁇ deficiency suppressed tumor growth in the syngeneic models of lung cancer, pancreatic cancer and melanoma (LLC, PAN02 and B16).
- PI3K ⁇ deficiency or inhibition also inhibited tumor growth in a spontaneous breast cancer model (Schmid et al., Cancer Cell, 2011, 19, 715-727).
- PI3K ⁇ deficiency could ameliorate inflammation and tumor growth in mice having colitis-associated colon cancer, (Gonzalez-Garcia et al., Gastroenterology, 2010, 138, 1373-1384).
- Detailed mechanistic analysis indicates that tumor infiltration by CD11b + myeloid cells can cause protumorigenic inflammation at tumor sites and PI3K ⁇ in the myeloid cells is critical in mediating signaling of various chemoattractants in bring the cells to the tumor (Schmid et al., Cancer Cell, 2011, 19, 715-727).
- Other studies suggest that PI3K ⁇ is also required for differentiation of na ⁇ ve myeloid cells into M2 macrophges at tumor sites.
- M2 macrophages promote tumor growth and progression by secreting immunosuppressive factors such arginase 1, which depletes the tumor microenvironment of arginine, thereby promoting T-cell death and NK cell inhibition (Schmidt et al., Cancer Res. 2012, 72 (Suppl 1: Abstract, 411; Kaneda et al., Cancer Res., 74 (Suppl 19: Abstact 3650)).
- PI3K ⁇ may play a direct role in cancer cells.
- PI3K ⁇ is reported to be required for signaling from the Kaposi's sarcoma-associated herpevirus encoded vGPCR oncogene and tumor growth in a mouse model of sarcoma (Martin et al., Cancer Cell, 2011, 19, 805-813).
- PI3K ⁇ was also suggested to be required for growth of T-ALL (Subramanjam et al., Cancer Cell, 2012, 21, 459-472), PDAC and HCC cells (Falasca and Maffucci, Frontiers in Physiology, 2014, 5, 1-10).
- PI3K ⁇ gene was found to contain second highest scoring predicted driven mutation (R839C) among the set of genes not previously identified as a driver in pancreatic cancer (Carter et al., Cancer Biol. Ther. 2010, 10, 582-587).
- PI3K ⁇ deficiency also has been reported to offer protection to experimental animals in different cardiovascular disease models.
- lack of PI3K ⁇ would reduce angiotension-evoked smooth muscle contraction and, therefore, protect mice from angiotension-induced hypertension (Vecchione et al., J. Exp. Med. 2005, 201, 1217-1228).
- PI3K ⁇ inhibition provided potent cardioprotection, reducing infarct development and preserving myocardial function (Doukas et al., Proc. Natl. Acad. Sci. USA, 2006, 103, 19866-19871).
- the present disclosure relates to, inter alia, compounds of Formula (I):
- compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the present disclosure further provides methods of inhibiting an activity of PI3K ⁇ kinase comprising contacting the kinase with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- the present disclosure further provides methods of treating a disease or a disorder associated with abnormal PI3K ⁇ kinase expression or activity in a patient by administering to said patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- the present disclosure further provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in any of the methods described herein.
- the present disclosure further provides use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in any of the methods described herein.
- each bond symbol represented by is independently a single or double bond
- W is CR 1 or N
- Z is CZ 1 or N
- X 1 is CR 1 or N
- X 2 is CR 2 or N
- X 3 is CR 3 or N
- R 1 , Z 1 , and R 12 are each independently selected from H, D, OH, NO 2 , CN, halo, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 1-3 haloalkyl, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, C 1-3 alkoxy-C 1-3 alkyl, C 3-6 cycloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 1-3 alkylsulfonyl, carbamyl, C 1-3 alkylcarbamyl, di(C 1-3 alkyl)carbamyl, carboxy, C 1-3 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-3 alkylcarbonylamin
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1
- each R 1 and R d1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alky
- any R c1 and R d1 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 1A substituents;
- each R e1 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl; each R f1 and R g1 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-
- each R jl and R kl is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R jl and R kl attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R 1A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a11 , SR a11 , NHOR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)NR c11 (OR a11 ), C(O)OR a11 , OC(O)R b11 , OC(O)NR
- each R a11 , R b11 , R c11 , and R d11 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R a1 and R d11 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- each R ell is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl; each R a1 and R b11 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each and Ri ll is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R jll and R kll is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R jll and R kll attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R M is independently selected from D, OH, NO 2 , CN, halo, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 1-3 haloalkyl, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, C 1-3 alkoxy-C 1-3 alkyl, C 3-6 cycloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 1-3 alkylsulfonyl, carbamyl, C 1-3 alkylcarbamyl, di(C 1-3 alkyl)carbamyl, carboxy, C 1-3 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-3 alkylcarbonylamino, C 1-3 alkoxycarbonyla
- R 2 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)NR c2
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2 -6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl
- any R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 2A substituents;
- each R ee is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f2 and Rg 2 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-; each R h2 and R i2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10
- each R 2A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl,
- each R a is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5
- each R 121 and Rg 21 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R h21 and R′ 21 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R 21 and R k21 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R 21 and R k21 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- R 1 and R 2 taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R 1A groups;
- R 3 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , ORa 3 , SRa 3 , NHORa 3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)NR c3 (ORa 3 ), C(O)ORa 3 , OC(O)R b3 , OC(O)NR c3 R d3
- any Rg 3 and R d3 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- each R ea is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R and Rg 3 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R h3 and R′ 3 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R 3 and Rk3 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R 3 and Rk3 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- R 2 and R 3 taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R 2A groups;
- X 4 is N or CR 4 ;
- X 5 is N or CR 5 ;
- R 4 and R 5 are each independently selected from H, D, halo, CN, OH, NH 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano-C 1-6 alkyl, HO—C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkylamino, di(C 1-6 alkyl)amino, and C(O)NR a4 R b4 ;
- each R 4 and R b4 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered
- any R a4 and R b4 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- X 6 is N or CR 6 ;
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a6 , SR a6 , NHOR a6 , C(O)R b6 , C(O)NR 6 R d6 , C(O)NR 6 (OR a6 ), C(O)OR a6 , OC(O)Rb 6 , OC(O)NR c6 m R d
- each R 6 , tc -r.136 , R c6 , and R d6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alky
- each R e6 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R j6 and R k6 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R h6 and R′ 6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R 6 and R k6 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R 6 and R k6 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R 6A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a61 , SR a61 , NHOR a61 , C(O)R b61 , C(O)NR c61 R d61 , C(O)NR c61 (OR a61 ), C(O)OR a61 , OC(O)R b61 , OC(O)NR
- each R a61, Rb61 , R c61 , and R d61 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C
- each R e61 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f61 and Rg 61 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-; each R h61 and R′ 61 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5
- each R j61 and R k61 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R J61 and R k61 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R 6B is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a62 , SR a62 , NHOR a62 , C(O)R b62 , C(O)NR c62 R d62 , C(O)NR c62 (OR a62 ), C(O)OR a62 , OC(O)R b62 , OC(O)NR
- each R a62 , R b62 , R c62 , and R d62 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c62 and R d62 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 6C substituents;
- each R e62 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f62 and Rg 62 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C2,6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R h62 and R i62 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R j62 and R k62 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R j62 and R k62 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R 6C is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C3,7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a63 , SR a63 , NHOR a63 , C(O)R b63 , C(O)NR c63 R d63 , C(O)NR c63 (OR a63 ), C(O)OR a63 , OC(O)R b63 , OC(O)NR c63 R
- each R a63 , R b63 , R c63 , and R d63 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C2,6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ch6 alkyl-, C 3-7 cycloalky
- any R c63 and R d63 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- each R e63 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f63 and R g63 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R j63 and R j63 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R j63 and R k63 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R j63 and R k63 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- X 7 is N, C, or CH
- X 8 is N, C, or CH
- X 9 is N, NR 9N , O, S, S(O), S(O) 2 , CR 9 , or C(R 9 ) 2 ;
- X 10 is N, NR 10N , O, S, CR 10 , or C(R 10 ) 2 ;
- X 11 is N, NR 11N , O, S, CR 11 , or C(R 11 ) 2 ;
- X 7 , X 8 , X 9 , X 10 , and X 11 are independently selected from C, CH, CR 9 , C(R 9 ) 2 , CR 10 , C(R 10 ) 2 , CR 11 , and C(R 11 ) 2 ; and
- R 9N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b9N , C(O)NR c9N , C(O)OR a9N , C( ⁇ NR e9N )R b9N , C( ⁇ NR e9N )NR c9N R d9N , C( ⁇ NCN)NR c9 R d9N , C( ⁇ NOR a9N )NR c
- each R a9N , R b9N , R c9N and R d9N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alky
- each R′ is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 9NA is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a9N2 , SR a9N2 , NHOR a9N2 , C(O)R b9 N2, C(O)NR c9N2 R d9N2 , C(O)NR c9N2 (OR a9N2 ), C(O)OR a9N2 , OC(O)R
- each R a9N2 , R b9N2 , R c9N2 , and R d9N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-
- any R c9N2 and R d9N2 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- each R e9N2 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f9N2 and Rg 91 ′ is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R h9N2 and R 19N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R′ 9N2 and R k ' is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R j9N2 and R k9N2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R 9 is independently selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR 91 , SR a91 , NHOR a91 , C(O)R b91 , C(O)NR d91 R d91 , C(O)NR c91 (OR a91 ), C(O)OR a91 , OC(O)R b91 , OC(O)NROR
- R a91 , R b91 , R c91 , and R d91 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-,
- each R e91 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f91 and R g91 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R h91 and R i9l is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R 91 and R k91 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R 91 and R k91 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R 9A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR 92 , SR a92 , NHOR a92 , C(O)R b92 , C(O)NR c92 R d92 , C(O)NR c92 (OR a92 ), C(O)OR a92 , OC(O)R b92 , OC(O)NR c92 R d
- each R a92 , R b92 , R c92 , and R d92 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloal
- any R c92 and R d92 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- each R e92 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f92 and R g92 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R h92 and R i92 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R j92 and R k92 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R j92 and R k92 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- R 10N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b10N , C(O)NR c10N R d10N , C(O)OR a10N , C( ⁇ NR e10N )R b10N , S(O)( ⁇ NR c10N )NR d10N , and S(O) 2 NR c10N R d10N , wherein the C 1-6 alky
- each R a10N , R b10N , R c10N , and R d10N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6
- any R c10N and R d10N attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 10NA substituents;
- each R e10N is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 10NA is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a10N2 , SR a10N2 , NHOR a10N2 , C(O)R b10N2 , C(O)NR c10N2 R d10N2 , C(O)NR c10N2 (OR a10N2 ), C(O)OR a10N2 , SR a
- each R a10N2 , R b10N2 , R c10N2 , and R d10N2 is independently selected from H, C 1-6 alk y l, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 al
- any R c10N2 and R d10N2 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- each R e10N2 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f10N2 and R g10N2 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R h10N2 and R i10N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R j10N2 and R k10N2 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R j10N2 and R k10N2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R 10 is independently selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a101 , SR a101 , NHOR a101 , C(O)R b101 , C(O)NR c101 R d101 , C(O)NR c101 (OR a101 ), C(O)OR a101 , OC(O)R b101 , OC(O)NR
- each R a101 , R b101 , R c101 , and R d101 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c101 and R d101 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 10A substituents;
- each R e101 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f101 and R g101 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R h101 and R i101 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R j101 and R k101 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R j101 and R k101 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R 10A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a102 , SR a102 , NHOR a102 , C(O)R b102 , C(O)NR c102 R d102 , C(O)NR c102 (OR a102 ), C(O)OR a102 , OC(O)R b102 , OC(O)NR c102 R
- each R a102 , R b102 , R c102 , and R d102 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloal
- any R c102 and R d102 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- each R e102 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f102 ) and R g101 ) 2 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R h102 and R i102 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R j102 and R k102 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R j102 and R k102 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- R 11N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b11N , C(O)NR c11N R d11N , C(O)OR a11N , C( ⁇ NR e11N )R b11N , C( ⁇ NR e11N )NR c11N R d11N , C( ⁇ NCN)NR c11N R d11N , C( ⁇ NOR a11
- each R a11N , N b11N , R c11N and R d11N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alky
- any R am and R d ' attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 11NA substituents;
- each R 11NA is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 11NA is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a11N2 , SR a11N2 , NHOR a11N2 , C(O)R b11N2 , C(O)NR c11N2 R d11N2 , C(O)NR c11N2 (OR a11N2 ), C(O)OR a11N2 , OC(O
- each R a11N2 , R b11N2 , R c11N2 , and R d11N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-
- each R f1 ' and Rg l ' is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R h11N2 and R j11N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-; each R i11N2 and R k11N2 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R i11N2 and R k11N2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R 11 is independently selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a111 , SR a111 , NHOR a111 , C(O)R b111 , C(O)NR c111 R d111 , C(O)NR c111 (OR a111 ), C(O)OR a111 , OC(O)R b111 , OC(O)NR
- each R a111 , R b111 , R c111 , and R d111 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c111 and R d111 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 11A substituents;
- each R em is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 11 and R 111 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R 11 and R 11 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R′ 111 and R k111 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R i111 and R k111 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl; and each R 11A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6
- each R a112 , R b112 , R c112 , R d112 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7
- any R c112 and R d112 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- each R e112 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f112 and R g112 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-; each R h112 and R i112 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7
- each R j112 and R k112 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R j112 and R k112 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl.
- Formula (I) is as otherwise defined above, wherein:
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a6 , SR a6 , NHOR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)NR c6 (OR a6 ), C(O)OR a6 , OC(O)R b6 , OC(O)NR c6
- each bond symbol represented by is independently a single or double bond
- W is CW 1 or N
- Z is CZ 1 or N
- X 1 is CR 1 or N
- X 2 is CR 2 or N
- X 3 is CR 3 or N
- W 1 , Z 1 , and R 12 are each independently selected from H, D, OH, NO 2 , CN, halo, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 1-3 haloalkyl, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, C 1-3 alkoxy-C 1-3 alkyl, C 3-6 cycloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 1-3 alkylsulfonyl, carbamyl, C 1-3 alkylcarbamyl, di(C 1-3 alkyl)carbamyl, carboxy, C 1-3 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-3 alkylcarbonylamin
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1
- each R a1 , R b1 , R c1 , and R d1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- each R cl is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f1 and R g1 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R m and R d is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-; each R′ and R id is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- each R M is independently selected from D, OH, NO 2 , CN, halo, C 1-3 alkyl, C 2-3 alkenyl,
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 2A substituents;
- each R e2 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R h2 and R i2 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R h2 and R′ 2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each RJ 2 and R u is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R 2 and R kz attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl; each R 2A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl,
- each R a21 , R b21 , R c21 , and R d21 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl,
- any R ai and R d21 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- each R e21 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl; each R 121 and Rg 21 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-; each
- each R 21 and R k21 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R 21 and R k21 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- R 1 and R 2 taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R 1A groups;
- each R 1A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a11 , SR a11 , NHOR a11 , C(O)R bil , C(O)NR c11 K C(O)NRcll(ORall), C(O)OR a11 , OC(O)R b11 , OC(O)NR c11 R c11 , NR
- RC(O)OR a11 and NR 11 C(O)NR c11 R d11 , wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl- of R 1A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- each R a11 , R b11 , R c11 , and R d11 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R ai and R d11 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- R 3 is selected H, D, OH, NO 2 , CN, halo, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 1-3 haloalkyl, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, C 1-3 alkoxy-C 1-3 alkyl, C 3-6 cycloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 1-3 alkylsulfonyl, carbamyl, C 1-3 alkylcarbamyl, di(C 1-3 alkyl)carbamyl, carboxy, C 1-3 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-3 alkylcarbonylamino, C 1-3 alkoxycarbonylamin
- R 2 and R 3 taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R 2A groups;
- X 4 is N or CR 4 ;
- X 5 is N or CR 5 ;
- R 4 and R 5 are each independently selected from H, D, halo, CN, OH, NH 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, cyano-C 1-6 alkyl, HO-C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkylamino, di(C 1-6 alkyl)amino, and C(O)NRa4 Rb4;
- each R 4 and R b4 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a6 , SR a6 , NHOR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)NR c6 (OR a6 ), C(O)OR a6 , OC(O)R b6 , OC(O)NR c6
- each R a6 , R b6 , R c6 , and R d6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c6 and R d6 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 6A substituents;
- each R e6 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl; each R f6 and Rg 6 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- C 2-6 alkynyl C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R 6 and R k6 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R 6 and R k6 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R 6A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a61 , SR a61 , NHOR a61 , C(O)R b61 , C(O)NR c61 R d61 , C(O)NR c61 (OR a61 ), C(O)OR a61 , OC(O)R b61 , OC(O)NR
- each R a61 , R b61 , R c61 , and R d61 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl,
- any R e61 and R d61 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- each R e61 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl; each R f61 and Rg 61 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-
- each R h61 and R′ 61 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R 61 and R k61 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R 61 and R k61 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- X 7 is N, C, or CH;
- X 8 is N, C, or CH;
- X 9 is N, NR 9N , 0, S, S(O), S(O) 2 , CR 9 , or C(R 9 ) 2;
- X 10 is N, NR 10N , 0, S, CR 10 , or C(R 10 ) 2 ;
- X 11 is N, NR 11N , 0, S, CR 11 , or C(R 11 ) 2 ; wherein no more than three of X 4 , X 5 , X 6 , X 7 , and X 8 are simultaneously N; and at least two of X 7 , X 8 , X 9 , X l ° , and X 11 are independently selected from C, CH, CR 9 , C(R 9 ) 2 , CR 10 , C(R 10 ) 2 , CR 11 , and C(R 11 ) 2 ; and no two adjacent members of X 9 , X l ° , and X 11 are simultaneously 0, S, S(O) or S(O) 2 ; provided that (a) when X 7 is N, then X 8 is C or CH; or (b) when X 8 is N, then
- R 9N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b9N , C(O)NR c9N R d9N , C(O)OR a9N , C( ⁇ NR e9N )R b9N , C( ⁇ NR e9N )NR c9N R d9N , C( ⁇ NCN)NR c9N R d9N , C( ⁇ NOR a9
- R a9N , R b9N , R c9N and R d9N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl
- any R c9N and R d9N attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- each R 9 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 9 is independently selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a91 , SR a91 , NHOR a91 , C(O)R b91 , C(O)NR c91 R d91 , C(O)NR c91 (OR a91 ), C(O)OR a91 , OC(O)R b91 , OC(O)NR
- each R a91 , R b91 , R c91 , and R d91 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- each R e91 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each el and Rg 91 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R h91 and R i91 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-; each R 91 and R k91 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R 91 and R k91 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- R 10N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b10N , C(O)NR c10 R d10N , C(O)OR a10N , C( ⁇ NR e10N )R b10N , C( ⁇ NR e10N )NR c10N R d10N , C( ⁇ NCN)NR c10N R d10N , C( ⁇ NOR a10N
- each R a10N , R b01 , R c10N , and R d10N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 al
- each R el ° N is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 10 is independently selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a101 , SR a101 , NHOR a101 , C(O)R b101 , C(O)NR c101 R d101 , C(O)NR c101 (OR a101 ), C(O)OR a101 , OC(O)R b101 , OC(O)NR
- each and R a101 , R b101 , R c101 , and R d101 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl
- each R d 01 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R e101 and R g101 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R h101 and R i101 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R j101 and R k101 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R j101 and R k101 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- R′ is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl
- each R a11N , R b11N , R c11N , and R d11N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6
- any R am and R d ' attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- each R e11N is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 11 is independently selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , ORdin, SR a111 , NHOR a111 , C(O)R b111 , C(O)NR c111 R d111 , C(O)NR c111 (OR a111 ), C(O)OR a111 , OC(O)R b111 , OC(O)NR c111 R
- each R a111 , R b111 , R c111 , and R d111 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c111 and R d111 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- each R e111 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R f111 and R g111 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R h111 and R i111 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C 1-6 alkyl-;
- each R j111 and R k111 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R j111 and R k111 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl.
- X 1 is N.
- X 1 is CR 1 .
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d
- any R d1 and R d1 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R 1A substituents.
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 ,C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, and NO 2 .
- R 1 is selected from H and C 1-6 alkyl.
- R 1 is selected from H and methyl.
- R 1 is H.
- R 1 is C 1-3 alkyl.
- R 1 is methyl
- X 2 is N.
- X 2 is CR 2 .
- R 2 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)
- any R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R 2A substituents.
- R 2 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R a2 , K b2 , R c2 and R d2 are each, optionally substituted with 1 or 2 independently selected R 2A substituents.
- R 2 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)
- R 2 is selected from H, C 1-6 alkyl, C(O)R b2 , C(O)NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 C(O)NR c2 R d2 .
- R 2 is selected from C 1-6 alkyl and C(O)NR c2 R d2 .
- R 2 is selected from H, C 1-6 alkyl, C(O)R b2 , and C(O)NR c2 R d2 .
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R a2 , R b2 , R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents.
- each R b2 R c2 and R d2 is independently selected from H, C 1-6 alkyl, C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl of R b2 R c2 and R d2 are each optionally substituted with 1 or 2, independently selected R 2A substituents.
- R b2 is a 4-7 membered heterocycloalkyl group optionally substituted with 1 or 2 independently selected R 2A substituents.
- R b2 is selected from azetidinyl and 2-oxa-6-azaspiro[3.3]heptanyl, each optionally substituted with 1 or 2 independently selected R 2A substituents.
- each R c2 and R d2 is independently selected from H, C 1-6 alkyl, C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl of R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents.
- R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1 or 2 independently selected R 2A substituents.
- each R c2 and R d2 is independently selected from H, methyl, ethyl, isopropyl, tetrahydropyranyl, bicyclo[1.1.1]pentanyl, cyclobuytl, bicycle [2.1.1]hexan-lyl, 2-oxa-6-azaspiro[3.3]heptanyl, sec-butyl, azetidinyl, and tetrahydrofuranyl, wherein each methyl, ethyl, isopropyl, tetrahydropyranyl, bicyclo[1.1.1]pentanyl, cyclobuytl, bicycle [2.1.1]hexan-lyl, 2-oxa-6-azaspiro[3.3]heptanyl, sec-butyl, azetidinyl, and tetrahydrofuranyl are optionally substituted with 1 or 2 independently selected R 2A substituents; or R c2 and R d2 , attached to
- each R 2A is independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, CN, and OH.
- each R 2A is independently selected from F, methyl, CF3, CN, and
- R b2 is selected from azetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-hydroxyazetidin-1-yl and 2-oxa-6-azaspiro[3.3]heptan-6-yl.
- each R c2 and R d2 is independently selected from H, methyl, ethyl, isopropyl, tetrahydro-2H-pyran-4-yl, bicyclo[1.1.1]pentanyl, cyclobut-1-yl, 3-hydroxycyclobut-1-yl, 1,1,1-trifluoropropan-2-yl, 4-cyanobicyclo[2.1.1]hexan-1-yl, 2-oxaspiro[3.3]heptan-6-yl, sec-butyl, 1-methylazetidin-3-yl, and tetrahydrofuran-3-yl;
- R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form an azetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-hydroxyazetidin-1-yl or 2-oxa-6-azaspiro[3.3]heptan-6-yl group.
- each R c2 and R d2 is independently selected from H, C 1-6 alkyl, and 4-6 membered heterocycloalkyl, wherein the C 1-6 alkyl and 4-6 membered heterocycloalkyl of R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents.
- each R c2 and R d2 is independently selected from H, C 1-6 alkyl, and 4-6 membered heterocycloalkyl.
- each R c2 and R d2 is independently selected from H, methyl, isopropyl, and tetrahydropyranyl.
- R 2 is selected from C 1-6 alkyl and C(O)NW2R d2 , wherein R c2 and R d2 are each independently selected from H, C 1-6 alkyl, and 4-6 membered heterocycloalkyl. In some embodiments, R 2 is selected from C 1-6 alkyl and C(O)NW2R d2 , wherein each R c2 and R d2 is independently selected from H, methyl, isopropyl, and tetrahydropyranyl.
- R 2 is selected from H, methyl, methylaminocarbonyl, dimethylaminocarbonyl, tetrahydropyranylaminocarbonyl, and isopropylaminocarbonyl.
- R 2 is selected from methyl, methylaminocarbonyl, dimethylaminocarbonyl, tetrahydropyranylaminocarbonyl, and isopropylaminocarbonyl.
- R 2 is selected from H, methyl, methylaminocarbonyl, dimethylaminocarbonyl, tetrahydropyranylaminocarbonyl, isopropylaminocarbonyl, bicyclo[1.1.1]pentan-1-ylcarbamoyl, 3,3-difluoroazetidine-1-carbonyl, 3-hydroxyazetidine-1-carbonyl, (3-hydroxycyclobutyl)carbamoyl, (1,1,1-trifluoropropan-2-yl)carbamoyl, (4-cyanobicyclo[2.1.1]hexan-1-yl)carbamoyl, (2-oxaspiro[3.3]heptan-6-yl)carbamoyl, azetidine-1-carbonyl, cyclobutylcarbamoyl, sec-butylcarbamoyl, (1-methylazetidin-3-yl)carbamoyl,
- X 3 is N.
- X 3 is CR 3 .
- R 3 is selected from H, D, halo, CN, OH, NH 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl.
- R 3 is selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl.
- R 3 is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- R 3 is H or methyl.
- X 3 is CH.
- W is N.
- W is CR 1 .
- R 1 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl.
- R 1 is H or methyl.
- W is CH.
- Z is N.
- Z is CZ 1 .
- Z 1 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl.
- Z 1 is H or methyl.
- Z is CH.
- R 12 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl.
- R 12 is H or methyl.
- R 12 is H.
- X 4 is N.
- X 4 is CR 4 .
- X 4 is CR 4 , whereinR 4 is selected from H, D, halo, CN, OH, NH 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl.
- X 4 is CR 4 , whereinR 4 is selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl. In some embodiments, X 4 is CR 4 , wherein R 4 is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- X 4 is CH.
- X 5 is N.
- X 5 is CR 5 , wherein R 5 is selected from H, D, halo, CN, OH, NH 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl.
- X 5 is CR 5 , wherein R 5 is selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl.
- X 5 is CR 5 , wherein R 5 is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- X 5 is CH.
- X 6 is N.
- X 6 is CR 6 .
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a6 , SR a6 , NHOR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)NR c6 (OR a6 ), C(O)OR a6 , OC(O)R b6 , OC(O)
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO 2 , OR a6 , SR a6 , C(O)R b6 , C(O)NRe6 R ′'d6 , C(O)ORa6, NR c6 Rd6
- each R a6 , R b6 , R c6 , R d6 and R e6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R a6 , R b6 , R c6 , R d6 and R e6 are each optionally substituted with 1, 2, 3, or 4 independently selected R 6A substituents; and
- each R 6A is independently selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, SR a6 , C(O)NR c6 R d6 , C(O)R b6 , S(O) 2 R b6 , S(O)( ⁇ NR e6 )R b6 , and N ⁇ S(O)R a6 R b6 , wherein the C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R 6A substituents;
- each R a6 , R b6 , R c6 , R d6 and R e6 are independently selected from H and C 1-6 alkyl;
- each R 6A is independently selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- R 6 is selected from H, halo, C 1-6 alkyl, S(O) 2 R b6 , S(O)( ⁇ NR e6 )R b6 , and N ⁇ S(O)R a6 R b6 , wherein the C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R 6A substituents;
- each R 6 , R b6 , and R e6 are independently selected from H and C 1-6 alkyl;
- each R 6A is OH.
- R 6 is selected from H, chloro, S(O) 2 CH 3 , 1,2-dihydroxyethyl, S(O)( ⁇ NH)CH 3 , S(O)( ⁇ NCH 3 )CH 3 , and N ⁇ S(O)(CH 3 ) 2 .
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a6 , SR a6 , NHOR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)NR c6 (OR a6 ), C(O)OR a6 , OC(O)R b6 , OC(O)
- each R 6 , tc -r.136 , R c6 , and R d6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alky
- each R 6A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a61 , SR a61 , NHOR a61 , C(O)R b61 , C(O)NR c61 , R d61 , C(O)NR c61 (OR a61 , C(O)OR a61 , OC(O)R b61 , OC(O)
- each R a61 , R b61 , R c61 , and R d61 is independently selected from H and C 1-6 alkyl.
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO 2 , OR a6 , C(O)R d6 , C(O)OR a6 , RN c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)OR a6 , NR c6 C(O)NR c6 R d6 , and S(O) 2 R b6 , wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, CN
- each R a6 , R b6 , R c6 , and R d6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R a6, Rb6, Rob and R d6 are each optionally substituted with 1, 2, 3, or 4 independently selected R 6A substituents; and
- each R 6A is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, SR a6 , C(O)NR c6 K C(O)R b6 , and S(O) 2 R b6 , wherein the C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R 6A substituents;
- each R a6 , R b6 , R cb and R d6 is independently selected from H and C 1-6 alkyl;
- each R 6A is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, S(O)R b6 S(O)NR c6 R d6 , S(O) 2 R b6 , and S(O) 2 NR c6 R d6 .
- R 6 is selected from H, halo, C 1-6 alkyl, S(O)R b6 , and S(O) 2 R b6
- R b6 is selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl.
- each R b6 , R c6 , and R d6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl.
- R 6 is selected from H, D, halo, C 1-6 alkyl, SR a6 , C(O)R b6 , and S(O) 2 R b6 , wherein the C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R 6A substituents;
- each R 6 and R b6 is independently selected from H and C 1-6 alkyl
- each R 6A is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- R 6 is selected from H, halo, and S(O) 2 R b6 , wherein R b6 is C 1-6 alkyl.
- R 6 is selected from H, D, halo, methyl, C(CH 3 ) 2 OH, CH(CH 3 )OH, C(O)CH 3 , S(O) 2 CH 3 , and SCH 3 .
- R 6 is selected from D, halo, methyl, C(CH 3 ) 2 OH, CH(CH 3 )OH, C(O)CH 3 , S(O) 2 CH 3 , and SCH 3 .
- R 6 is CH(OH)-CH 2 OH.
- R 6 is C(CH 3 )(OH)-CH 2 OH.
- R 6 is C(OH)(C 1 -haloalkyl)-CH 2 OH.
- R 6 is C(OH)(S( ⁇ O)R b6 )-CH 2 OH.
- R 6 is C(OH)(C1-haloalkyl)-C(O)NH 2 .
- R 6 is C(O)NH 2 .
- R 6 is methyl
- R 6 is H.
- R 6 is a C(OH)(R 6A ) 2 , wherein at least one R 6A is C 1-6 haloalkyl. In some embodiments, R 6 is a C(OH)(R 6A ) 2 , wherein at least one R 6A is C 1-6 haloalkyl and each halogen of the haloalkyl group of R6A is F. In some embodiments, R 6 is a C(OH)(R 6A ) 2 , wherein at least one R 6A is C 1-6 haloalkyl and the haloalkyl group of R 6A is optionally substituted with 1 or 2 independently selected Y 2 substituents.
- each Y 2 is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, cyano-C 1-6 alkyl, HO-C 1-6 alkyl, C 1-6 alkoxy-C 1-6 alkyl, C 3-10 cycloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 al
- At least one R 6A is selected from CF3, CC13, CF2H, CC12H, CF2Y 2 ,
- At least one R 6A is selected from CF3, CF2H, CF2Y 2 , CFH2, CFHY 2 , and CF(Y 2 ) 2.
- At least one R 6A is C 1-6 haloalkyl, wherein each halogen is F.
- At least one R 6A is C 1-6 haloalkyl, wherein each halogen is Cl.
- At least one R 6A is selected from CH 2 F, CHF2, CF3, and CF 2 CF 3 .
- At least one R 6A is CF3.
- At least one R 6A is CH 2 F.
- At least one R 6A is CHF2.
- At least one R 6A is CF2CF3.
- R 6 is selected from H, chloro, and S(O) 2 CH 3.
- X 7 is N.
- X 7 is C.
- X 8 is N.
- X 8 is C.
- both X 7 and X 8 are C.
- X 7 is N and X 8 is C.
- X 7 is C and X 8 is N.
- X 9 is NR 9N .
- X 9 is N.
- X 9 is O.
- X 9 is S.
- X 9 is S(O).
- X 9 is S(O) 2 .
- X 9 is CR 9 .
- X 9 is C(R 9 ) 2 .
- each R 9 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, of
- R 9 are each optionally substituted with 1, 2, 3, or 4 independently selected R 9A substituents; or, alternatively, two R 9 groups together form an oxo group.
- each R 9 is H.
- X 9 is CR 9 , wherein R 9 is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- X 9 is CH.
- X 9 is C(O).
- X 10 is NR 10 N .
- R im is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered and heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b10N , C(O)NR c10N R d10N , CO)OR a10N , C( ⁇ NCN)NR c10N R d10N , C( ⁇ NOR a10N )NR c10N , S(O) 2 R b10N , S(O)( ⁇ NR c10N )R
- each R a10N , R b101 , R c10N , and R d10N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 al
- each R 10NA is selected from H, D, halo, CN, OH, NH 2 , C 1-6 alkyl, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-.
- R 10N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-,
- R 10N is selected from C 1-6 alkyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-6 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-6 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-6 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl- and (4-6 membered heterocycloalkyl)-C 1-6 alkyl- of R 10N are each optionally substituted with 1 or 2 independently
- R 10N is selected from C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl- of R 10N are each optionally substituted with 1 or 2 independently selected R 10NA substituents.
- R 10N is selected from H, C 1-6 alkyl, C 6-10 aryl-C 1-6 alkyl-, and C 3-10 cycloalkyl-C 1-6 alkyl-.
- R 10N is C 3-6 cycloalkyl-C 1-6 alkyl-.
- R 10N is cyclopropylethyl.
- R 10N is 1-cyclopropylethyl.
- R 10N is (S)-1-cyclopropylethyl.
- X 10 is N.
- X 10 is O.
- X 10 is S.
- X 10 is CR 10 .
- X 10 is)C(R 10 ) 2 .
- X 10 is CR 10 , wherein R 10 is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- X 10 is CH.
- X10 is c(R)0), wherein each R 10 is independently selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- two R 10 groups together form an oxo group.
- X 11 is NR 11N .
- X 11 is N.
- X 11 is O.
- X 11 is S.
- X 11 is CR 11 .
- X 11 is C(R 11 ) 2 .
- each R 11 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, of R 11 are each optionally substituted with 1, 2, 3, or 4 independently selected R 11A substituents.
- X 11 is CR 11 , wherein R 11 is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- X 11 is CH.
- X 11 is C(R 11 ) 2 , wherein each R 11 is independently selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl.
- two R 11 groups together form an oxo group.
- X 11 is CH 2 .
- W is CR 1 ; and Z is CZ 1 .
- W is N; and Z is CZ 1 .
- W is CR 1 ; and Z is N.
- X 7 is N or C
- X 8 is N or C
- X 9 is N or C(R 9 ) 2 ;
- X 10 is N or NR 10 N ;
- X 11 is N, CR 11 , or C(R 11 ) 2 .
- X 7 is C
- X 8 is C
- X 9 is N or C(R 9 ) 2 ;
- X 10 is N or NR 10 N ;
- X 11 is N, CR 11 , or C(R 11 ) 2 .
- each bond symbol represented by is independently a single or double bond
- X 1 is N or CR 1 ;
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl- CN, NO 2 , OR SR a1 , NHOR a1 , C(O)R b1 ,C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 , R d1
- X 2 is N or CR 2 ;
- R 2 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 ,C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)NR c2
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R a2 , R b2 R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents;
- X 3 is N or CR 3 ;
- W is N or CR 1 ;
- R 1 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl;
- Z is N or CZ 1 ;
- Z 1 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl;
- R 12 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl.
- X 4 is N or CR 4 ;
- X 5 is N or CR 5 ;
- R 4 and R 5 are each independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl;
- X 6 is N or CR 6 ;
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , and S(O) 2 NR c6 R d6 ;
- each R b6 , R c6 , and R d6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl;
- X 7 is N or C
- X 8 is N or C
- X 9 is N or C(R 9 ) 2 ;
- X 10 is N or NR 10N ;
- X 11 is N or C(R 11 ) 2 ;
- X 7 , X 8 , X 9 , and X′ are independently selected from C, C(R 9 ) 2 , and
- each R 9 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, of R 9 are each optionally substituted with 1, 2, 3, or 4 independently selected R 9A substituents; or, alternatively, two R 9 groups together form an oxo group;
- R 10N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 to cycloalkyl-C 1-6 alkyl-, (5-10
- each bond symbol represented by is independently a single or double bond;
- X 1 is CR 1 ;
- R 1 is selected from H and C 1-6 alkyl;
- X 2 is CR 2 ;
- R 2 is selected from H, C 1-6 alkyl, C(O)R b2 , C(O)NRc2 R d2, NR c2 C(O)Rb2, NR c2 C(O)ORa2, and NR c2 C(O)NR c2Rd2;
- each R a2 , RC 2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2 - R b2 , 6 alkenyl, C 2-6 alkynyl, and 4-6 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, -rb2, C 2-6 alkynyl, and 4-6 membered heterocycloalkyl of Ra e , K R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents;
- X 3 is N; W is CR 1 ; R 1 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl; Z is CZ 1 ;
- Z 1 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl;
- R 12 is H or methyl;
- X 4 is CR 4 ;
- X 5 is CR 5 ;
- R 4 and R 5 are each independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl;
- X 6 is CR 6 ; R 6 is selected from H, halo, C 1-6 alkyl, S(O)R b6 , and S(O) 2 R b6 ; X 7 is C; X 8 is C;
- X 9 is C(R 9 ) 2;
- X lci is NR 10 N ;
- each R 9 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, of R 9 are each optionally substituted with 1, 2, 3, or 4 independently selected R 9A substituents; or, alternatively, two R 9 groups together form an oxo group;
- R 10N is selected from C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl- of R 10N are each optionally substituted with 1 or 2 independently selected R 10NA substituents; and
- each R 11 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl.
- the compound of Formula (I) is a compound of Formula (Ib):
- the compound of Formula (I) is a compound of Formula (II):
- the compound of Formula (I) is a compound of Formula (IIb):
- the compound of Formula (I) is a compound of Formula (IIc):
- the compound of Formula (I) is a compound of Formula (IId):
- the compound of Formula (I) is a compound of Formula (IIe):
- the compound of Formula (I) is a compound of Formula (IIf):
- the compound of Formula (I) is a compound of Formula (IIg):
- the compound of Formula (I) is a compound of Formula (IIh):
- the compound of Formula (I) is a compound of Formula
- the compound of Formula (I) is a compound of Formula (IV
- the compound of Formula (I) is a compound of Formula (Ilk):
- the compound of Formula (I) is a compound of Formula (IIm):
- the compound of Formula (I) is a compound of Formula (IIn):
- the compound of Formula (I) is a compound of Formula (IIo):
- X 1 is CR 1 and X 2 is CR 2 .
- X 1 is N and X 2 is CR 2 .
- X 1 is CR 1 and X 2 is N.
- X 1 is N or CR 1 ;
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1
- each R a1 , R b1 , R c1 , and R d1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl,
- X 2 is N or CR 2 ;
- R 2 is H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , IR a2 , SR a2 , NHOR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)NR 2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R a2 , R b2 , R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents;
- each R 2A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkyny;
- R 1 , Z 1 , and R 2 are each independently selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl;
- R 4 and R 5 are each independently selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl;
- R 6 is selected from H, D, halo, C 1-6 alkyl, SR a6 , C(O)R b6 , and S(O) 2 R b6 , wherein the C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R 6A substituents;
- each R 6 and R b6 is independently selected from H and C 1-6 alkyl
- each R 6A is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl;
- R 10N is selected from C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl- of R10N are each optionally substituted with 1 or 2 independently selected le NA substituents;
- each R 10NA is selected from H, D, halo, CN, OH, NH 2 , C 1-6 alkyl, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl; and
- R 11 is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl;
- the compound of Formula (I) is a compound of Formula (IIp):
- X 4 is CR 4 ;
- X 5 is CR 5 ; and
- X 11 is N, NH, CR 11 , or C(R 11 ) 2 .
- X 4 is N; X 5 is CR 5 ; and is N, NH, CR 11 , or C(R 11 ) 2 .
- X 4 is CR 4 ; X 5 is N; and X 11 is C(R 11 ) 2 .
- X 4 is N; X 5 is CR 5 ; and X 11 is C(R 11 ) 2 .
- R 2 is H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C h6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 ,C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R
- each R 2A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkyny;
- R 2 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl;
- X 4 is N or CR 4 ;
- X 5 is N or CR 5 ;
- R 4 and R 5 are each independently selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl;
- R 6 is selected from H, D, halo, C 1-6 alkyl, SR 6 , C(O)R b6 , and S(O) 2 R b6 , wherein the C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R 6A substituents;
- each R 6 and R b6 is independently selected from H and C 1-6 alkyl; each R 6A is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl;
- R 10N is selected from C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl- of R 10N are each optionally substituted with 1 or 2 independently selected le NA substituents;
- each R 10NA is selected from H, D, halo, CN, OH, NH 2 , C 1-6 alkyl, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl; and
- R H is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl; or, alternatively, two R 11 groups together form an oxo group.
- the compound of Formula (I) is a compound of Formula (IIq):
- X 4 is CR 4 ;
- X 5 is CR 5 ; and
- X 11 is N, NH, CR 11 , or
- X 4 is N; X 5 is CR 5 ; and X 11 is N, NH, CR 11 , or C(R 11 ) 2 .
- X 4 is CR 4 ; X 5 is N; and X 11 is C(R 11 ) 2 .
- X 4 is N; X 5 is CR 5 ; and X 11 is C(R 11 ) 2 .
- R 2 is H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 ,C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R a2 , R b2 , R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents;
- each R 2A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkyny;
- R 12 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl;
- X 4 is N or CR 4 ;
- X 5 is N or CR 5 ;
- R 4 and R 5 are each independently selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl;
- R 10N is selected from C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl- of R 10N are each optionally substituted with 1 or 2 independently selected le NA substituents;
- each 1Z 10NA is selected from H, D, halo, CN, OH, NH 2 , C 1-6 alkyl, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl; and is selected from H, D, halo, CN, OH, NH 2 , and C 1-6 alkyl; or, alternatively, two R 11 groups together form an oxo group.
- the compound of Formula (I) is a compound of Formula (IIu):
- Z is CZ 1 or N;
- Z 1 and R 12 are each independently selected from H, D, OH, NO 2 , CN, halo, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 1 , 3 haloalkyl, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, C 1-3 alkoxy-C 1-3 alkyl, C 3-6 cycloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 1-3 alkylsulfonyl, carbamyl, C 1-3 alkylcarbamyl, di(C 1-3 alkyl)carbamyl, carboxy, C 1-3 alkylcarbonyl, C 1-4 alk
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1
- each R a1 , R b1 , R c1 , and R d1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c1 and R d1 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 1A substituents;
- each R 1A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a11 , SR a11 , NHOR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)NR c11 (OR a11 ), C(O)OR a11 , OC(O)R b11 , OC(O)NR
- each R a11 , R b11 , R c11 , and R d11 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R ai and R d11 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents; each R M is independently selected from D, OH, NO 2 , CN, halo, C 1-3 alkyl, C 2-3 alkenyl,
- NR c2 C(O)OR a2 and NR c2 C(O)NR c2 R d2 , w h ere in the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl- of R 2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 2A substituents; each Ra2, R b2 , R C2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl
- each R 2A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a21 , SR a21 , NHOR a21 , C(O)R b21 ,
- K C(O) OR a21 , and NR c21 C(O)NR c21 R d21 , w h ere in the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl- of R 2A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- R b21 , -c21, each R a21 , and R d21 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl,
- any R ai and R d21 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- R 1 and R 2 taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R 1A groups;
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a6 , SR a6 , NHOR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)NR c6 (OR a6 ), C(O)OR a6 , OC(O)R b6 , OC(O)NR c6
- each R a6 , R b6 , R c6 and R d6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C
- any R c6 and R d6 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 6A substituents;
- each R 6A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a61 , SR a61 , NHOR a61 , C(O)R b61 , C(O)NR c61 R d61 , C(O)NR c61 (OR a61 ), C(O)OR a61 , OC(O)R b61 , OC(O)NR
- each R a61 , R b61 , R c61 , and R d61 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c61 and R d61 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- X 9 is NR 9N or C(R 9 ) 2 ;
- X 11 is NR 11N or C(R 11 ) 2 ;
- R 9N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b9N , C(O)NR c9N R d9N , C(O)OR a9N , C( ⁇ NR e9N )R b9N , C( ⁇ NR e9N )NR c9N R d9N , C( ⁇ NCN)NR c9N R d9N , C( ⁇ NOR a9
- each R a9N , R b9N , R c9N , and R d9N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6
- each R′ is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 9NA is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a9N2 , SR a9N2 , NHOR a9N2 , C(O)R b9N2 , C(O)NR c9N 2 Rd9N2 , C(O)NR C9N2 (ORa9N2), C(O)OR a9N2 , OC(O)R b
- NR C9N2 NR C9N2 R d9 N2, NR C9N2 C(O)R b9 N2, c9N2 c9N2 R d9N2, w h ere i n l(O)OR a9N2 , and NR C(O)iNK the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl- of R 9NA are each optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- each R and R d9N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3
- each R 9 is independently selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalky
- R b91 , - K c91, each Ra 91 , and R d91 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl,
- each R 9A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a92 , SR a92 , NHOR a92 , C(O)R b62 , C(O)NR c92 R d92 , C(O)NR c92 (OR a92 ), C(O)OR a92 , OC(O)R b92 , OC(O)NR c92 R
- each R a92 , R b92 , R c92 , and R d92 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloal
- any R c92 and R d92 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- R 10N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b10N , C(O)NR c10N R d10N , C(O)OR a10N , C( ⁇ NR e10N )R b10N , C( ⁇ NR e10N )NR c10N R d10N , C( ⁇ NCN)NR c10N R d10N , C( ⁇ NOR a10
- each R a10N , R b10N , R c10N , and R d10N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6
- any R c10N and R d10N attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 10NA substituents;
- each R e10N is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 10NA is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a10N2 , SR a10N2 , NHOR a10N2 , C(O)R b10N2 , C(O)NR c10N2 R d10N2 , C(O)NR c10N2 (OR a10N2 ), C(O)OR a10N2 , OC(O
- each R a10N2 , R b10N2 , R c10N2 , and R d10N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-
- any R c10N2 and R d10N2 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- R 11N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b11N , C(O)NR c11N R d11N , C(O)OR a11N , C( ⁇ NR e11N )R b11N , C( ⁇ NR e11N )NR c11N R d11N , C( ⁇ NCN)NR c11N R d11N , C( ⁇ NOR a11
- each R a11N , R b11N , R c11N , and R d11N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6
- any R c11N and R d11N attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 11NA substituents;
- each R e11N is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 11NA is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a11N2 , SR a11N2 , NHOR a11N2 , C(O)R b11N2 , CO(NR c11N2 R d11N2 , C(O)NR c11N2 (OR a11N2 ), C(O)OR a11N2 , OC(O)R
- each R a11N2 , R b11N2 , R c11N2 and R d11N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl,
- each le is independently selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a111 , SR a111 , NHOR a111 , C(O)R b111 , C(O)NR c111 , R d111 , C(O)NR c111 (OR a111 ), C(O)OR a111 , OC(O)R b111 , OC(O)NR
- each R a111 , R b111 , R c111 , and R d111 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c111 and R d111 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 11A substituents; and
- each R 11A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a112 , SR a112 , SR a112 , NHOR a112 , C(O)R b112 , C(O)NR c112 R d112 , C(O)NR c112 (OR a112 ), C(O)OR a112 , OC(O)
- each R a112 , R b112 , R c112 , and R d112 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7
- any R c112 and R d112 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents.
- Z is CZ 1 or N
- Z 1 and R 12 are each independently selected from H, D, OH, NO 2 , CN, halo, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 1-3 haloalkyl, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, C 1-3 alkoxy-C 1-3 alkyl, C 3-6 cycloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 1-3 alkylsulfonyl, carbamyl, C 1-3 alkylcarbamyl, di(C 1-3 alkyl)carbamyl, carboxy, C 1-3 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-3 alkylcarbonylamino, C 1-3 al
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1
- each R a1 , R b1 , R c1 , and R d1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c1 and R d1 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 1A substituents;
- each R 1A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a11 , SR a11 , NHOR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)NR c11 (OR a11 ), C(O)OR a11 , OC(O)R b11 , OC(O)NR
- each R a11 , R b11 , R c11 , and R d11 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c11 and R d11 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- each R M is independently selected from D, OH, NO 2 , CN, halo, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 1-3 haloalkyl, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, C 1-3 alkoxy-C 1-3 alkyl, C 3-6 cycloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 1-3 alkylsulfonyl, carbamyl, C 1-3 alkylcarbamyl, di(C 1-3 alkyl)carbamyl, carboxy, C 1-3 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-3 alkylcarbonylamino, C 1-3 alkoxycarbonyla
- R 2 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)NR c2
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 2A substituents;
- each R 2A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a21 , SR a21 , NHOR a21 , C(O)R b21 , C(O)NR c21 R d21 , C(O)NR c21 (OR a21 ), C(O)OR a21 , OC(O)R b21 , OC(O)NR
- each R a21 , R b21 , R c21 , and R d21 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c21 and R d21 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- R 1 and R 2 taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R 1A groups;
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a6 , SR a6 , NHOR a6 , C(O)RNR c6 R d6 , C(O)NR c6 (OR a6 ), C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR
- each R a6 , R b6 , R c6 , R d6 and R e6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6
- any R c6 and R d6 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 6A substituents;
- each R 6A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a61 , SR a61 , NHOR a61 , C(O)R b61 , C(O)NR c61 R d61 , C(O)NR c61 (OR a61 ), C(O)OR a61 , OC(O)R b61 , OC(O)NR
- each R a61 , R b61 , R c61 , and R d61 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- any R c61 and R d61 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R M substituents;
- X 9 is NR 9N or C(R 9 ) 2 ;
- X 11 is NR 11N or C(R 11 ) 2 ;
- R 9N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b9N , C(O)NR c9N R d9N , C(O)OR a9N , C( ⁇ NR e9N )R d9N , C( ⁇ NR e9N )NR c9N R d9N , C( ⁇ NCN)NR c9N , R d9N , C( ⁇ NOR
- each R a9N , R b9N , R c9N , and R d9N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6
- any R c9N and R d9N attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 9NA substituents;
- each R e11N is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 9NA is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a9N2 , SR a9N2 , NHOR a9N2 , C(O)R b9N2 , C(O)NR c9N2 R d9N2 , C(O)NR c9N2 (OR a9N2 ), C(O)OR a9N2 , OC(O
- each R a9N2 , R b9N2 , R c9N2 and R d9N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C
- any R c9N2 and R d9N2 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- each R 9 is independently selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a91 , SR a91 , NHOR a91 , C(O)R b91 , C(O)NR c91 R d91 , C(O)NR c91 (OR a91 ), C(O)OR a91 , OC(O)R b91 , OC(O)NR
- each Ra 91 , R b91 , R c91 , and R d91 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-,
- any R c91 and R d91 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 9A substituents;
- each R 9A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a92 , SR a92 , NHOR a92 , C(O)R b92 , C(O)NR c92 R d92 , C(O)NR c92 (OR a92 ), C(O)OR a92 , OC(O)R b92 , OC(O)NR c92 R
- each R a92 , R b92 , R c92 and R d92 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl,
- any R c92 and R d92 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- R 10N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b10N , C(O)NR c10N , R d10N , C(O)OR a10N , C( ⁇ NR e10N )R b10N , C( ⁇ NR e10N )NR c10N R d10N , C( ⁇ NCN)NR c10N R d10N , C( ⁇ NOR
- each R a10N , R b10N , R c10N , and R d10N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6
- any R c10N and R d10N attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 10NA substituents;
- each R e10N is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 10NA is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a10N2 , SR a10N2 , NHOR a10N2 , C(O)R b10N2 , C(O)NR c10N2 R d10N2 , C(O)NR c10N2 (OR a10N2 ), C(O)OR a10N2 , OC(O
- each R a10N2 , R b10N2 , R c10N2 , and R d10N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-
- any R c10N2 and R d10N2 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- R 11N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 arYl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, C(O)R b11N , C(O)NR c11N R d11N , C(O)OR a11N , C( ⁇ NR e11N )R b11N , C( ⁇ NR e11N )NR c11N R d11N , C( ⁇ NCN)NR c11N R d11N , C( ⁇ NOR a11
- each R a11N , R b11N , R c11N , and R d11N is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6
- any R c11N and R d11N attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 11NA substituents;
- each R e11N is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, and C 2-6 alkynyl;
- each R 11NA is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a11N2 , SR a11N2 , NHOR a11N2 , C(O)R b11N2 , C(O)NR c11N2 R d11N2 , C(O)NR c11N2 (OR a11N2 ), C(O)OR a11N2 , OC(O
- each R a11N2 , R b11N2 , R c11N2 , and R d11N2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-
- any R c11N2 and R d11N2 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents;
- each R 11 is independently selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a111 , SR a111 , NHOR a111 , C(O)R b111 , C(O)NR c111 R d111 , C(O)NR c111 (OR a111 ), C(O)OR a111 , OC(O)R b111 , OC(O)NR
- each R a111 , R b111 , R c111 , and R d111 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-
- each R 11A is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a112 , SR a112 , NHOR a112 , C(O)R b112 , C(O)NR c112 R d112 , C(O)NR c112 (OR a112 ), C(O)OR a112 , OC(O)R b112 ,
- R a112 , R b112 , R c112 , and R d112 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-,
- any R c112 and R d112 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R M substituents.
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 ,C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1
- R 2 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 ,C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)NR c2
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R a2 , R b2 , R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents;
- Z is N or CZ 1 ;
- Z 1 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl;
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , and S(O) 2 NR c6 R d6;
- each R b6 , R c6 , and R d6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, and C 2-6 alkynyl;
- X 9 is N or C(R 9 ) 2 ;
- X 11 is N or C(R 11 ) 2 ;
- each R 9 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, of R 9 are each optionally substituted with 1, 2, 3, or 4 independently selected R 9A substituents;
- R 10N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 member
- each R 11 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, of R 11 are each optionally substituted with 1, 2, 3, or 4 independently selected R 11A substituents.
- R 1 is selected from H and C 1-6 alkyl
- R 2 is selected from H, C 1-6 alkyl, C(O)R b2 , C(O)NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 C(O)NR c2 R d2 ;
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, and 4-6 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and 4-6 membered heterocycloalkyl of R a2 , R b2 , R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents;
- Z is CZ 1 ;
- Z 1 is selected from H, D, C 1-3 alkyl, C 1-3 haloalkyl, C 2-3 alkenyl, and C 2-3 alkynyl;
- R 6 is selected from H, halo, C 1-6 alkyl, S(O)R b6 , and S(O) 2 R b6 ;
- X 9 is C(R 9 ) 2 ;
- X 11 is C(R 11 ) 2 ;
- each R 9 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, of R 9 are each optionally substituted with 1, 2, 3, or 4 independently selected R 9A substituents; or, alternatively, two R 9 groups together form an oxo group;
- R 10N is selected from C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl- of R 10N are each optionally substituted with 1 or 2 independently selected R 10NA substituents; and
- each R 11 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl.
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1
- R 2 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)NR c2
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R a2 , R b2 , R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents;
- any R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1 or 2 independently selected R 2A substituents;
- each R 2A is selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, CN, and OH,
- Z is N or CH
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , S(O) 2 NR c6 R d6 S(O)( ⁇ NR e6 )R b6 , and N ⁇ S(O)R a6 R b6 , wherein the C 1-6 haloalkyl is optionally substituted with 1, 2 or 3 R 6A independently selected from D, halo, CN, OH, NH 2 , and C 1-6 alkyl;
- each R a6 , R b6 , R c6 , R d6 , and R e6 is independently selected from H and C 1-6 alkyl;
- X 9 is N or C(R 9 ) 2 ;
- X 11 is N or C(R 11 ) 2 ;
- each R 9 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, of R 9 are each optionally substituted with 1, 2, 3, or 4 independently selected R 9A substituents;
- R 10N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 member
- each R 11 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, of R 11 are each optionally substituted with 1, 2, 3, or 4 independently selected R 11A substituents.
- R 1 is selected from H and C 1-6 alkyl
- R 2 is selected from H, C 1-6 alkyl, C(O)R b2 , C(O)NR c2 , R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 C(O)NR c2 R d2 ;
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and 4-7 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 3-7 cycloalkyl, and 4-7 membered heterocycloalkyl of R a2 , R b2 , R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, CN, and OH;
- any R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1 or 2 independently selected R 2A substituents selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, CN, and OH;
- Z is N or CH
- R 6 is selected from H, halo, C 1-6 alkyl, S(O)R b6 , S(O) 2 R b6 , S(O)( ⁇ NR e6 )R b6 , and N ⁇ S(O)R a6 R b6 , wherein the C 1-6 alkyl is optionally substituted with 1 or 2 OH;
- each R 6 , R b6 , and R e6 is independently selected from H, and C 1-6 alkyl.
- X 9 is C(R 9 ) 2 ;
- X 11 is C(R 11 ) 2 ;
- each R 9 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, of R 9 are each optionally substituted with 1, 2, 3, or 4 independently selected R 9A substituents; or, alternatively, two R 9 groups together form an oxo group;
- R 10N is selected from C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl- of R 10N are each optionally substituted with 1 or 2 independently selected R 10NA substituents selected from C 1-6 alkyl, C 3-7 cycloalkyl, and 4-7 membered heterocycloalkyl; and each R H is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl.
- the disclosure provides a compound of Formula (IIw)
- X 1 is CR 1 or N
- X 2 is CR 2 or N
- X 3 is CR 3 or N
- R 1 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl- CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 C
- R 2 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a2 , SR a2 , NHOR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)NR c2 (OR a2 ), C(O)OR a2 , OC(O)R b2 , OC(O)NR c2
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of Ra z , tc '.132 , Ro z and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents;
- any Ro z and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1 or 2 independently selected R 2A substituents;
- each R 2A is selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, CN, and OH,
- R 3 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a1 , SR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1
- Z is N or CH
- R 6 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , S(O) 2 NR c6 R d6 , S(O)( ⁇ NR e6 )R b6 , and N ⁇ S(O)R a6 R b6 , wherein the C 1-6 haloalkyl is optionally substituted with 1, 2 or 3 R 6A independently selected from D, halo, CN, OH, NH 2 , and C 1-6 alkyl;
- each R a6 , R b6 , R c6 , R d6 , and R e6 is independently selected from H and C 1-6 alkyl;
- R 10N is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 membered heteroaryl)-C 1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-6 alkyl-, C 3-10 cycloalkyl-C 1-6 alkyl-, (5-10 member
- R 1 is selected from H and C 1-6 alkyl
- R 2 is selected from H, C 1-6 alkyl, C(O)R b2 , C(O)NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 , and NR c2 C(O)NR c2 R d2 ;
- each R a2 , R b2 , R c2 , and R d2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and 4-7 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 3-7 cycloalkyl, and 4-7 membered heterocycloalkyl of R a2 , R b2 , R c2 and R d2 are each optionally substituted with 1 or 2 independently selected R 2A substituents selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, CN, and OH;
- any R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1 or 2 independently selected R 2A substituents selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, CN, and OH;
- R 3 is selected from H and C 1-6 alkyl
- Z is N or CH
- R 6 is selected from H, halo, C 1-6 alkyl, S(O)R b6 , S(O) 2 R b6 , S(O)( ⁇ NR e6 )R b6 , and N ⁇ S(O)R a6 R b6 , wherein the C 1-6 alkyl is optionally substituted with 1 or 2 OH;
- each R a6 , R b6 , and R e6 is independently selected from H, and C 1-6 alkyl;
- R 10N is selected from C 1-6 alkyl, C 3-6 cycloalkyl, and C3-6cycloalkyl C 1-6 alkyl-, wherein the C 1-6 alkyl, C 3-6 cycloalkyl, and C 3-6 cycloalkyl-C 1-6 alkyl- of R 10N are each optionally substituted with 1 or 2 independently selected R 10NA substituents independently selected from C 1-6 alkyl, C 3-7 cycloalkyl, and 4-7 membered heterocycloalkyl.
- the compound of Formula (I) is a compound of Formula (III):
- the compound of Formula (I) is a compound of Formula (IIIb):
- the compound of Formula (I) is a compound of Formula (IIIc):
- the compound of Formula (I) is a compound of Formula (IIId):
- the compound of Formula (I) is a compound of Formula (Me):
- the compound of Formula (I) is a compound of Formula (IIIf):
- the compound of Formula (I) is a compound of Formula (IIIg):
- the compound of Formula (I) is a compound of Formula (IIIh):
- the compound of Formula (I) is a compound of Formula (IV):
- the compound of Formula (I) is a compound of Formula (IVb):
- the compound of Formula (I) is a compound of Formula (IVc):
- the compound of Formula (I) is a compound of Formula (IVd):
- the compound of Formula (I) is a compound of Formula (IVe):
- the compound of Formula (I) is a compound of Formula (IVf):
- the compound of Formula (I) is a compound of Formula (IVg):
- the compound of Formula (I) is a compound of Formula (IVh):
- the compound of Formula (I) is a compound of Formula 3-6 of Scheme III, a compound of Formula 5-2 of Scheme V, a compound of Formula 13-8 of Scheme XIII, a compound of Formula 14-5 of Scheme XIV, or a compound of Formula 15-5 of Scheme
- the compound is the (S)-enantiomer of one of the preceding compounds, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is the (R)-enantiomer of one of the preceding compounds, or a pharmaceutically acceptable salt thereof.
- each divalent linking substituent include both the forward and backward forms of the linking substituent.
- —NR(CWR′′).- includes both —NR(CR′R′′), and —(CR′R′′)NR.
- n-membered where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n.
- piperidinyl is an example of a 6-membered heterocycloalkyl ring
- pyrazolyl is an example of a 5-membered heteroaryl ring
- pyridyl is an example of a 6-membered heteroaryl ring
- 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
- the phrase “optionally substituted” means unsubstituted or substituted.
- the substituents are independently selected, and substitution may be at any chemically accessible position.
- substituted means that a hydrogen atom is removed and replaced by a substituent.
- a single divalent substituent, e.g., oxo, can replace two hydrogen atoms. It is to be understood that substitution at a given atom is limited by valency.
- each ‘variable’ is independently selected from means substantially the same as wherein “at each occurrence ‘variable’ is selected from.”
- C indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include
- alkyl refers to a saturated hydrocarbon group that may be straight-chain or branched, having n to m carbons.
- alkyl moieties include, but are not limited to, chemical groups such as methyl (Me), ethyl (Et), n-propyl (n-Pr), isopropyl (iPr), n-butyl, teat-butyl, isobutyl, sec-butyl;
- the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms.
- C. alkenyl refers to an alkyl group having one or more double carbon-carbon bonds and having n to m carbons.
- Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.
- the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
- C_m alkynyl refers to an alkyl group having one or more triple carbon-carbon bonds and having n to m carbons.
- Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
- C_m alkoxy refers to a group of formula -0-alkyl, wherein the alkyl group has n to m carbons.
- Example alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), butoxy (e.g., n-butoxy and tent-butoxy), and the like.
- the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- amino refers to a group of formula —NH 2.
- aryl employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or polycycliC(e.g., having 2 fused rings).
- C.aryl refers to an aryl group having from n to m ring carbon atoms.
- Aryl groups include, e.g., phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like.
- aryl groups have from 6 to 10 carbon atoms.
- the aryl group is phenyl or naphthyl.
- the aryl is phenyl.
- halo refers to F, Cl, Br, or I. In some embodiments, a halo is F, Cl, or Br. In some embodiments, a halo is F or Cl. In some embodiments, a halo is F. In some embodiments, a halo is Cl.
- C. haloalkoxy refers to a group of formula —0-haloalkyl having n to m carbon atoms.
- Example haloalkoxy groups include OCF3 and OCHF2.
- the haloalkoxy group is fluorinated only.
- the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- C.haloalkyl refers to an alkyl group having from one halogen atom to 2s+1 halogen atoms which may be the same or different, where “s” is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms.
- the haloalkyl group is fluorinated only.
- the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- Example haloalkyl groups include CF3, C2F5, CHF2, CH 2 F, CC13, CHC12, C2C15 and the like.
- C. alkylamino refers to a group of formula -NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- C.alkoxycarbonyl refers to a group of formula —C(O)O-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- C.alkylcarbonyl refers to a group of formula -C(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. As used herein, the term “C.alkylcarbonylamino” refers to a group of formula -NHC(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- C. alkoxycarbonylamino refers to a group of formula —NHC(O)0(C. alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- C.alkylsulfonylamino refers to a group of formula -NHS(O) 2 -alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- the term “aminosulfonyl” refers to a group of formula -S(O) 2 NH 2.
- C.alkylaminosulfonyl refers to a group of formula -S(O) 2 NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- di(C. alkyl)aminosulfonyl refers to a group of formula -S(O) 2 N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- aminosulfonylamino refers to a group of formula —NHS(O) 2 NH 2.
- C.alkylaminosulfonylamino refers to a group of formula —NHS(O) 2 NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- di(C.alkyl)aminosulfonylamino refers to a group of formula -NHS(O) 2 N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- aminocarbonylamino employed alone or in combination with other terms, refers to a group of formula -NHC(O)NH 2.
- CHm alkylaminocarbonylamino refers to a group of formula —NHC(O)NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- di(C.H. alkyl)aminocarbonylamino refers to a group of formula -NHC(O)N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- Cn_malkylcarbamyl refers to a group of formula —C(O)—NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- thio refers to a group of formula -SH.
- Cn_malkylthio refers to a group of formula -S-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- Cn_malkylsulfinyl refers to a group of formula -S(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- Cn_malkylsulfonyl refers to a group of formula -S(O) 2 -alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- carbamyl to a group of formula —C(O)NH 2.
- carbonyl employed alone or in combination with other terms, refers to a -C(O)- group.
- cyano-C 1-3 alkyl refers to a group of formula -(C 1-3 alkylene)-CN.
- HO-C 1-6 alkyl refers to a group of formula -(C 1-6 alkylene)-OH.
- HO-C 1-3 alkyl refers to a group of formula -(C 1-3 alkylene)-OH.
- C 1-6 alkoxy-C 1-6 alkyl refers to a group of formula -(C 1-6 alkylene)- 0 (C -6 alkyl).
- C 1-3 alkoxy-Ci3 alkyl refers to a group of formula -(C 1-3 alkylene)-0(C 1-3 alkyl).
- the term “carboxy” refers to a group of formula -C(O)OH.
- di(C0-m-alkyl)amino refers to a group of formula -N(alkyl) 2 , wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- di(C0-m-alkyl)carbamyl refers to a group of formula — C(O)N(alkyl) 2 , wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- aminocarbonyloxy refers to a group of formula -OC(O)NH 2.
- C 1-3 alkylcarbonyloxy refers to a group of formula —OC(O)(C1 — 3 alkyl).
- C 1-3 alkylaminocarbonyloxy refers to a group of formula —OC(O)NH(C 1-3 alkyl).
- di(C 1-3 alkyl)aminocarbonyloxy refers to a group of formula —OC(O)N(C 1-3 alkyl) 2 , wherein the two alkyl groups each has, independently, 1 to 3 carbon atoms.
- cycloalkyl refers to non-aromatic cyclic hydrocarbons including cyclized alkyl and alkenyl groups.
- Cycloalkyl groups can include mono- or polycycliC(e.g., having 2 fused rings) groups, spirocycles, and bridged rings (e.g., a bridged bicycloalkyl group). Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo or sulfido (e.g., C(O) or C(S)).
- cycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of cyclopentane, cyclohexane, and the like.
- a cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
- Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbons (i.e., C3_10).
- the cycloalkyl is a C 3-10 monocyclic or bicyclic cycloalkyl. In some embodiments, the cycloalkyl is a C 3-10 monocyclic cycloalkyl which is optionally substituted by CH 2 F, CHF2, CF3, and CF2CF3. In some embodiments, the cycloalkyl is a C 3-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C4-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C4_10 spirocycle or bridged cycloalkyl (e.g., a bridged bicycloalkyl group).
- Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, cubane, adamantane, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, and the like.
- cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
- heteroaryl refers to a monocyclic or polycycliC(e.g., having 2 fused rings) aromatic heterocycle having at least one heteroatom ring member selected from N, 0, S and B, wherein any ring forming N is optionally an N-oxide group.
- the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from N, 0, S and B.
- any ring-forming N in a heteroaryl moiety can be an N-oxide.
- the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, 0, S and B.
- the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, 0, and S. In some embodiments, the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, 0, S and B. In some embodiments, the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, 0, and S. In some embodiments, the heteroaryl is a 5-6 monocyclic heteroaryl having 1 or 2 heteroatom ring members independently selected from N, 0, S and B.
- the heteroaryl is a 5-6 monocyclic heteroaryl ring having 1 or 2 heteroatom ring members independently selected from N, 0 or S. In some embodiments, the heteroaryl group contains 3 to 10, 4 to 10, 3 to 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to 4 ring-forming heteroatoms, 1 to 3 ring-forming heteroatoms, 1 to 2 ring-forming heteroatoms or 1 ring-forming heteroatom. When the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different.
- Example heteroaryl groups include, but are not limited to, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, azolyl, oxazole, isoxazole, thiophene, thiazole, isothiazole, imidazole, furan, thiophene, triazole, tetrazole, thiadiazole, quinoline, isoquinoline, indole, benzothiophene, benzofuran, benzisoxazole, imidazo[1,2-b]thiazole, purine, triazine, thieno[3,2-b]pyridine, imidazo[1,2-a]lpyridine, 1,5-naphthyridine, 1H-pyrazolo[4,3-b]pyridine, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl
- heterocycloalkyl refers to monocyclic or polycyclic heterocycles having at least one non-aromatic ring (saturated or partially unsaturated ring), wherein one or more of the ring-forming carbon atoms of the heterocycloalkyl is replaced by a heteroatom selected from N, 0, S and B, and wherein the ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group can be optionally substituted by one or more oxo or sulfido (e.g., C(O), S(O), C(S), or S(O) 2 , etc.).
- oxo or sulfido e.g., C(O), S(O), C(S), or S(O) 2 , etc.
- Heterocycloalkyl groups include monocyclic and polycycliC(e.g., having 2 fused rings) systems. Included in heterocycloalkyl are monocyclic and polycyclic 3-10-, 4-10-, 3-7-, 4-7-, and 5-6- membered heterocycloalkyl groups. Heterocycloalkyl groups can also include spirocycles and bridged rings (e.g., a 5-10 membered bridged biheterocycloalkyl ring having one or more of the ring-forming carbon atoms replaced by a heteroatom independently selected from N, 0, S and B). The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double bonds.
- heterocycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the non-aromatic heterocyclic ring, for example, benzo or thienyl derivatives of piperidine, morpholine, azepine, etc.
- a heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
- the heterocycloalkyl group contains 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, 3 to 7 ring-forming atoms, or 5 to 6 ring-forming atoms.
- the heterocycloalkyl group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms or 1 heteroatom.
- the heterocycloalkyl is a monocyclic 4-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, 0, S and B and having one or more oxidized ring members.
- Example heterocycloalkyl groups include pyrrolidin-2-one, 1,3-isoxazolidin-2-one, pyranyl, tetrahydropyran, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazapene, 1,2,3,4-tetrahydroisoquinoline, azabicyclo[3.1.0]hexanyl, diazabicyclo[3.1.0]hexanyl, oxabicyclo[2.1.1]hexanyl, azabicyclo [2.2.1]hep tanyl, di
- C o-p cycloalkyl-Cn_malkyl- refers to a group of formula cycloalkyl-alkylene-, wherein the cycloalkyl has o to p carbon atoms and the alkylene linking group has n to m carbon atoms.
- C o-p aryl-Cn_malkyl- refers to a group of formula aryl-alkylene-, wherein the aryl has o to p carbon atoms and the alkylene linking group has n to m carbon atoms.
- heteroaryl-Cn_malkyl- refers to a group of formula heteroaryl-alkylene-, wherein alkylene linking group has n to m carbon atoms.
- heterocycloalkyl-Cn_m alkyl- refers to a group of formula heterocycloalkyl-alkylene-, wherein alkylene linking group has n to m carbon atoms.
- the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas a pyridin-3-yl ring is attached at the 3-position.
- a dashed bond represents a single or double bond depending on the nature of the atoms in each ring and as required to complete the valencies of the atoms being linked by the bond.
- the compounds described herein can be asymmetriC(e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
- Compounds of the present disclosure that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C ⁇ N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present disclosure.
- Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separated isomeric forms.
- the compound has the (R)-configuration.
- the compound has the (S)-configuration.
- the Formulas e.g., Formula (I), (II), etc. provided herein include stereoisomers of the compounds.
- An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid.
- Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as (3-camphorsulfonic acid.
- resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of ⁇ -methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.
- Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
- an optically active resolving agent e.g., dinitrobenzoylphenylglycine
- Suitable elution solvent composition can be determined by one skilled in the art.
- Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
- Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
- Example prototropic tautomers include ketone — enol pairs, amide - imidic acid pairs, lactam — lactim pairs, enamine — imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H-isoindole, 2-hydroxypyridine and 2-pyridone, and 1H- and 2H-pyrazole.
- Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
- All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g. hydrates and solvates) or can be isolated.
- preparation of compounds can involve the addition of acids or bases to affect, for example, catalysis of a desired reaction or formation of salt forms such as acid addition salts.
- the compounds provided herein, or salts thereof are substantially isolated.
- substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
- Partial separation can include, for example, a composition enriched in the compounds provided herein.
- Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds provided herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- the present application also includes pharmaceutically acceptable salts of the compounds described herein.
- the present disclosure also includes pharmaceutically acceptable salts of the compounds described herein.
- pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- the pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- ACN acetonitrile
- the compounds provided herein can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
- Y A is a halogen (e.g., Cl, Br or I) or pseudohalogen (e.g., OMs or OTf) and P is a suitable protecting group (e.g., trimethylsilylethoxymethyl)
- P is a suitable protecting group (e.g., trimethylsilylethoxymethyl)
- a palladium catalyst such as tetrakis(triphenylphosphine)palladium(O), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane or bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) and a base (e.g., a carbonate base such as potassium carbonate, or cesium fluoride)) or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as
- compounds of Formula (I) can be prepared as shown in Scheme 2.
- Y A is an appropriate halogen (e.g., Cl, Br, or I) or pseudohalogen (e.g., OMs or OTf)
- M A is B(OR) 2 , BF 3 K, SnR 3 , or Zn
- a diboron reagent such as bis(pinacolato)diboron
- a palladium catalyst such as dichloro[bis(triphenylphosphoranyl]palladium or [1,1]-bis(diphenylphosphino)ferroceneldichloropalladium(II), complex with dichloromethane, and a base, such as potassium acetate).
- Intermediate 2-2 can undergo Suzuki, Stille or Negishi couplings with appropriate halo-derivatives 2-3, wherein Y B is a suitable halogen (e.g., Cl, Br, or I) or pseudohalogen (e.g., OMs or OTO, to provide compounds of Formula (I).
- Y B is a suitable halogen (e.g., Cl, Br, or I) or pseudohalogen (e.g., OMs or OTO, to provide compounds of Formula (I).
- Y B is a suitable halogen (e.g., Cl, Br, or I) or pseudohalogen (e.g., OMs or OTO, to provide compounds of Formula (I).
- Y B is a suitable halogen (e.g., Cl, Br, or I) or pseudohalogen (e.g., OMs or OTO, to provide compounds of Formula (I).
- the compounds of Formula (I) can be prepared by either route depending on the compatibility of functional groups present in the
- X 1 is CR'
- X 2 is CR 2
- X 3 is N
- Nitrile containing starting material 3-4 wherein Y A is a suitable halogen (e.g., Cl, Br or I) or pseudohalogen (e.g., OMs or OTO, can be reacted with a suitable metal 3-2, wherein M B is a boronic acid, boronic ester, or an appropriately substituted metal such as Sn(Bu)4 or Zn, under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O) or 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1) and a base (e.g., a bicarbon
- the nitrile of intermediate 3-5 can be converted to a substituted imidazole as shown in 3-6 via several routes, some of which are outlined in Scheme 4.
- the order of steps can be reversed, such that imidazole formation to furnish 3-7 (by methods such as shown in Scheme 4) can precede the coupling to 3-2.
- the NH of the heterocycle (3-7) can be optionally protected (e.g., using SEM-Cl and base) to give a N-protected derivative (3-8), which can be coupled with 3-2 as described for the transformation from 3-4 to 3-5 above, to provide 3-9, which upon N-deprotection (e.g., reaction with a strong acid, such as TFA) will furnish compounds 3-6.
- the compounds of Formula (I) can be prepared by either route depending on the compatibility of functional groups present in the intermediates.
- the nitrile is not present in starting material 3-4, it can be installed from an appropriately substituted starting material 3-1, wherein Y c and Y A are independently halogen (e.g., Y c is Cl or Br) or pseudohalogen (OMs or OTO, via Negishi coupling with Zn(CN) 2 (e.g., in the presence of a Pd(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O)).
- a Pd(O) catalyst such as tetrakis(triphenylphosphine)palladium(O)
- a selective Suzuki, Stille or Negishi cross coupling of appropriately substituted starting material 3-1 with appropriately substituted metal 3-2 can provide intermediate 3-3, which can be converted to nitrile-containing intermediate 3-5 via Negishi coupling with Zn(CN) 2 (e.g., in the presence of a Pd(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O)).
- a Pd(O) catalyst such as tetrakis(triphenylphosphine)palladium(O)
- Nitrile containing intermediate 4-1 can be converted to an imidate (e.g., by reacting with catalytic sodium methoxide in an alcohol or by reacting with HC1 in an alcohol) and the intermediate imidate can be reacted with an amino ketal or amino acetal (4-2, wherein R is an alkyl group such as methyl or ethyl) in the presence of acid (e.g., AcOH or HC1) and heat to form imidazole 4-3.
- an imidate e.g., by reacting with catalytic sodium methoxide in an alcohol or by reacting with HC1 in an alcohol
- acid e.g., AcOH or HC1
- the intermediate imidate can be reacted with NH 4 C1 to afford an amidine, which can be alkylated with an ⁇ -halo ketone (4-4) in the presence of base (e.g., KHCO 3 , or K2CO 3 ) in a solvent such as an alcohol, or preferably, DMF, to furnish imidazole 4-3.
- base e.g., KHCO 3 , or K2CO 3
- the imidate intermediate formed by reacting nitrile 4-1 with catalytic sodium methoxide can be treated with a diamine (4-5) (e.g., a phenylenediamine derivative) and cyclized under acidic conditions and heat to afford imidazole 4-3.
- a diamine 4-5
- a phenylenediamine derivative e.g., a phenylenediamine derivative
- carboxylic acid 4-6 can be coupled to a diamine (4-5) in the presence of a coupling reagent (e.g., HATU) and base (e.g., Hunig's Base or triethylamine).
- a coupling reagent e.g., HATU
- base e.g., Hunig's Base or triethylamine
- the intermediate amide can be cyclized to imidazole 4-3 by heating in acid (e.g., AcOH).
- Carboxylic acid 4-6 can also be reacted with ⁇ -halo ketones (4-4) in the presence of base (e.g., K2CO 3 ) to afford an ester intermediate that can be heated in the presence of NH 4 OAc to afford imidazole 4-3.
- base e.g., K2CO 3
- R A is Cy that contains a nucleophilic functional group (e.g., isoindolinone)
- further transformations may be carried out as shown in Scheme 5.
- base e.g.,Na2CO 3, K2CO 3 , Cs2CO 3 , NaH, KO′Bu, etc.
- further transformations e.g., hydrolysis, amide formation, reduction, alkylation, acylation, sulfonylation
- further transformations e.g., hydrolysis, amide formation, reduction, alkylation, acylation, sulfonylation
- Heterocycles may be installed in the compounds provided herein as shown in Schemes 6 to 9.
- a regioselective cross-coupling can be achieved between appropriate substituted metal M B -Cy and 6-1 wherein Y A and Y c are independently suitable halogens (e.g., Cl, Br or I) or pseudohalogens (e.g., OMs, OTI).
- suitable halogens e.g., Cl, Br or I
- pseudohalogens e.g., OMs, OTI
- M B -Cy wherein M B is a boronic acid, boronic ester, or an appropriately substituted metal such as Sn(Bu)4 or Zn
- M B is a boronic acid, boronic ester, or an appropriately substituted metal such as Sn(Bu)4 or Zn
- a palladium(O) catalyst such as tetrakis(triphenylphosphine)palladium(O) or 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1) and a base (e.g., a bicarbonate or carbonate base, or CsF) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O)), with intermediate 6-1 to give derivative 6-2.
- a palladium(O) catalyst such as tetrakis
- the desired heterocycle (e.g., illustrated by optionally protected imidazole isomer 6-3 wherein M D is a boronic acid, boronic ester, or an appropriately substituted metal such as Sn(Bu)4 or Zn) can be coupled with 6-2 under Suzuki, Stille or Negishi conditions as described above to afford (on subsequent N-deprotection) product 6-4.
- M D is a boronic acid, boronic ester, or an appropriately substituted metal such as Sn(Bu)4 or Zn
- the amine of 7-4 can optionally be alkylated by reaction of the amine with an aldehyde (e.g., RCHO) in the presence of a reducing agent (e.g., sodium cyanoborohydride or sodium triacetoxyborohydride) to give 7-5.
- an aldehyde e.g., RCHO
- a reducing agent e.g., sodium cyanoborohydride or sodium triacetoxyborohydride
- Compounds of Formula (I) wherein X 1 is C-NHW', and X 2 and X 3 are N can be prepared, as shown in Scheme 8, by reacting an ester (8-2, wherein R is an alkyl group (e.g., methyl or ethyl), prepared by Suzuki, Stille or Negishi coupling of 8-1 with M B -Cy) with hydrazine hydrate at elevated temperature to form an acyl hydrazide 8-3.
- Intermediate 8-3 can be reacted with an alkylated thiourea (8-5) in the presence of heat and base (e.g., 2,6-lutidine) to afford aminotriazole product 8-6.
- the requisite intermediate 8-5 can be prepared by alkylating available thiourea 8-4 with methyl iodide.
- an imidazole such as 10-1 containing an unfunctionalized carbon, can be nitrated (e.g., using HNO 3 in H2504) to provide nitro derivative 10-2, which can be reduced (e.g., using iron in AcOH or in aq. HC1 and alcoholic solvent) to amino derivative 10-3.
- the synthesis may alternatively be carried out with a halogen at that position, and the desired cyclic group (Cy) introduced by Suzuki, Stille, or Negishi conditions on the product of nitration or reduction (10-2, or 10-3, respectively), as appropriate.
- the compounds of Formula (I) can be prepared by either route depending on the compatibility of functional groups present in the intermediates.
- an imidazole such as 11-1 containing an unfunctionalized carbon
- a halogenating reagent e.g., N-iodosuccinimide or N-bromosuccinimide
- halo-containing intermediate 11-2 e.g., to provide a compound wherein X 2 is Cl, Br or I
- Pd-catalyzed cross-coupling reaction e.g., Suzuki, Stille, Negishi and the like
- NaOH in THF and an alcohol can be carried out to afford a carboxylic acid which can be coupled with an amine, R 2 cR 2d NH, under standard conditions (e.g., HATU in the presence of Hunig's base or triethylamine) to form amide 12-3.
- Amide 12-3 can also be prepared by heating ester 12-2 with amine R 2 cR 2d NH in the presence of a suitable lewis acid (e.g., A1C13).
- Direct conversion of halo-containing intermediate 12-1 to amide 12-3 can also be effected by reacting 12-1 with carbon monoxide and a Pd catalyst in the presence of an amine R 2 cR 2d NH.
- aldehyde 12-4 can be prepared.
- the aldehyde can be converted to an amine-containing compound (12-5) by reductive amination with R 2 CR 2d NH in the presence of a reducing agent (e.g., sodium cyanoborohydride, sodium triacetoxyborohydride).
- a reducing agent e.g., sodium cyanoborohydride, sodium triacetoxyborohydride.
- Numerous other functional group transformations can be carried out on intermediates 12-2 and 12-4, such as, but not limited to, Grignard addition, reduction, and deoxyfluorination (e.g., with Deoxo-Fluor).
- the Cy group in compounds of Formula (I) can be prepared as shown in Scheme 13.
- Appropriately substituted ester 13-1 e.g., R is -CH 3 , -CH 2 CH 3 and the like
- Y B is a halo (e.g., Cl, Br, or I) or pseudohalo group (e.g., OTf or OMs)
- Y 6 is a suitable halogen (e.g. Cl, Br or
- a suitably substituted starting material 13-2 bearing an alcohol substituent on alkyl group X 11 can be halogenated by treatment with a suitable halogenating reagent (e.g., SOC12 or triphenylphosphine dibromide) to afford 13-3 wherein L H is a halogen (e.g., Cl, Br or I).
- a suitable halogenating reagent e.g., SOC12 or triphenylphosphine dibromide
- 13-2 can be treated with a sulfonyl chloride (e.g., p-toluenesulfonyl chloride or methanesulfonyl chloride) in the presence of a base (e.g., triethylamine or Hunig's base) to afford 13-3 wherein L′′ is a sulfonyl-based leaving group (e.g., OMs or OTs).
- a sulfonyl chloride e.g., p-toluenesulfonyl chloride or methanesulfonyl chloride
- a base e.g., triethylamine or Hunig's base
- L′′ is a sulfonyl-based leaving group (e.g., OMs or OTs).
- Intermediate 13-3 can be converted to intermediate 13-4 via reaction with an amine
- R ioN N — ri2 in the presence of base (e.g., triethylamine or N,N-diisopropylethylamine), or in the presence of acid (e.g., boric acid) and base (e.g., a carbonate base such as K2CO 3 , Cs2CO 3 or
- Y B halo (e.g., Cl, Br, or I) or pseudohalo group (e.g., OTf or OMs) of intermediate 13-6 can be converted to an appropriately substituted metal (e.g., M B is B(OH) 2 , Bpin, BF 3 K, Sn(Bu) 3 , or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl)]palladium or [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane, and a base, such as potassium acetate) to afford compound 13-7.
- a diboron reagent such as bis(pinacolato)diboron
- a palladium catalyst such as dichloro[bis(triphenylphosphoran
- a suitably substituted intermediate 14-1 wherein Y B and Y 6 are independently halogen (e.g., Cl, Br, or I) or pseudohalogen (e.g., OTf or OMs) can be converted to an appropriately substituted metal 14-2 (e.g., M B is B(OH) 2 , Bpin, BF 3 K, Sn(Bu) 3 , or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl]palladium or [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane, and a base, such as potassium acetate).
- a diboron reagent such as bis(pinacolato)diboron
- a palladium catalyst such as dichloro[bis(
- Oxidation of compound 14-4 with a suitable oxidizing agent can provide compounds 14-5.
- intermediate 15-2 treatment of intermediate 15-2 with an alkylating agent R 10 N -L, wherein L is a suitable leaving group (e.g., a halogen (e.g., Cl, Br, or I) or pseudohalo group (e.g., OTs or OMs)), in the presence of a base (e.g., sodium hydride or carbonate base (e.g., cesium carbonate)) can provide intermediate 15-3.
- a suitable leaving group e.g., a halogen (e.g., Cl, Br, or I) or pseudohalo group (e.g., OTs or OMs)
- a base e.g., sodium hydride or carbonate base (e.g., cesium carbonate)
- the steps can be performed in reverse order (i.e., 15-1 may be alkylated with R 10 N -L under conditions described above, to provide compound 15-4, which can subsequently converted to metal 15-3 under conditions described above) to afford intermediate 15-3, which can be converted to compounds of Formula (I) as outlined in preceding Schemes (e.g., Scheme 1).
- the reactions for preparing compounds described herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis.
- suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, (e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature).
- a given reaction can be carried out in one solvent or a mixture of more than one solvent.
- suitable solvents for a particular reaction step can be selected by the skilled artisan.
- ambient temperature or “room temperature” or “rt” as used herein, are understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20° C. to about 30° C.
- Preparation of compounds described herein can involve the protection and deprotection of various chemical groups.
- the need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art.
- the chemistry of protecting groups can be found, for example, in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3r d Ed., Wiley & Sons, Inc., New York (1999).
- Reactions can be monitored according to any suitable method known in the art.
- product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1 1-1 or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC).
- HPLC high performance liquid chromatography
- LCMS liquid chromatography-mass spectroscopy
- TLC thin layer chromatography
- Compounds can be purified by those skilled in the art by a variety of methods, including high performance liquid chromatography (HPLC) and normal phase silica chromatography.
- the compounds, salts or stereoisomers thereof described herein inhibit activity of PI3K ⁇ kinase. Accordingly, the compounds, salts or stereoisomers described herein can be used in methods of inhibiting PI3K ⁇ kinase by contacting the kinase with any one or more of the compounds, salts, or compositions described herein. In some embodiments, the compounds or salts can be used in methods of inhibiting activity of PI3K ⁇ in an individual/patient in need of the inhibition by administering an effective amount of a compound or salt of described herein. In some embodiments, modulating is inhibiting. In some embodiments, the contacting is in vivo. In some embodiments, the contacting is ex vivo.
- the compounds as described herein demonstrate better efficacy and favorable safety and toxicity profiles in animal studies.
- the PI3K ⁇ includes a mutation.
- a mutation can be a replacement of one amino acid for another, or a deletion of one or more amino acids.
- the mutation can be present in the kinase domain of the PI3K ⁇ .
- the compound or salt further inhibits PI3K6.
- the compounds or salts described herein can be selective.
- selective is meant that the compound binds to or inhibits PI3K ⁇ with greater affinity or potency, respectively, compared to at least one other kinase.
- the compounds of the disclosure are selective inhibitors of PI3K ⁇ over PI3K6, PI3K ⁇ , and PI3K13.
- the compounds of the disclosure are selective inhibitors of PI3K ⁇ over PI3K ⁇ and PI3K13.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application is a divisional of U.S. application Ser. No. 16/681,267, filed Nov. 12, 2019, which claims the benefit of priority of U.S. Prov. Appin. No. 62/760,479, filed Nov. 13, 2018, each of which is incorporated by reference in its entirety.
- The present disclosure provides compounds that modulate the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
- The phosphoinositide 3-kinases (PI3Ks) belong to a large family of lipid signaling kinases that phosphorylate phosphoinositides at the D3 position of the inositol ring (Cantley, Science, 2002, 296(5573):1655-7). PI3Ks are divided into three classes (class I, II, and III) according to their structure, regulation and substrate specificity. Class I PI3Ks, which include PI3Kα, PI3Kβ, PI3Kγ , and PI3Kδ, are a family of dual specificity lipid and protein kinases that catalyze the phosphorylation of phosphatidylinosito-4,5-bisphosphate (PIP2) giving rise to phosphatidylinosito-3,4,5-trisphosphate (PIP3). PIP3 functions as a second messenger that controls a number of cellular processes, including growth, survival, adhesion and migration. All four class I PI3K isoforms exist as heterodimers composed of a catalytic subunit (p110) and a tightly associated regulatory subunit that controls their expression, activation, and subcellular localization. PI3Kα, PI3Kβ, and PI3Kδ associate with a regulatory subunit known as p85 and are activated by growth factors and cytokines through a tyrosine kinase-dependent mechanism (Jimenez, et al., J Biol Chem., 2002, 277(44):41556-62) whereas PI3Kγ associates with two regulatory subunits (p101 and p84) and its activation is driven by the activation of G-protein-coupled receptors (Brock, et al., J Cell Biol., 2003, 160(1):89-99). PI3Kα and PI3Kδ are ubiquitously expressed. In contrast, PI3Kγ and PI3Kδ are predominantly expressed in leukocytes (Vanhaesebroeck, et al., Trends Biochem Sci., 2005, 30(4):194-204).
- Expression of PI3Kγ is mainly restricted to hematopoietic system, although it can be also detected at lower level in endothelium, heart and brain. PI3Kγ knock-out or kinase dead knock in mice are normal and fertile and do not present any overt adverse phenotypes. Analysis at the cellular level indicates that PI3Kγ is required for GPCR ligand-induced PtdINs (3,4,5)P3 production, chemotaxis and respiratory burst in neutrophils. PI3Kγ-null macrophages and dendritic cell exhibit reduced migration towards various chemoattractants. T-cells deficient in PI3Kγ show impaired cytokine production in response to anti-CD3 or Con A stimulation. PI3Kγ working downstream of adenosine A3A receptor is critical for sustained degranulation of mast cells induced by FCεRI cross-linking with IgE. PI3Kγ is also essential for survival of eosinophils (Ruckle et al., Nat. Rev. Drug Discovery, 2006, 5, 903-918)
- Given its unique expression pattern and cellular functions, the potential role of PI3Kγ in various autoimmune and inflammatory disease models has been investigated with genetic and pharmacological tools. In asthma and allergy models, PI3Kγ −/− mice or mice treated with PI3Kγ inhibitor showed a defective capacity to mount contact hypersensitivity and delayed-type hypersensitivity reactions. In these models, PI3Kγ was shown to be important for recruitment of neutrophils and eosinopohils to airways and degranulation of mast cells (see e.g. Laffargue et al., Immunity, 2002, 16, 441-451; Prete et al., The EMBO Journal, 2004, 23, 3505-3515; Pinho et al., L. Leukocyte Biology, 2005, 77, 800-810; Thomas et al., Eur. I Immunol. 2005, 35, 1283-1291; Doukas et al., J. Pharmacol. Exp Ther. 2009, 328, 758-765).
- In two different acute pancreatitis models, genetic ablation of PI3Kγ significantly reduced the extent of acinar cell injury/necrosis and neutrophil infiltration without any impact on secretive function of isolated pancreatic acini (Lupia et al., Am. J. Pathology, 2004, 165, 2003-2011). PI3Kγ −/− mice were largely protected in four different models of rheumatoid arthritis (CIA, α-CII-IA, K/BxN serum transfer and TNF transgenic) and PI3Kγ inhibition suppressed the progression of joint inflammation and damage in the CIA and α-CII-IA models (see e.g., Camps et al., Nat. Medicine, 2005, 11, 939-943; Randis et al., Eur. I Immunol, 2008, 38, 1215-1224; Hayer et al., FASB J, 2009, 4288-4298). In the MRL-lpr mouse model of human systemic lupus erythematous, inhibition of PI3Kγ reduced glomerulonephritis and prolonged life span (Barber et al., Nat. Medicine, 2005, 9, 933-935).
- There is evidence suggesting that chronic inflammation due to infiltration by myeloid-derived cells is a key component in the progression of neurodegeneration diseases, such as Alzheimer's disease (AD) (Giri et al., Am. J. Physiol. Cell Physiol., 2005, 289, C264-C276; E1 Khoury et al., Nat. Med., 2007, 13, 432-438). In line with this suggestion, PI3Kγ inhibition was shown to attenuate Aβ(1-40)-induced accumulation of activated astrocytes and microglia in the hippocampus and prevent the peptide-induced congnitive deficits and synaptic dysfunction in a mouse model of AD (Passos et al., Brain Behay. Immun. 2010, 24, 493-501). PI3Kγ deficiency or inhibition also was shown to delay onset and alleviate symptoms in experimental autoimmune encephalomyelitis in mice, a mouse model of human multiple sclerosis, which is another form of neurodegeneration disease (see e.g., Rodrigues et al., I Neuroimmunol. 2010, 222, 90-94; Berod et al., Euro. I Immunol. 2011, 41, 833-844; Comerford et al., PLOS one, 2012, 7, e45095; Li et al., Neuroscience, 2013, 253, 89-99).
- Chronic inflammation has been formally recognized as one of the hallmarks for many different types of cancers. Accordingly, selective anti-inflammatory drugs represent a novel class of anti-cancer therapies (Hanahan and Weinberg, Cell, 2011, 144, 646-674). Since PI3Kγ is reported to mediate various inflammatory processes, its role as an immune oncology target has also been investigated. A recent study reported that PI3Kγ deficiency suppressed tumor growth in the syngeneic models of lung cancer, pancreatic cancer and melanoma (LLC, PAN02 and B16). PI3Kγ deficiency or inhibition also inhibited tumor growth in a spontaneous breast cancer model (Schmid et al., Cancer Cell, 2011, 19, 715-727). A further study reported that PI3Kγ deficiency could ameliorate inflammation and tumor growth in mice having colitis-associated colon cancer, (Gonzalez-Garcia et al., Gastroenterology, 2010, 138, 1373-1384). Detailed mechanistic analysis indicates that tumor infiltration by CD11b+ myeloid cells can cause protumorigenic inflammation at tumor sites and PI3Kγ in the myeloid cells is critical in mediating signaling of various chemoattractants in bring the cells to the tumor (Schmid et al., Cancer Cell, 2011, 19, 715-727). Other studies suggest that PI3Kγ is also required for differentiation of naïve myeloid cells into M2 macrophges at tumor sites. M2 macrophages promote tumor growth and progression by secreting immunosuppressive factors such arginase 1, which depletes the tumor microenvironment of arginine, thereby promoting T-cell death and NK cell inhibition (Schmidt et al., Cancer Res. 2012, 72 (Suppl 1: Abstract, 411; Kaneda et al., Cancer Res., 74 (Suppl 19: Abstact 3650)).
- In addition to its potential role in promoting protumorigenic microenvironment, PI3Kγ may play a direct role in cancer cells. PI3Kγ is reported to be required for signaling from the Kaposi's sarcoma-associated herpevirus encoded vGPCR oncogene and tumor growth in a mouse model of sarcoma (Martin et al., Cancer Cell, 2011, 19, 805-813). PI3Kγ was also suggested to be required for growth of T-ALL (Subramanjam et al., Cancer Cell, 2012, 21, 459-472), PDAC and HCC cells (Falasca and Maffucci, Frontiers in Physiology, 2014, 5, 1-10). Moreover, in a survey of driver mutations in pancreatic cancer, PI3Kγ gene was found to contain second highest scoring predicted driven mutation (R839C) among the set of genes not previously identified as a driver in pancreatic cancer (Carter et al., Cancer Biol. Ther. 2010, 10, 582-587).
- Finally, PI3Kγ deficiency also has been reported to offer protection to experimental animals in different cardiovascular disease models. For examples, lack of PI3Kγ would reduce angiotension-evoked smooth muscle contraction and, therefore, protect mice from angiotension-induced hypertension (Vecchione et al., J. Exp. Med. 2005, 201, 1217-1228). In rigorous animal myocardial infarction models, PI3Kγ inhibition provided potent cardioprotection, reducing infarct development and preserving myocardial function (Doukas et al., Proc. Natl. Acad. Sci. USA, 2006, 103, 19866-19871).
- For these reasons, there is a need to develop new PI3Kγ inhibitors that can be used for the treatment of diseases such as cancer, autoimmune disorders, and inflammatory and cardiac diseases. This application is directed to this need and others.
- The present disclosure relates to, inter alia, compounds of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein constituent members are defined herein.
- The present disclosure further provides pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- The present disclosure further provides methods of inhibiting an activity of PI3Kγ kinase comprising contacting the kinase with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- The present disclosure further provides methods of treating a disease or a disorder associated with abnormal PI3Kγ kinase expression or activity in a patient by administering to said patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- The present disclosure further provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in any of the methods described herein.
- The present disclosure further provides use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in any of the methods described herein.
- The present application provides, inter alia, compounds of Formula (I):
- or a pharmaceutically acceptable salt thereof; wherein:
-
- W is CR1 or N;
- Z is CZ1 or N;
- X1 is CR1 or N;
- X2 is CR2 or N;
- X3 is CR3 or N;
- wherein X1, X2, and X3 are not each simultaneously N;
- R1, Z1, and R12 are each independently selected from H, D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, di(C1-3 alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
- R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, SRa1, NHORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NEc1Rd1, C(═NRe1)Rb1, NRc1C(═NCN)NRc1Rd1, BRc1C(═NRe1)Rb1, NRc1C(═NRe1)NRc1Rd1, (═NOH)NRc1Rd1, NRc1C(═NCN)NRc1Rd1, NRc1C(═RNe1)Rb1, NRc1S(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)(═NRe1)Rb1, OS(O)2Rb1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, S(O)2NRc1K S(O)(═NRe1)Rb1, OS(O)(═NRe1)Rb1, OS(O)2Rb1, SF5, P(O)Rf1Rg1, OP(O)(ORhl)(ORil), P(O)(ORh1)(ORil), and BRjlRkl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
- each R1and Rd1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra1, Rb1, Rc1 and Rd1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
- or, any Rc1 and Rd1, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
- each Re1 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl; each Rf1 and Rg1 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-; each Rhl and Ril is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rjl and Rkl is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Rjl and Rkl attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R1A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, OR a11, SRa11, NHORa11, C(O)Rb11, C(O)NRc11Rd11, C(O)NRc11(ORa11), C(O)ORa11, OC(O)Rb11, OC(O)NRc11Rd11, NRc11Rd11, NRc11NRc11Rd11, NRc11C(O)Rb11, NRc11C(O)ORa11, NRc11C(O)NRc11Rd11, C(═NRe11)Rb11, C(═NOH)Rb11, C(═NCN)Rb11, C(═NRe11)NRc11Rd11, NRc11C(═NRe11)NRc11Rd11, NRc11C(═NOH)NRc11Rd11, NRc11C(═NCN)NRc11Rd11, NRc11C(═NRe11)Rb11, NRc11S(O)NRc11Rd11, NRc11S(O)Rb11, NRc11S(O)2Rb11, NRc11S(O)(═NRe11)Rb11, NRc11S(O)2NRc11Rd11, S(O)Rb11, S(O)NRc11Rd11, S(O)2Rb11, S(O)2NRc11Rd11, S(O)(═NRe11(Rb11, OS(O)(═NRe11)Rb11, OS(O)2Rb11, SF5, P(O)Rf11Rg11, OP(O)(ORh1)(ORi11), P(O)(ORh1)(ORill), and BRjllRk11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra11, Rb11, Rc11, and Rd11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra11, Rb11, Rc11 and Rd11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Ra1 and Rd11, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Rell is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl; each Ra1 and Rb11 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each and Rill is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rjll and Rkll is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any Rjll and Rkll attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each RM is independently selected from D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, di(C1-3 alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
- R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2NRc2Rd2, NRc2(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2, Rd2, C(═NRe2)Rb2, C(═NOH)Rb2, C(═NCN)Rb2, C(═NRe2)NRc2Rd2, NRc2C(═NRe2)NR c2Rd2, NelRd2)Rb2, NRc2S(O)NR c2Rd2, NRc2S(O)Rb2, NRc2S(O)Rb2, NRc2S(O)(═NRe2)Rb2, OS(O)2Rb2, S(O)Rb2, S(O)NRc2, Rd2, S(O)2Rb2, S(O)2NR2eRd2, S(O)(═NRe2)Rb2, OS(O)(═NRe2)Rb2, OS(O)2Rb2, SFS, P(O)Rf2Rg2, OP(O)(ORb2)(ORi2), P(O)(ORb2)(OR12), and BRj2Rk2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2 -6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
- or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
- each Ree is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf2 and Rg2 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-; each Rh2 and Ri2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-; each R2 and Rk2 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any R2 and Rk2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl; each R2A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl,
- C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa21, SRa21, NHORa21, C(O)Rb21, C(O)NRc21Rd21, C(O)NRc21(ORa21), C(O)ORa21, OC(O)Rb21, OC(O)NRc21Rd21, NRc21Rd21, NRc2NRc21Rd21, NRc21C(O)Rb21, NRc21C(O)ORa21, NRc21C(O)NRc21Rd21, C(═NRe21)Rb21, C(═NOF)Rb21, C(═NCN)Rb21, (═NRe21)NRc21Rd21, NRc21C(═NRe21)Rc21Rd21, NRc21C(═NOH)NRc21Rd21, NRc21, (═NCN)NRc21Rd21, NRc21C(═NRe21)Rb21, NRc21, S(O)NRc21Rd21, NRc21S(O)Rb21, NRc21S(O)2Rb21, NRc21S(O)2NRc21Rd21, S(O)Rb21, S(O)NRc21Rd21, S(O)2Rb21, S(O)2NRc21Rd21, S(O)(═NRe21)Rb21, OS(O)(═NRe21)Rb21, OS(O)2Rb21, SF5, P(O)Rf21Rg21, OP(O)(ORh21)(ORi21), P(O)(ORh21)(ORi21), and BRj21Rk21, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each R a is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra21, Rb21, Rc21, and Rd21 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents; or, any Rc21 and Rd21, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R′ substituents; each Re21 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R121 and Rg21 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh21 and R′21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each R21 and Rk21 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any R21 and Rk21 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- or alternatively, R1 and R2, taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R1A groups;
- R3 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa3, SRa3, NHORa3, C(O)Rb3, C(O)NRc3Rd3, C(O)NRc3(ORa3), C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NR3Rd3, NR3NR3Rd3, NR3C(O)Rb3, NR3C(O)ORa3, NR3C(O)NRc3Rd3, C(═NRe3)Rb3, C(═NOH)Rb3, C(═NCN)Rb3, C(═NRe3)NR3Rd3, NRc3C(═NRe3)NRc3Rd3, NRc3C(═NOH)NRc3Rd3, NRc3C(═NCN)NRc3Rd3, NRc3C(═NRe3)Rb3,
- NRc3S(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)(═NRe3)Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(0)2Rb3, S(O)2NRc3Rd3, S(O)(═NRe3)Rb3, OS(O)(═NRe3)Rb3, OS(O)2Rb3, SFS, P(O)Rf3Rg3, OP(O)(ORh3)(OR13), P(O)(ORi3)(OR13), and BRJ3Rk, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R3 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents; each Ra3, Rb3, R3, and Rd3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra3, Rb3, R3 and Rd3 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rg3 and Rd3, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Rea is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R and Rg3 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh3 and R′3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each R3 and Rk3 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any R3 and Rk3 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- or alternatively, R2 and R3, taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2A groups;
- X4 is N or CR4;
- X5 is N or CR5;
- R4 and R5 are each independently selected from H, D, halo, CN, OH, NH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, cyano-C1-6 alkyl, HO—C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkylamino, di(C1-6 alkyl)amino, and C(O)NRa4Rb4;
- each R4 and Rb4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R4 and Rb4 are each optionally substituted with 1, 2, 3 or 4 independently selected RM substituents;
- or, any Ra4 and Rb4, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; X6 is N or CR6;
- R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa6, SRa6, NHORa6, C(O)Rb6, C(O)NR6Rd6, C(O)NR6(ORa6), C(O)ORa6, OC(O)Rb6, OC(O)NRc6m Rd6, NRc6, Rd6, NRc6NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)ORa6, NRc6C(O)NRc6, Rd6, C(═NRe6)Rb6, C(═NOH)Rb6, C(═NCN)Rb6, (═NRe6)NRc6Rd6, NRc6C(═NRe6)NRc6Rd6, NRc6C(═NRe6)Rb6, NRc6S(O)NRc6Rd6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)(═NRe6)Rb6, S(O)Rb6, S(O)NRc6 K S(O)2Rb6, S(O)2NRc6Rd6, S(O)(═NRe6)Rb6, OS(O)(═NRe6)Rb6, OS(O)2Rb6, SFS, P(O)Rf6Rg6, OP(O)(ORh6)(OR16), P(O)(ORh6)(OR16), and BRj6Rk6, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- each R6, tc-r.136, Rc6, and Rd6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6, tc-r.136, Rob and Rd6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- or, any Rcb and Rd6, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents; each Re6 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rj6 and Rk6 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh6 and R′6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each R6 and Rk6 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any R6 and Rk6 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R6A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa61, SRa61, NHORa61, C(O)Rb61, C(O)NRc61Rd61, C(O)NRc61(ORa61), C(O)ORa61, OC(O)Rb61, OC(O)NRc61Rd61, NRc61Rd61, NRc61NRc61Rd61, NRc61C(O)Rb61, NRc61C(O)ORa61, NRc61C(O)NRc61Rd61, C(═NRe61)Rb61, C(═NOH)Rb61, C(═NCN)RB61, C(═NRe61)NRc61Rd61, NRc61C(═NRe61)NRc61Rd61, NRc61C(═NOH)NHc61Rd61, NRc61C(═NCN)NRc61Rd61, NRc61C(═NRe61)Rb61, NRc61S(O)NRc61Rd61, NRc61S(O)Rb61, NRc61S(O)2Rb61, NRc61S(O)(═NRe61)Rb61, NRc61S(O)2NRc61Rd61, S(O)Rb61, S(O)NRc61Rd61, S(O)2Rb61, S(O)2NRc61Rd61, S(O)(═NRe61)Rb61, OS(O)(═NRe61)Rb61, OS(O)2Rb61, SF5, P(O)Rf61Rg61, OP(O)(ORh61)(ORi61), P(O)(ORh61)(ORi61), and BRj61Rk61, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6B substituents;
- each Ra61, Rb61, Rc61, and Rd61 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra61, Rb61, Rc61 and Rd61 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6B substituents; or, any Rc61 and Rd61, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6B substituents;
- each Re61 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf61 and Rg61 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-; each Rh61 and R′61 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rj61 and Rk61 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any RJ61 and Rk61 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R6B is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa62, SRa62, NHORa62, C(O)Rb62, C(O)NRc62Rd62, C(O)NRc62(ORa62), C(O)ORa62, OC(O)Rb62, OC(O)NRc62Rd62, NRc62Rd62, NRc62NRc62Rd62, NRc62C(O)Rb62, c62Rd62, (═NRe62)Rb62, C(═NOH)Rb62, C(═NCN)Rb62, (═NRe62)NRc62Rd62, NRc62C(═NRe62)NRc62Rd62, NRc62C(═NOH)NRc62Rd62, NRc62, (═NCN)NRc62Rd62, NRc62C(═NRe62)Rb62, NRc62S(O)NRc62Rd62, NRc62S(O)Rb62, NRc62S(O)2Rb62, NRc62S(O)(═NRe62)Rb62, NRc62S(O)2NRc62Rd62, S(O)Rb62, S(O)NRc62Rd62, S(O)2Rb62, S(O)2NRc62Rd62, S(O)(═NRe62)Rb62, OS(O)(═NRe62)Rb62, OS(O)2Rb62, SF5, P(O)Rf62Rg62, OP(O)(ORh62)(ORi62), P(O)(ORh62)(ORi62), and BRj62Rk62, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6B are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6C substituents;
- each Ra62, Rb62, Rc62, and Rd62 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra62, Rb62, Rc62 and Rd62 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6C substituents;
- or, any Rc62 and Rd62, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6C substituents;
- each Re62 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf62 and Rg62 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2,6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh62 and Ri62 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rj62 and Rk62 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Rj62 and Rk62 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R6C is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3,7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa63, SRa63, NHORa63, C(O)Rb63, C(O)NRc63Rd63, C(O)NRc63(ORa63), C(O)ORa63, OC(O)Rb63, OC(O)NRc63Rd63, NRc63Rd63, NRc63NRc63Rd63, NRc63C(O)Rb63, NRc63C(O)ORa63, NRc63C(O)NRc63Rd63, C(═NRe63)Rb63, C(═NOH)Rb63, C(═NCN)Rb63, C(═NRe63)NRc63)NRc63Rd63, NRc63C(═NRe63)NRc63Rd63, NRc63C(═NOH)NRc63Rd63, NRc63C(═NCN)NRc63Rd63, NRc63C(═NRe63)Rb63, NRc63S(O)NRc63Rd63, NRc63S(O)Rb63, NRc63S(O)2Rb63, NRc63S(O)(═NRe63)Rb63, NRc63S(O)2NRc63Rd63, S(O)Rb63, S(O)NRc63Rd63, S(O)2Rb63, S(O)2NRc63Rd63, S(O)(═NRe63)Rb63, OS(O)(═NRe63)Rb63, OS(O)2Rb63, SF5, P(O)Rf63Rg63, OP(O)(ORh63)(ORi63), P(O)(ORh63)(ORi63), and BRj63Rk63, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R6C are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra63, Rb63, Rc63, and Rd63 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2,6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ch6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra63, Rc63 and Rd63 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc63 and Rd63, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Re63 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf63 and Rg63 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rj63 and Rj63 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rj63 and Rk63 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Rj63 and Rk63 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- X7 is N, C, or CH;
- X8 is N, C, or CH;
- X9 is N, NR9N, O, S, S(O), S(O)2, CR9, or C(R9)2;
- X10 is N, NR10N, O, S, CR10, or C(R10)2;
- X11 is N, NR11N, O, S, CR11, or C(R11)2;
- wherein no more than three of X4, X5, X6, X7, and X8 are simultaneously N; and
- at least two of X7, X8, X9, X10, and X11 are independently selected from C, CH, CR9, C(R9)2, CR10, C(R10)2, CR11, and C(R11)2; and
- no two adjacent members of X9, X10, and X11 are simultaneously O, S, S(O) or S(O)2;
- provided that (a) when X7 is N, then X8 is C or CH; or (b) when X8 is N, then X7 is C or CH;
- R9N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb9N, C(O)NRc9N, C(O)ORa9N, C(═NRe9N)Rb9N, C(═NRe9N)NRc9NRd9N, C(═NCN)NRc9Rd9N, C(═NORa9N)NRc9N, S(O)2Rb9N, S(O)(═NRc9N)Rd9N, and S(O)2NRc9NRd9N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
- each Ra9N, Rb9N, Rc9N and Rd9N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra9N, Rb9N, Rc9N, and Rd9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
- or, any R′ and Rd9N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents; each R′ is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R9NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa9N2, SRa9N2, NHORa9N2, C(O)Rb9N2, C(O)NRc9N2Rd9N2, C(O)NRc9N2 (ORa9N2), C(O)ORa9N2, OC(O)Rb9N2, OC(O)NRc9N2Rd9N2, NRc9N2Rd9N2, NRc9N2NRc9N2Rd9N2, NRc9N2C(O)Rb9N2, NRc9N2-C(O)ORa9N2, NRc9N2C(O)NRc9N2Rd9N2, C(═NRe9N2)Rb9N2, C(═NOH)Rb9N2, C(═NCN)Rb9N2, C(═NRe9N2)NRc9N2Rd9N2, NRc9N2C(═NRe9N2)NRc9N2Rd9N2, NRc9N2, C(═NOH)NRc9N2Rd9N2, NRc9N2C(═NCN)NRc9N2Rd9N2, NRc9N2C(═NRe9N2)Rb9N2, NRc9N2S(O)NRc9N2Rd9N2, NRc9N2S(O)Rb9N2, NRc9N2S(O)2R b9N2, NRc9N2S(O)(═NRe9N2)Rb9N2, NRc9N2C(O)2NRc9N2Rd9N2, S(O)(═NRe9N2)Rb9N2, OS(O)2Rb9N2, SF5, P(O)Rf9N2Rg9N2, OP(O)(ORh9N2)(ORi9N2), P(O)(ORh9N2)(ORi9N2), and BRj9N2Rk9N2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R9NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra9N2, Rb9N2, Rc9N2, and Rd9N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 a9N2, R b9N2, Rc9N2 and Kd9N2 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc9N2 and Rd9N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Re9N2 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf9N2 and Rg91′ is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rh9N2 and R19N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each R′9N2 and Rk' is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Rj9N2 and Rk9N2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R9 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, OR 91, SRa91, NHORa91, C(O)Rb91, C(O)NRd91Rd91, C(O)NRc91(ORa91), C(O)ORa91, OC(O)Rb91, OC(O)NRORa91, NRc91Rd91, NRc91NRc91C(O)Rb91, NRc91C(O)Rb91, NRc91C(O)ORa91, NRc91C(O)NRc91Rd91, C(═NRe91)Rb91, C(═NOH)Rb91, C(═NCN)Rb91, (═NRe91)NRc91Rd91, NRc91C(═NRe91)NRc91Rd91, NRc91C(═NOH)NRc91Rd91, NRc91C(═NCN)NRc91Rd91, NRc91C(═NRe91)Rb91, Cc91S(O)NRc91, NRc91S(O)Rb91, NRc91S(O)2Rb91, NRc91S(O)(═NRe91)Rb91, NR91C(═NRe91)Rb91, NRc91S(O)NRc91Rd91, S(O)NRc91Rd91, S(O)2Rb91, S(O)2NRc91R91, S(O)(═NRe91)Rb91, OS(O)(═NRe91)Rb91, OS(O)2Rb91, SF5, P(O)Rf91Rg91, OP(O)(ORh91)(ORi91), P(O)(ORh91)(ORi91), and BRj91Rk91, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
- or, alternatively, two R9 groups together form an oxo group;
- Ra91, Rb91, Rc91, and Rd91 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra91, Rb91, Rc91 and Rd91 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
- or, any Rc91 and Rd91, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents; each Re91 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf91 and Rg91 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh91 and Ri9l is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each R91 and Rk91 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any R91 and Rk91 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R9A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, OR92, SRa92, NHORa92, C(O)Rb92, C(O)NRc92Rd92, C(O)NRc92(ORa92), C(O)ORa92, OC(O)Rb92, OC(O)NRc92Rd92, NRc92Rd92, NRc92NRc92Rd92, NRc92C(O)Rb92, NRc92C(O)ORa92, NRc92C(O)NRc92Rd92, C(═NRe92)Rb92, C(═NOH)Rb92, C(═NCN)Rb92, C(═NRe92)NRc92Rd92, NRc92Rd92, NRc92C(═NRe92)NRc92Rd92, NRc92C(═NOH)NRc92Rd92, NRc92C(═NCN)NRc92Rd92, NRc92C(═NRe92)Rb92, NRc92S(O)NRc92Rd92, NRc92S(O)Rb92, NRc92S(O)2Rb92, NRc92S(O)(═NRe92)Rb92, NRc92S(O)2NRc92Rd92, S(O)Rb92, S(O)NRc92Rd92, S(O)2Rb92, S(O)2NRc92Rd92, S(O)(═NRe92)Rb92, OS(O)(═NRe92)Rb92, OS(O)2Rb92, SF5, P(O)Rf92Rg92, OP(O)(ORh92)(ORi92(ORi92), P(O)(ORh92)(ORi92), and BRj92Rk92, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R9A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra92, Rb92, Rc92, and Rd92 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra92, Rb92, Rc92 and Rd92 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc92 and Rd92, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Re92 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf92 and Rg92 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rh92 and Ri92 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rj92 and Rk92 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Rj92 and Rk92 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb10N, C(O)NRc10NRd10N, C(O)ORa10N, C(═NRe10N)Rb10N, S(O)(═NRc10N)NRd10N, and S(O)2NRc10NRd10N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
- each Ra10N, Rb10N, Rc10N, and Rd10N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N, Rb10N, Rc10N, and Rd10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
- or, any Rc10N and Rd10N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
- each Re10N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R10NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa10N2, SRa10N2, NHORa10N2, C(O)Rb10N2, C(O)NRc10N2Rd10N2, C(O)NRc10N2(ORa10N2), C(O)ORa10N2, SRa10N2, NHORa10N2, C(O)Rb10N2, NRc10N2Rd10N2, NRc10N2NRc10N2Rd10N2, NRc10N2C(O)Rb10N2, NRc10N2C(O)ORa10N2, NRc10N2C(O)NRc10N2Rd10N2, C(═NRe10N2)Rb10N2, C(═NOH)Rb10N2, C(═NCN)Rb10N2, C(═NRe10N2)NRc10N2Rd10N2, NRc10N2C(═NRe10N2)NRc10N2Rd10N2, NRc10N2C(═NOH)NRc10N2Rd10N2, NRc10N2C(═NCN)NRc10N2Rd10N2, NRc10N2C(═NRe10N2)Rb10N2, NRc10N2S(O)NRc10N2Rd10N2, NRc10N2S(O)Rb10N2, NRc10N2S(O)2Rb10N2S(O)(═NRe10N2)Rb10N2, NRc10N2S(O)2NRc10N2, Rd10N2, S(O)Rb10N2, S(O)NRc10N2Rd10N2, S(O)2Rb10N2, S(O)2NRc10N2Rd10N2, S(O)(═NRe10N2)Rb10N2, OS(O)(═NRe10N2)Rb10N2, OS(O)2Rb10N2, SF5, P(O)Rf10N2Rg10N2, OP(O)(ORh10N2)(ORi10N2), P(O)(ORh10N2)(ORi10N2), and BRj10N2Rk10N2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R10NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra10N2, Rb10N2, Rc10N2, and Rd10N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N2, Rb10N2, Rc10N2 and Rd10N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc10N2 and Rd10N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Re10N2 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf10N2 and Rg10N2 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rh10N2 and Ri10N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rj10N2 and Rk10N2 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Rj10N2 and Rk10N2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R10 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa101, SRa101, NHORa101, C(O)Rb101, C(O)NRc101Rd101, C(O)NRc101(ORa101), C(O)ORa101, OC(O)Rb101, OC(O)NRc101Rd101, NRc101Rd101, NRc101NRc101Rd101, NRc101C(O)Rb101, C(O)ORa101, NR101C(O)NRc101Rd101, C(═NRe101)Rb101, C(═NOH)Rb101, C(═NCN)Rb101, C(═NRe101)NRc101Rd101, NRc101C(═NRe101)NRc101Rd101, NRc101C(═NOH)NRc101Rd101C(═NCN)NRc101Rd101, NRc101C(═NRe101)Rb101, NRc101S(O)NRc101Rd101, NRc101S(O)Rb101, NRc101S(O)2Rb101, NRc101S(O)(═NRe101)Rb101, NRc101S(O)2NRc101Rd101, S(O)Rb101, S(O)NRc101Rd101, S(O)2Rb101, S(O)2NRc101Rd101, S(O)(═NRe101)Rb101, OS(O)(═NRe101)Rb101, OS(O)2Rb101, SF5, P(O)Rf101Rg101, OP(O)(ORh101)(ORi101), P(O)(ORh101)(ORi101), and BRj101Rk101, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10A substituents;
- or, alternatively, two R10 and Rd101 groups together form an oxo group;
- each Ra101, Rb101, Rc101, and Rd101 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra101, Rb101, Rc101 and Rd101 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10A substituents;
- or, any Rc101 and Rd101, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10A substituents;
- each Re101 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf101 and Rg101 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh101 and Ri101 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rj101 and Rk101 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Rj101 and Rk101 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R10A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa102, SRa102, NHORa102, C(O)Rb102, C(O)NRc102Rd102, C(O)NRc102(ORa102), C(O)ORa102, OC(O)Rb102, OC(O)NRc102Rd102, NRc102Rd102, NRc102NRc102Rd102, NRc102C(O)Rb102, NRc102C(O)ORa102, NRc102C(O)NRc102Rd102, C(═NRe102)Rb102, C(═NOH)Rb102, C(═NCN)Rb102, C(═NRe102)NRc102Rd102, NRc102C(═NRe102)NRc102Rd102, NRc102C(═NOH)NRc102Rd102, NRc102C(═NCN)NRc102Rd102, NRc102C(═NRe102)Rb102, NRc102S(O)NRc102Rd102, NRc102S(O)Rb102, NRc102S(O)2Rb102, NRc102S(O)(═NRe102)Rb102, NRc102S(O)2NRc102Rd102, S(O)Rb102, S(O)NRc102Rd102, S(O)2Rb102, S(O)2NRc102Rd102, S(O)(═NRe102)Rb102, OS(O)(═NRe102)Rb102, OS(O)2Rb102, SF5, P(O)Rf102Rg102, OP(O)(ORh102)(ORi102), P(O)(ORh102)(ORi102), and BRj102Rk102, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R10A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra102, Rb102, Rc102, and Rd102 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra102, Rb102, Rc102 and Rd102 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc102 and Rd102, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Re102 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf102) and Rg101)2 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rh102 and Ri102 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rj102 and Rk102 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Rj102 and Rk102 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- R11N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb11N, C(O)NRc11NRd11N, C(O)ORa11N, C(═NRe11N)Rb11N, C(═NRe11N)NRc11NRd11N, C(═NCN)NRc11NRd11N, C(═NORa11N)NRc11N, S(O)2Rb11N, S(O)(═NRc11N)Rd11N, and S(O)2NRc11NRd11N, wherein the C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
- each Ra11N, Nb11N, Rc11N and Rd11N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra111, Rb111, Rc111, and Rd111 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
- or, any Ram and Rd', attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
- each R11NA is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R11NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6alkyl-, CN, NO2, ORa11N2, SRa11N2, NHORa11N2, C(O)Rb11N2, C(O)NRc11N2Rd11N2, C(O)NRc11N2(ORa11N2), C(O)ORa11N2, OC(O)Rb11N2, OC(O)NRc11N2Rd11N2, NRc11N2Rd11N2, NRc11N2NRc11N2Rd11N2, NRc11N2C(O)Rb11N2, NRc11N2C(O)ORa11N2, NRc11N2C(O)NRc11N2Rd11N2, C(═NRe11N2)Rb11N2, C(═NOH)Rb11N2, C(═NCN)Rb11N2, C(═NRe11N2)NRc11N2Rd11N2, NRc11N2C(═NRe11N)NRc11N2, NRc11N2C(═NOH)NRc11N2Rd11N2, NRc11N2C(═NCN)NRc11N2Rd11N2, NRc11N2C(═NRe11N2)Rb11N2, NRc11N2S(O)NRc11N2Rd11N2, NRc11N2C(O)Rb11N2, NRc11N2S(O)2Rb11N2, NRc11N2S(O)(═NRe11N2Rb11N2, NRc11N2S(O)2NRc11N2Rd11N2, S(O)Rb11N2, S(O)NRc11N2Rd11N2, S(O)2Rb11N2, S(O)2NRc11N2Rd11N2, S(O)(═NRe11N2)Rb11N2, OS(O)(═NRe11N2Rb11N2, OS(O)2Rb11N2, SF5, P(O)Rf11N2Rg11N2, OP(O)(ORh11N2)(ORillN2), P(O)(ORh11N2(ORi11N2), and BRj11N2Rk11N2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R11NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra11N2, Rb11N2, Rc11N2, and Rd11N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra11N2, Rb11M2, Rc11N2 and Rd11N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; or, any Rc11N2 and Rd11N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; each Rel' is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf1' and Rgl' is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rh11N2 and Rj11N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-; each Ri11N2 and Rk11N2 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Ri11N2 and Rk11N2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R11 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa111, SRa111, NHORa111, C(O)Rb111, C(O)NRc111Rd111, C(O)NRc111(ORa111), C(O)ORa111, OC(O)Rb111, OC(O)NRc111Rd111, NRc111Rd111, NRc111, NRc111, Rd111, NRc111C(O)Rb111, NRc111C(O)ORa111, NRb111C(O)NRc111Rd111, C(═NRe111)Rb111, C(═NOH)Rb111, C(═NCN)Rb111, C(═NRe111)NRc111Rd111, NRc111C(═NRe111)Rb111, NRc111S(O)NRc111Rd111, NRc111S(O)Rb111, NRc111S(O)2Rb111, NRc111S(O)(═NRe111)Rb111, NRc111S(O)2NRc111Rd111, S(O)Rb111, S(O)NRc111Rd111, S(O)2Rb111, S(O)2NRc111Rd111, S(O)(50 NRe111)Rb111, OS(O)(═NRe111)Rb111, OS(O)2Rb111, SF5, P(O)Rf111Rg111, OP(O)(ORh111(ORi111), P(O)(ORh111)(ORi111), and BRj111Rk111, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents;
- or, alternatively, two R11 groups together form an oxo group;
- each Ra111, Rb111, Rc111, and Rd111 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra111, Rb111, Rc111 and Rd111 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents;
- or, any Rc111 and Rd111, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents;
- each Rem is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R11 and R111 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each R11 and R11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each R′111 and Rk111 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any Ri111 and Rk111 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl; and each R11A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered a112 sRa112, mioRa112, C(O)Rb112, C(O)NRc112Rd112, heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa112, SRa112, NHORa112, C(O)Rb112, C(O)NRc112Rd112, C(O)NRc112(ORa112), C(O)ORa112, OC(O)Rb112, OC(O)NRc112Rd112, NRc112Rc112Rd112, NRc112C(O)Rb112, NRc112C(O)ORa112, NRc112C(O)NRc112Rd112, C(═NRe112)Rb112, C(═NOH)Rb112, C(═NCN)Rb112, C(═NRe112)NRc112Rd112, NRc112C(═NRe112)NRc112Rd112, NRc112C(═NOH)NRc112Rd112, NRc112C(═NCN)NRc112Rd112, NRc112C(═NRe112)Rb112, NRc112S(O)NRc112Rd112, NRc112S(O)Rb112, NRc112S(O)2Rb11, NRc112S(O)(═NRe112)Rb112, NRc112S(O)2NRc112Rd112, S(O)Rb112, S(O)NRc112Rd112, S(O)2Rb112, S(O)2NRc112Rd112, S(O)(═NRe112)Rb112, OS(O)(═NRe112)Rb112, OS(O)2Rb112, SF5, P(O)Rf112Rg112, OP(O)(ORh112)(ORi112), P(O)(ORh112)(ORi112), and BRj112Rk112, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R11A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra112, Rb112, Rc112, Rd112 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra112, Ra112, Rc112 are Rd112 each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc112 and Rd112, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Re112 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf112 and Rg112 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-; each Rh112 and Ri112 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
- each Rj112 and Rk112 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Rj112 and Rk112 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl.
- In some embodiments, Formula (I) is as otherwise defined above, wherein:
- R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa6, SRa6, NHORa6, C(O)Rb6, C(O)NRc6Rd6, C(O)NRc6(ORa6), C(O)ORa6, OC(O)Rb6, OC(O)NRc6Rd6, NRc6Rd6, NRc6NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)ORa6, NRc6C(O)NRc6Rd6, C(═NRe6)Rb6, C(═NOH)Rb6, C(═NCN)Rb6, C(═NRe6)NRc6Rd6, NRc6C(═NRe6)NRc6Rd6, NRc6Rd6, NRc6C(═NOH)NRc6Rd6, NRc6C(═NCN)NRc6Rd6, NRd6c(═NRe6)Rd6, NRc6S(O)NRc6Rd6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)2NRc6Rd6, S(O)Rb6, S(O)NRc6, Rd6, S(O)2Rb6, S(O)2NRc6Rd6, S(O)(═NRe6)Rb6, N═S(O)Ra6Rb6, OS(O)(═NRe6)Rb6, OS(O)2Rb6, SF5, P(O)Rf6Rg6, OP(O)(ORh6)(ORi6), P(O)(ORh6)(ORi6), and BRJ6Rk6, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents.
- In some embodiments,
-
- W is CW1 or N;
- Z is CZ1 or N;
- X1 is CR1 or N;
- X2 is CR2 or N;
- X3 is CR3 or N;
- wherein X1, X2, and X3 are not each simultaneously N;
- W1, Z1, and R12 are each independently selected from H, D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, di(C1-3 alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
- R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, SRa1, NHORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1, Rd1, NRclRd1, NRc1NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(═NRe1)Rb1, C(═NOH)Rb1, C(═NCN)Rb1, C(═NRe1)NRc1Rd1, NRclC(═NRe1)NRc1Rd1, NRc1C(═NOH)NRc1Rd1, NRc1C(═NCN)NRc1Rd1, NRc1C(═NRe1)Rb1, NRc1S(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)(═NRe1)Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, S(O)2NRc1Rd1, S(O)(═NRe1)Rb1OS(O)(═NRe1)Rb1, OS(O)2Rb1, SF5, P(O)Rf1Rg1, OP(O)(ORh1(ORi1), P(O)(ORh1)(ORi1), and BRj1Rk1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra1, Rb1, Rc1, and Rd1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra1, Rb1, Rc1 and Rai are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents; or, any Rc1 and Rd1, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Rcl is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf1 and Rg1 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rm and Rd is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-; each R′ and Rid is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any R′ and Rid attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl; each RM is independently selected from D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl,
- C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, di(C1-3 alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino; R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(═NRe2)Rb2, C(═NOH)Rb2, C(═NCN)Rb2, C(═NRe2NRc2Rd2, NRc2C(═NRe2)NRc2Rd2, NRc2C(═NOH)NRc2Rd2, NRc2C(═NCN)NRc2Rd2, NRc2C(═NRe2)Rb2, NRc2S(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)(═NRe2)Rb2, NRc2S(O)2Nc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, S(O)2NRc2Rd2, S(O)(═NRe2)Rb2, OS(O)(═NRe2)Rb2, OS(O)2Rb2, SF5, P(O)Rf2Rg2, OP(O)(ORh2(ORi2), P(O)(ORh2(OR12), and BRj2Rk2, wherein the C1-16 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
- or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
- each Re2 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rh2 and Ri2 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh2 and R′2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each RJ2 and Ru is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any R2 and Rkz attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl; each R2A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl,
- C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa21, SRa21, NHORa21, C(O)Rb21, C(O)NRc21Rd21, C(O)NRc21(ORa21), C(O)ORa21, OC(O)Rb21, OC(O)NRc21Rd21, NRc21Rd21, NRc21NRc21Rd21, NRc21C(O)Rb21, NRc21C(O)ORa21, NRc21C(O)NRc21Rd21, C(═NRe21)Rb21, C(═NOH)Rb21, C(═NCN)Rb21, C(═NRe21NRc21Rd21, NRc21C(═NRe21)NRc21Rd21, NRc21C(═NOH)NRc21Rd21, NRc21C(═NCN)NRc21Rd21, NRc21C(═NRe21)Rb21, NRc21S(O)NRc21Rd21, NRc21S(O)Rb21, NRc21S(O)2Rb21, NRc21S(O)(═NRe21)R21, NRc21S(O)2NRc21Rd21, S(O)Rb21, S(O)NRc21Rd21, S(O)2Rb21, S(O)2NRc21Rd21, S(O)(═NR21)Rb21, OS(O)(═NRe21)Rb21, OS(O)2Rb21, SF5, P(O)Rf21Rg21, OP(O)(ORh21)(ORi21), P(O)(ORh21)(OR121), and BRj21Rk21, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra21, Rb21, Rc21, and Rd21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl,
- C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Raz' Rb21, Rc21 and -d21 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rai and Rd21, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Re21 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl; each R121 and Rg21 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-; each Rb21 and R′21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each R21 and Rk21 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any R21 and Rk21 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- or alternatively, R1 and R2, taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R1A groups;
- each R1A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, OR a11, SRa11, NHORa11, C(O)Rbil, C(O)NRc11 K C(O)NRcll(ORall), C(O)ORa11, OC(O)Rb11, OC(O)NRc11 Rc11, NR c11, NRa11NRc11Rc11, NRc11(O)Rb11, Rc11,
- RC(O)ORa11, and NR11C(O)NRc11Rd11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra11, Rb11, Rc11, and Rd11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Rall RN' Rai and Rall are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rai and Rd11, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- R3 is selected H, D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, CI-3 alkylsulfonylamino, aminosulfonyl, CI-3 alkylaminosulfonyl, di(C1-3 3 alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
- or alternatively, R2 and R3, taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2A groups;
- X4 is N or CR4; X5 is N or CR5; R4 and R5 are each independently selected from H, D, halo, CN, OH, NH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, cyano-C1-6 alkyl, HO-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkylamino, di(C1-6 alkyl)amino, and C(O)NRa4Rb4;
- each R4 and Rb4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R4 and Rb4 are each optionally substituted with 1, 2, 3 or 4 independently selected RM substituents; or, any Rao and Rb4, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; X6 is N or CR6;
- R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa6, SRa6, NHORa6, C(O)Rb6, C(O)NRc6Rd6, C(O)NRc6(ORa6), C(O)ORa6, OC(O)Rb6, OC(O)NRc6Rd6, NRc6Rd6, NRc6NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)ORa6, NRc6C(O)NRc6Rd6, C(═NRe6)Rb6, C(═NOH)Rb6, C(═NCN)Rb6, C(═NRe6)NRc6Rd6, NRc6C(═NRe6)NRc6Rd6, NRc6C(═NOH)NRc6Rd6, BRc6C(═NRe6)Rb6, NRc6S(O)NRc6Rd6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)(═NRe6)Rb6, NRc6S(O)2NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, S(O)2NRc6Rd6, S(O)(═NRe6)Rb6, OS(O)(═NRe6)Rb6, OS(O)2Rb6, SF5, P(O)Rf6Rg6, OP(O)(ORh6)(ORi6), P(O)(ORh6(ORi6), and BRj6Rk6, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- each Ra6, Rb6, Rc6, and Rd6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of W6 Kb6, Rob and Rd6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- or, any Rc6 and Rd6, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- each Re6 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl; each Rf6 and Rg6 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-; each Rh6 and R′6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl,
- C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each R6 and Rk6 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any R6 and Rk6 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- each R6A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, OR a61, SRa61, NHORa61, C(O)Rb61, C(O)NRc61Rd61, C(O)NRc61(ORa61), C(O)ORa61, OC(O)Rb61, OC(O)NRc1Rd61, NRc61Rd61, NRc61NRc61Rd61, NRc61, C(O)Rb61, NRc61C(O)ORa61, NRc61Rd61, C(═NRe61)Rb61, C(═NOH)Rb61, C(═NCN)Rb61, C(═NRe61)NRc61Rd61, NRc61C(═NRe61)NRc61Rd61, NRc61C(═NOH)NRc61Rd61, NRc61C(═NCN)NRc61Rd61, NRc61C(═NRe61)Rb61, NRc61S(O)NRc61Rd61, NRc61S(O)Rb61, NRc61S(O)2Rb61, NRc61S(O)(═NRe61)Rb61, NRc61S(O)2NRc61Rd61, S(O)Rb61, S(O)NRc61Rd61, S(O)2Rb61, S(O)2NRc61Rd61, S(O)(═NRe61)Rb61, OS(O)(═NRe61)Rb61, OS(O)2Rb61, SF5, P(O)Rf61Rg61, OP(O)(ORh61)(ORi61), P(O)(ORh61)(ORi61), and BRj61Rk61, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra61, Rb61, Rc61, and Rd61 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl,
- C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra61, Rb61, Rc61 and Rd61 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Re61 and Rd61, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Re61 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl; each Rf61 and Rg61 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh61 and R′61 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each R61 and Rk61 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any R61 and Rk61 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- X7 is N, C, or CH; X8 is N, C, or CH; X9 is N, NR9N, 0, S, S(O), S(O)2, CR9, or C(R9)2;
- X10 is N, NR10N, 0, S, CR10 , or C(R10)2; X11 is N, NR11N, 0, S, CR11, or C(R11)2; wherein no more than three of X4, X5, X6, X7, and X8 are simultaneously N; and at least two of X7, X8, X9, Xl° , and X11 are independently selected from C, CH, CR9, C(R9)2, CR10 , C(R10)2, CR11, and C(R11)2; and no two adjacent members of X9, Xl° , and X11 are simultaneously 0, S, S(O) or S(O)2; provided that (a) when X7 is N, then X8 is C or CH; or (b) when X8 is N, then X7 is C or CH;
- R9N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb9N, C(O)NRc9NRd9N, C(O)ORa9N, C(═NRe9N)Rb9N, C(═NRe9N)NRc9NRd9N, C(═NCN)NRc9NRd9N, C(═NORa9N)NRc9N, S(O)2Rb9N, S(O)(═NRc9N)Rd9N, and S(O)2NRc9NRd9N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- Ra9N, Rb9N, Rc9N and Rd9N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra9N, Rb9N, Rc9N, and Rd9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rc9N and Rd9N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each R9 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R9 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa91, SRa91, NHORa91, C(O)Rb91, C(O)NRc91Rd91, C(O)NRc91(ORa91), C(O)ORa91, OC(O)Rb91, OC(O)NRc91Rd91, NRc91Rd91, NRc91NRc91Rd91, NRc91C(O)Rb91, NRc91C(O)ORa91, NRc91C(O)NRc91Rd91, C(═NRe91)Rb91, C(═NOH)R691, C(═NCN)Rb91, C(═NRe91)NRc91Rd91, NRc91C(═NRe91)NRc91Rd91, NRc91C(═NOH)NRc91Rd91, NRc91C(═NCN)NRc91Rd91, NRc91C(═NRe91)Rb91, NRc91S(O)NRc91Rd91, NRc91S(O)Rb91,NRc91S(O)2Rb91, NRc91S(O)(═NRe91)Rb91, NRx91S(O)2NRc91Rd91, S(O)Rb91, SO)NRc91Rd91, S(O)2Rb91, S(O)2NRc91Rd91, S(O)(═NRe91)Rb91, OS(O)(═NRe91)Rb91, OS(O)2Rb91, SF5, P(O)Rf91Rg91, OP(O)(ORh91(ORi91), P(O)(ORi91)and BRj91Rk91, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, alternatively, two R9 groups together form an oxo group;
- each Ra91, Rb91, Rc91, and Rd91 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra91 K1391 Rc91 and Rd91 are each and -C optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Re91 and Rd91, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents; each Re91 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each el and Rg91 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh91 and Ri91 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-; each R91 and Rk91 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any R91 and Rk91 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl;
- R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb10N, C(O)NRc10Rd10N, C(O)ORa10N, C(═NRe10N)Rb10N, C(═NRe10N)NRc10NRd10N, C(═NCN)NRc10NRd10N, C(═NORa10N)NRc10N, S(O)2Rb10N, S(O)(═NRc10N)Rd10N, and S(O)2NRc10NRd10N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra10N, Rb01, Rc10N, and Rd10N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N, Rb101N, Rc10N, and Rd10N are
- each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rm and Rd', attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents; each Rel° N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R10 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa101, SRa101, NHORa101, C(O)Rb101, C(O)NRc101Rd101, C(O)NRc101(ORa101), C(O)ORa101, OC(O)Rb101, OC(O)NRc101Rd101, NRc101Rd101, NRc101NRc101Rd101, NRc101C(O)Rb101, NRc101C(O)ORa101, NRc101C(O)NRc101Rd101, C(═NRe101)Rb101, C(═NOH)Rb101, C(═NCN)Rb101, C(═NRe101)NRc101Rd101, NRc101C(═NRe101)NRc101Rd101, NRc101C(═NOH)NRc101Rd101, NRc101C(═NCN)NRc101Rd101, NRc101C(═NRe101)Rb101, NRc101S(O)NRc101Rd101, NRc101S(O)Rb101, NRc101S(O)2Rb101, NRc101S(O)(═NRe101)Rb101, NRc101S(O)2NRc101Rd101, S(O)Rb101, S(O)NRc101, Rd101, S(O)2Rb101, S(O)2NRc101Rd101, S(O)(═NRe101)Rb101, OS(O)(═NRe101)Rb101, OS(O)2Rb101, SF5, P(O)Rf101Rg101, OP(O)(ORh101)(ORi101), P(O)(ORh101)(ORi101), and BRj101Rk101, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, alternatively, two R10 groups together form an oxo group;
- each and Ra101, Rb101, Rc101, and Rd101 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra101, Rb101, Rc101 and Rd101 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any iv attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Rd 01 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Re101 and Rg101 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh101 and Ri101 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rj101 and Rk101 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy; or any Rj101 and Rk101 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl; R′ is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered INRd11N C(O)ORa1 lN, c(═NRe11N)Rb11N, heterocycloalkyl)-C1-6 alkyl-, C(O)Rb11N, C(O)NRc1 (═NRellN)NRcl1NRdllN C(═NCN)NRcliNRdllN c(—NORa11N)NRc11N s(O)2Rb11N,
- S(O)(=RN cl1N)RdllN, and S(O)2NRc11NRd11N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra11N, Rb11N, Rc11N, and Rd11N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra11N, Rb111, Rc11N, and Rd11N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Ram and Rd', attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Re11N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R11 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORdin, SRa111, NHORa111, C(O)Rb111, C(O)NRc111Rd111, C(O)NRc111(ORa111), C(O)ORa111, OC(O)Rb111, OC(O)NRc111Rd111, NRc111Rd111, NRc111NRc111Rd111, NRc111C(O)Rb111, NRc111C(O)ORa111, NRc111C(O)NRc111Rd111, C(═NRe111)Rb111, C(═NOH)Rb111, C(═NCN)Rb111, C(═NRe111)NRc111Rd111, NRc111C(═NRe111)NRc111Rd111, NRc111C(═NOH)NRc111Rd111, NRc111C(═NCN)NRc111Rd111, NRc111C(═NRe111)Rb111, NRc111S(O)NRd111, NRc111S(O)Rb111, NRc111S(O)2Rb111, NRc111S(O)(═NRe111)Rb111, NRc111S(O)2NRc111Rd111, S(O)Rb111, S(O)NRc111Rd111, S(O)2Rb111, S(O)2NRc111Rd111, S(O)(═NRe111)Rb111, OS(O)(═NRe111)Rb111, OS(O)2Rb111, SF5, P(O)Rf111Rg111, OP(O)(ORh111)(ORi111), P(O)(ORh111)(ORi111), and BRj111Rk111, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, alternatively, two R11 groups together form an oxo group;
- each Ra111, Rb111, Rc111, and Rd111 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra111, Rb111, Rc111 and Rd111 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rc111 and Rd111, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Re111 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each Rf111 and Rg111 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rh111 and Ri111 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered hetereocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered hetereocycloalkyl)-C1-6 alkyl-;
- each Rj111 and Rk111 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
- or any Rj111 and Rk111 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, and 4-10 membered hetereocycloalkyl.
- In some embodiments, X1 is N.
- In some embodiments, X1 is CR1.
- In some embodiments, R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, NHORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1 are each optionally substituted with 1, 2, 3 or 4 independently selected R1A substituents; and
- each Ra1, Rb1, Rc1 and Rd1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra1, Rb1, Rc1 and Rd1 are each optionally substituted with 1, 2, 3, or 4 independently selected R1A substituents;
- or, any Rd1 and Rd1, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R1A substituents.
- In some embodiments, R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, SRa1, NHORa1, C(O)Rb1,C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NR1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, S(O)Rb1, S(O)NRc1Rdl, S(O)2Rb1, and S(O)2NRc1Rd1.
- In some embodiments, R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, SRa1, NHORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rc1, NR1C(C)RM, NR1C(O)ORa1, and NRc1C(O)NRc1Rd1.
- In some embodiments, R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, and NO2.
- In some embodiments, R1 is selected from H and C1-6 alkyl.
- In some embodiments, R1 is selected from H and methyl.
- In some embodiments, R1 is H.
- In some embodiments, R1 is C1-3 alkyl.
- In some embodiments, R1 is methyl.
- In some embodiments, X2 is N.
- In some embodiments, X2 is CR2.
- In some embodiments, R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2NRc2Rd2, NRc2C(O)Rb2, r-c2
- RC(O)ORa2, NRc2C(O)NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2,
- S(O)2Rb2, and S(O)2NRc2Rd2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2 are each optionally substituted with 1, 2, 3, or 4 independently selected R2A substituents; and each Raz, R132, RC2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Raz, R132, RC2 and Rd2 are each optionally substituted with 1, 2, 3, or 4 independently selected R2A substituents;
- or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R2A substituents. In some embodiments, R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, S(O)Rb2, S(O)Rb2, S(O)MRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2 are each optionally substituted with 1, 2, 3, or 4 independently selected R2A substituents; and
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Ra2, Kb2, Rc2 and Rd2 are each, optionally substituted with 1 or 2 independently selected R2A substituents. In some embodiments, R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2.
- In some embodiments, R2 is selected from H, C1-6 alkyl, C(O)Rb2, C(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2.
- In some embodiments, R2 is selected from C1-6 alkyl and C(O)NRc2Rd2.
- In some embodiments, R 2 is selected from H, C1-6 alkyl, C(O)Rb2, and C(O)NRc2Rd2.
- In some embodiments, each Ra2, R b2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents.
- In some embodiments, each Rb2 Rc2 and Rd2 is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl and 4-7 membered heterocycloalkyl, wherein the C1-6 alkyl, C3-7 cycloalkyl and 4-7 membered heterocycloalkyl of Rb2 Rc2 and Rd2 are each optionally substituted with 1 or 2, independently selected R2A substituents.
- In some embodiments, Rb2 is a 4-7 membered heterocycloalkyl group optionally substituted with 1 or 2 independently selected R2A substituents.
- In some embodiments, Rb2 is selected from azetidinyl and 2-oxa-6-azaspiro[3.3]heptanyl, each optionally substituted with 1 or 2 independently selected R2A substituents.
- In some embodiments, each Rc2 and Rd2 is independently selected from H, C1-6 alkyl, C3-7 cycloalkyl and 4-7 membered heterocycloalkyl, wherein the C1-6 alkyl, C3-7 cycloalkyl and 4-7 membered heterocycloalkyl of Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents.
- In some embodiments, Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1 or 2 independently selected R2A substituents.
- In some embodiments, each Rc2 and Rd2 is independently selected from H, methyl, ethyl, isopropyl, tetrahydropyranyl, bicyclo[1.1.1]pentanyl, cyclobuytl, bicycle [2.1.1]hexan-lyl, 2-oxa-6-azaspiro[3.3]heptanyl, sec-butyl, azetidinyl, and tetrahydrofuranyl, wherein each methyl, ethyl, isopropyl, tetrahydropyranyl, bicyclo[1.1.1]pentanyl, cyclobuytl, bicycle [2.1.1]hexan-lyl, 2-oxa-6-azaspiro[3.3]heptanyl, sec-butyl, azetidinyl, and tetrahydrofuranyl are optionally substituted with 1 or 2 independently selected R2A substituents; or Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form an azetidinyl or 2-oxa-6-azaspiro[3.3]heptanyl which are each optionally substituted with 1 or 2 independently selected R2A substituents.
- In some embodiments, each R2A is independently selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, and OH.
- In some embodiments, each R2A is independently selected from F, methyl, CF3, CN, and
- OH.
- In some embodiments, Rb2 is selected from azetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-hydroxyazetidin-1-yl and 2-oxa-6-azaspiro[3.3]heptan-6-yl. In some embodiments, each Rc2 and Rd2 is independently selected from H, methyl, ethyl, isopropyl, tetrahydro-2H-pyran-4-yl, bicyclo[1.1.1]pentanyl, cyclobut-1-yl, 3-hydroxycyclobut-1-yl, 1,1,1-trifluoropropan-2-yl, 4-cyanobicyclo[2.1.1]hexan-1-yl, 2-oxaspiro[3.3]heptan-6-yl, sec-butyl, 1-methylazetidin-3-yl, and tetrahydrofuran-3-yl;
- or Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form an azetidin-1-yl, 3,3-difluoroazetidin-1-yl, 3-hydroxyazetidin-1-yl or 2-oxa-6-azaspiro[3.3]heptan-6-yl group.
- In some embodiments, each Rc2 and Rd2 is independently selected from H, C1-6 alkyl, and 4-6 membered heterocycloalkyl, wherein the C1-6 alkyl and 4-6 membered heterocycloalkyl of Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents. In some embodiments, each Rc2 and Rd2 is independently selected from H, C1-6 alkyl, and 4-6 membered heterocycloalkyl.In some embodiments, each Rc2 and Rd2 is independently selected from H, methyl, isopropyl, and tetrahydropyranyl.
- In some embodiments, R2 is selected from C1-6 alkyl and C(O)NW2Rd2, wherein Rc2 and Rd2 are each independently selected from H, C1-6 alkyl, and 4-6 membered heterocycloalkyl. In some embodiments, R2 is selected from C1-6 alkyl and C(O)NW2Rd2, wherein each Rc2 and Rd2 is independently selected from H, methyl, isopropyl, and tetrahydropyranyl.
- In some embodiments, R2 is selected from H, methyl, methylaminocarbonyl, dimethylaminocarbonyl, tetrahydropyranylaminocarbonyl, and isopropylaminocarbonyl.
- In some embodiments, R2 is selected from methyl, methylaminocarbonyl, dimethylaminocarbonyl, tetrahydropyranylaminocarbonyl, and isopropylaminocarbonyl.
- In some embodiments, R2 is selected from H, methyl, methylaminocarbonyl, dimethylaminocarbonyl, tetrahydropyranylaminocarbonyl, isopropylaminocarbonyl, bicyclo[1.1.1]pentan-1-ylcarbamoyl, 3,3-difluoroazetidine-1-carbonyl, 3-hydroxyazetidine-1-carbonyl, (3-hydroxycyclobutyl)carbamoyl, (1,1,1-trifluoropropan-2-yl)carbamoyl, (4-cyanobicyclo[2.1.1]hexan-1-yl)carbamoyl, (2-oxaspiro[3.3]heptan-6-yl)carbamoyl, azetidine-1-carbonyl, cyclobutylcarbamoyl, sec-butylcarbamoyl, (1-methylazetidin-3-yl)carbamoyl, (tetrahydrofuran-3-yl)carbamoyl, methyl(tetrahydro-2H-pyran-4-yl)carbamoyl, 2-oxa-6-azaspiro[3.3]heptane-6-carbonyl, aminocarbonyl, ethylaminocarbonyl, ethylmethylaminocarbonyl, isopropylmethylaminocarbonyl, and cyclobutylmethylaminocarbonyl
- In some embodiments, X3 is N.
- In some embodiments, X3 is CR3.
- In some embodiments, R3 is selected from H, D, halo, CN, OH, NH2, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.
- In some embodiments, R3 is selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.
- In some embodiments, R3 is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, R3 is H or methyl.
- In some embodiments, X3 is CH.
- In some embodiments, W is N.
- In some embodiments, W is CR1.
- In some embodiments, R1 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl.
- In some embodiments, R1 is H or methyl.
- In some embodiments, W is CH.
- In some embodiments, Z is N.
- In some embodiments, Z is CZ1.
- In some embodiments, Z1 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl.
- In some embodiments, Z1 is H or methyl.
- In some embodiments, Z is CH.
- In some embodiments, R12 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl.
- In some embodiments, R12 is H or methyl.
- In some embodiments, R12 is H.
- In some embodiments, X4 is N.
- In some embodiments, X4 is CR4.
- In some embodiments, X4 is CR4, whereinR4 is selected from H, D, halo, CN, OH, NH2, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.
- In some embodiments, X4 is CR4, whereinR4 is selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl. In some embodiments, X4 is CR4, wherein R4 is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, X4 is CH.
- In some embodiments, X5 is N.
- In some embodiments, X5 is CR5, wherein R5 is selected from H, D, halo, CN, OH, NH2, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.
- In some embodiments, X5 is CR5, wherein R5 is selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.
- In some embodiments, X5 is CR5, wherein R5 is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, X5 is CH.
- In some embodiments, X6 is N.
- In some embodiments, X6 is CR6.
- In some embodiments, R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa6, SRa6, NHORa6, C(O)Rb6, C(O)NRc6Rd6, C(O)NRc6(ORa6), C(O)ORa6, OC(O)Rb6, OC(O)NRc6 R d6, NRc6Rd6, NRc6NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)ORa6, NRc6C(O)NRc6Rd6, C(═NRe6)Rb6, C(═NOH)Rb6, C(═NCN)Rb6, C(═NRe6)NRc6Rd6, NRc6C(═NRe6)NRc6Rd6, NRc6C(═NOH)NRc6Rd6, NRc6C(═NCN)NRc6Rd6, NRc6C(═NRe6)Rb6, NRc6S(O)NRc6Rd6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)(═NRe6)Rb6, NRc6S(O)2NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, S(O)2NRc6Rd6, S(O)(═NRe6)Rb6, N═S(O)Ra6Rb6, OS(O)(═NRe6)Rb6, OS(O)2Rb6, and SF5, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents.
- In some embodiments, R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, OR a6, SRa6, C(O)Rb6, C(O)NRe6R ′'d6, C(O)ORa6, NRc6Rd6
- NRc6C(O)Rb6, NRc6c(O)
- ORa6, NRe6C(O)NRe6Rd6, S(O)2Rb6, S(O)(═NR6)Rb6, and N=S(O)Ra6Rb6, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R6 are each optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents;
- each Ra6, Rb6, Rc6, Rd6 and Re6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of Ra6, Rb6, Rc6, Rd6 and Re6 are each optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents; and
- each R6A is independently selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, SRa6, C(O)NRc6Rd6, C(O)Rb6, S(O)2Rb6, S(O)(═NRe6)Rb6, and N═S(O)Ra6Rb6, wherein the C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents;
- each Ra6, Rb6, Rc6, Rd6 and Re6 are independently selected from H and C1-6 alkyl; and
- each R6A is independently selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, R6 is selected from H, halo, C1-6 alkyl, S(O)2Rb6, S(O)(═NRe6)Rb6, and N═S(O)Ra6Rb6, wherein the C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents;
- each R6, Rb6, and Re6 are independently selected from H and C1-6 alkyl; and
- each R6A is OH.
- In some embodiments, R6 is selected from H, chloro, S(O)2CH3, 1,2-dihydroxyethyl, S(O)(═NH)CH3, S(O)(═NCH3)CH3, and N═S(O)(CH3)2.
- In some embodiments, R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa6, SRa6, NHORa6, C(O)Rb6, C(O)NRc6Rd6, C(O)NRc6(ORa6), C(O)ORa6, OC(O)Rb6, OC(O)NRc6Rd6, NRc6Rd6, NRc6NRc6Rd6, NRc6C(O)Rb6, NRc6C(O)ORa6, NRc6C(O)NRc6Rd6, C(═NOH)Rb6, C(═NCN)Rb6, NRc6C(═NOH)NRc6Rd6, NRc6C(═NCN)NRc6Rd6, NRc6S(O)NRc6Rd6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)2NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, S(O)2NRc6Rd6, and OS(O)2Rb6, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6 are each optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents;
- each R6, tc-r.136, Rc6, and Rd6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6, tc-r.136, Rob and Rd6 are each optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents;
- each R6A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, OR a61, SRa61, NHORa61, C(O)Rb61, C(O)NRc61, Rd61, C(O)NRc61(ORa61, C(O)ORa61, OC(O)Rb61, OC(O)NRc61, Rd61, NRc61, Rd61, NRc61NRc61Rd61, NRc61C(O)Rb61, NRc61C(O)ORa61, NRc61C(O)NRc61Rd61, C(═NOH)Rb61, C(═NCN)Rb61, NRc61C(═NOH)NRc61Rd61, NRc61C(═NCN)NRc61Rd61, NRc61S(O)NRc61Rd61, NRc61S(O)Rb61, NRc61S(O)2Rb61, NRc61S(O)2NRc61Rd61, S(O)Rb61, S(O)NRc61Rd61, S(O)2Rb61, S(O)2NRc61Rd61, and OS(O)2Rb61, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; and
- wherein each Ra61, Rb61, Rc61, and Rd61 is independently selected from H and C1-6 alkyl.
- In some embodiments, R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, ORa6, C(O)Rd6, C(O)ORa6, RNc6Rd6, NRc6C(O)Rb6, NRc6C(O)ORa6, NRc6C(O)NRc6Rd6, and S(O)2Rb6, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of R6 are each optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents;
- each Ra6, Rb6, Rc6, and Rd6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of Ra6, Rb6, Rob and Rd6 are each optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents; and
- each R6A is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, SRa6, C(O)NRc6K C(O)Rb6, and S(O)2Rb6, wherein the C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents;
- each Ra6, Rb6, Rcb and Rd6 is independently selected from H and C1-6 alkyl; and
- each R6A is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, S(O)Rb6 S(O)NRc6Rd6, S(O)2Rb6, and S(O)2NRc6Rd6.
- In some embodiments, R6 is selected from H, halo, C1-6 alkyl, S(O)Rb6, and S(O)2Rb6, and Rb6 is selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.
- In some embodiments, each Rb6, Rc6, and Rd6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.
- In some embodiments, R6 is selected from H, D, halo, C1-6 alkyl, SRa6, C(O)Rb6, and S(O)2Rb6, wherein the C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents;
- each R6 and Rb6 is independently selected from H and C1-6 alkyl; and
- each R6A is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, R6 is selected from H, halo, and S(O)2Rb6, wherein Rb6 is C1-6 alkyl.
- In some embodiments, R6 is selected from H, D, halo, methyl, C(CH3)2OH, CH(CH3)OH, C(O)CH3, S(O)2CH3, and SCH3.
- In some embodiments, R6 is selected from D, halo, methyl, C(CH3)2OH, CH(CH3)OH, C(O)CH3, S(O)2CH3, and SCH3.
- In some embodiments, R6 is CH(OH)-CH2OH.
- In some embodiments, R6 is C(CH3)(OH)-CH2OH.
- In some embodiments, R6 is C(OH)(C1-haloalkyl)-CH2OH.
- In some embodiments, R6 is C(OH)(S(═O)Rb6)-CH2OH.
- In some embodiments, R6 is C(OH)(C1-haloalkyl)-C(O)NH2.
- In some embodiments, R6 is C(O)NH2.
- In some embodiments, R6 is methyl.
- In some embodiments, R6 is H.
- In some embodiments, R6 is a C(OH)(R6A)2, wherein at least one R6A is C1-6 haloalkyl. In some embodiments, R6 is a C(OH)(R6A)2, wherein at least one R6A is C1-6 haloalkyl and each halogen of the haloalkyl group of R6A is F. In some embodiments, R6 is a C(OH)(R6A)2, wherein at least one R6A is C1-6 haloalkyl and the haloalkyl group of R6A is optionally substituted with 1 or 2 independently selected Y2 substituents.
- In some embodiments, each Y2 is independently selected from OH, NO2, CN, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, cyano-C1-6 alkyl, HO-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, C3-10 cycloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, thio, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, carboxy, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl, C1-6 alkylaminosulfonyl, di(C1-6 alkyl)aminosulfonyl, aminosulfonylamino, C1-6 alkylaminosulfonylamino, di(C1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C1-6 alkylaminocarbonylamino, and di(C1-6 alkyl)aminocarbonylamino.
- In some embodiments, at least one R6A is selected from CF3, CC13, CF2H, CC12H, CF2Y2,
- CC12Y2, CFH2, CC1H2, CFHY2, CC1HY2, CF(Y2)2 and CC1(Y2)2.
- In some embodiments, at least one R6A is selected from CF3, CF2H, CF2Y2, CFH2, CFHY2, and CF(Y2)2.
- In some embodiments, at least one R6A is C1-6 haloalkyl, wherein each halogen is F.
- In some embodiments, at least one R6A is C1-6 haloalkyl, wherein each halogen is Cl.
- In some embodiments, at least one R6A is selected from CH2F, CHF2, CF3, and CF2CF3.
- In some embodiments, at least one R6A is CF3.
- In some embodiments, at least one R6A is CH2F.
- In some embodiments, at least one R6A is CHF2.
- In some embodiments, at least one R6A is CF2CF3.
- In some embodiments, R6 is selected from H, chloro, and S(O)2CH3.
- In some embodiments, X7 is N.
- In some embodiments, X7 is C.
- In some embodiments, X8 is N.
- In some embodiments, X8 is C.
- In some embodiments, both X7 and X8 are C.
- In some embodiments, X7 is N and X8 is C.
- In some embodiments, X7 is C and X8 is N.
- In some embodiments, X9 is NR9N.
- In some embodiments, X9 is N.
- In some embodiments, X9 is O.
- In some embodiments, X9 is S.
- In some embodiments, X9 is S(O).
- In some embodiments, X9 is S(O)2.
- In some embodiments, X9 is CR9.
- In some embodiments, X9 is C(R9)2.
- In some embodiments, each R9 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of
- R9 are each optionally substituted with 1, 2, 3, or 4 independently selected R9A substituents; or, alternatively, two R9 groups together form an oxo group.
- In some embodiments, each R9 is H.
- In some embodiments, X9 is CR9, wherein R9 is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, X9 is CH.
- In some embodiments, X9 is C(O).
- In some embodiments, X10 is NR10 N.
- In some embodiments, Rim is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered and heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb10N, C(O)NRc10NRd10N, CO)ORa10N, C(═NCN)NRc10NRd10N, C(═NORa10N)NRc10N, S(O)2Rb10N, S(O)(═NRc10N)Rd10N, and S(O)2NRc10NRd10N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, or 4 independently selected R10NA substituents;
- each Ra10N, Rb101, Rc10N, and Rd10N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N, Rb10N, Rc10N, and Rd10N are each optionally substituted with 1, 2, 3, or 4 independently selected R10NA substituents;
- each R10NA is selected from H, D, halo, CN, OH, NH2, C1-6 alkyl, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-.
- In some embodiments, R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, or 4 independently selected R10NA substituents.
- In some embodiments, R10N is selected from C1-6 alkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-6 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-6 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-6 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl- and (4-6 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1 or 2 independently selected R10NA substituents.
- In some embodiments, R10N is selected from C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl-, wherein the C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl- of R10N are each optionally substituted with 1 or 2 independently selected R10NA substituents.
- In some embodiments, R10N is selected from H, C1-6 alkyl, C6-10 aryl-C1-6 alkyl-, and C3-10 cycloalkyl-C1-6 alkyl-.
- In some embodiments, R10N is C3-6 cycloalkyl-C1-6 alkyl-.
- In some embodiments, R10N is cyclopropylethyl.
- In some embodiments, R10N is 1-cyclopropylethyl.
- In some embodiments, R10N is (S)-1-cyclopropylethyl.
- In some embodiments, X10 is N.
- In some embodiments, X10 is O.
- In some embodiments, X10 is S.
- In some embodiments, X10 is CR10.
- In some embodiments, X10 is)C(R10)2.
- In some embodiments, X10 is CR10, wherein R10 is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, X10 is CH.
- In some embodiments, X10 is c(R)0), wherein each R10 is independently selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, two R10 groups together form an oxo group.
- In some embodiments, X11 is NR11N.
- In some embodiments, X11 is N.
- In some embodiments, X11 is O.
- In some embodiments, X11 is S.
- In some embodiments, X11 is CR11.
- In some embodiments, X11 is C(R11)2.
- In some embodiments, each R11 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of R11 are each optionally substituted with 1, 2, 3, or 4 independently selected R11A substituents.
- In some embodiments, X11 is CR11, wherein R11 is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, X11 is CH.
- In some embodiments, X11 is C(R11)2, wherein each R11 is independently selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl.
- In some embodiments, two R11 groups together form an oxo group.
- In some embodiments, X11 is CH2.
- In some embodiments, X1 is CR1; X2 is CR2; and X3 is N.
- In some embodiments, X1 is N; X2 is CR2; and X3 is N.
- In some embodiments, X1 is CR1; X2 is N; and X3 is N.
- In some embodiments, W is CR1; and Z is CZ1.
- In some embodiments, W is N; and Z is CZ1.
- In some embodiments, W is CR1; and Z is N.
- In some embodiments, X1 is CR1; X2 is CR2; X3 is N; W is CR1; and Z is CZ1.
- In some embodiments:
- X7 is N or C;
- X8 is N or C;
- X9 is N or C(R9)2;
- X10 is N or NR10 N; and
- X11 is N, CR11, or C(R11)2.
- In some embodiments:
- X7 is C;
- X8 is C;
- X9 is N or C(R9)2;
- X10 is N or NR10 N; and
- X11 is N, CR11, or C(R11)2.
- In some embodiments:
-
- X1 is N or CR1;
- R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- CN, NO2, OR SRa1, NHORa1, C(O)Rb1,C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1, Rd1, NRc1C(O)Rb1, NRc1, C(O)ORa1, NRc1, C(O)NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1;
- X2 is N or CR2;
- R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2,C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Ra2, Rb2Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents;
- X3 is N or CR3;
- W is N or CR1;
- R1 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl;
- Z is N or CZ1;
- Z1 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl;
- R12 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl.
- X4 is N or CR4;
- X5 is N or CR5;
- R4 and R5 are each independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- X6 is N or CR6;
- R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, and S(O)2NRc6Rd6;
- each Rb6, Rc6, and Rd6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- X7 is N or C;
- X8 is N or C;
- X9 is N or C(R9)2;
- X10 is N or NR10N;
- X11 is N or C(R11)2;
- wherein no more than three of X4, X5, X6, X7, and X8 are simultaneously N; and
- at least two of X7, X8, X9, and X′ are independently selected from C, C(R9)2, and
- C(R11)2;
- provided that (a) when X7 is N, then X8 is C; or (b) when X8 is N, then X7 is C;
- each R9 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of R9 are each optionally substituted with 1, 2, 3, or 4 independently selected R9A substituents; or, alternatively, two R9 groups together form an oxo group;
- R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 to cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, or 4 independently selected R10NA substituents; and each RH is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of R11 are each optionally substituted with 1, 2, 3, or 4 independently selected R11A substituents.
-
- R2 is selected from H, C1-6 alkyl, C(O)Rb2, C(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2;
- each Ra2, RC2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2- Rb2, 6 alkenyl, C2-6 alkynyl, and 4-6 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, -rb2, C2-6 alkynyl, and 4-6 membered heterocycloalkyl of Rae, K Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents;
- X3 is N; W is CR1; R1 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl; Z is CZ1;
- Z1 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl; R12 is H or methyl; X4 is CR4; X5 is CR5; R4 and R5 are each independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- X6 is CR6; R6 is selected from H, halo, C1-6 alkyl, S(O)Rb6, and S(O)2Rb6; X7 is C; X8 is C;
- X9 is C(R9)2;
- Xlci is NR10 N;)
- 01 is c(R11)2;
- each R9 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of R9 are each optionally substituted with 1, 2, 3, or 4 independently selected R9A substituents; or, alternatively, two R9 groups together form an oxo group;
- R10N is selected from C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl-, wherein the C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl- of R10N are each optionally substituted with 1 or 2 independently selected R10NA substituents; and
- each R11 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl.
- In some embodiments, the compound of Formula (I) is a compound of Formula (Ib):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (II):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIb):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIc):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IId):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIe):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIf):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIg):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIh):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IV
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (Ilk):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIm):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIn):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIo):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments of Formula (IIo), X1 is CR1 and X2 is CR2.
- In some embodiments of Formula (IIo), X1 is N and X2 is CR2.
- In some embodiments of Formula (IIo), X1 is CR1 and X2 is N.
- In some embodiments of Formula (IIo):
- X1 is N or CR1;
- R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, SRa1, NHORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1, NRc1(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rdl, S(O)NRc1Rd1, S(O)2, and S(O)2NRc1Rd1;
- each Ra1, Rb1, Rc1, and Rd1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl,
- X2 is N or CR2;
- R2 is H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, IRa2, SRa2, NHORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)NR2 (ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2c(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents;
- each R2A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkyny;
- R1, Z1, and R2 are each independently selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl;
- R4 and R5 are each independently selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl; R6 is selected from H, D, halo, C1-6 alkyl, SRa6, C(O)Rb6, and S(O)2Rb6, wherein the C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents;
- each R6 and Rb6 is independently selected from H and C1-6 alkyl;
- each R6A is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl;
- R10N is selected from C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl-, wherein the C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl- of R10N are each optionally substituted with 1 or 2 independently selected leNA substituents;
- each R10NA is selected from H, D, halo, CN, OH, NH2, C1-6 alkyl, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl; and
- R11 is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl;
- or, alternatively, two R11 groups together form an oxo group.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIp):
- or a pharmaceutically acceptable salt thereof
- In some embodiments of Formula (IIp), X4 is CR4; X5 is CR5; and X11 is N, NH, CR11, or C(R11)2.
- In some embodiments of Formula (IIp), X4 is CR4; X5 is N; and X11 is N, NH, CR11, or C(R11)2.
- In some embodiments of Formula (IIp), X4 is N; X5 is CR5; and is N, NH, CR11, or C(R11)2.
- In some embodiments of Formula (IIp), X4 is N; X5 is N; and X11 is N, NH, CR11, or C(R11)2.
- In some embodiments of Formula (IIp), X4 is CR4; X5 is CR5; and X11 is C(R11)2.
- In some embodiments of Formula (IIp), X4 is CR4; X5 is N; and X11 is C(R11)2.
- In some embodiments of Formula (IIp), X4 is N; X5 is CR5; and X11 is C(R11)2.
- In some embodiments of Formula (IIp), X4 is N; X5 is N; and X11 is C(R11)2.
- In some embodiments of Formula (IIp):
- R2 is H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-Ch6alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2,C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Ra2, Rb2, Roz and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents;
- each R2A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkyny;
- R2 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl; X4 is N or CR4; X5 is N or CR5;
- R4 and R5 are each independently selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl; R6 is selected from H, D, halo, C1-6 alkyl, SR6, C(O)Rb6, and S(O)2Rb6, wherein the C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R6A substituents;
- each R6 and Rb6 is independently selected from H and C1-6 alkyl; each R6A is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl;
- R10N is selected from C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl-, wherein the C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl- of R10N are each optionally substituted with 1 or 2 independently selected leNA substituents;
- each R10NA is selected from H, D, halo, CN, OH, NH2, C1-6 alkyl, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl; and
- RH is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl; or, alternatively, two R11 groups together form an oxo group. In some embodiments, the compound of Formula (I) is a compound of Formula (IIq):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments of Formula (IIq), X4 is CR4; X5 is CR5; and X11 is N, NH, CR11, or
- C(R11)2.
- In some embodiments of Formula (IIq), X4 is CR4; X5 is N; and X11 is N, NH, CR11, or C(R11)2.
- In some embodiments of Formula (IIq), X4 is N; X5 is CR5; and X11 is N, NH, CR11, or C(R11)2.
- In some embodiments of Formula (IIq), X4 is N; X5 is N; and X11 is N, NH, CR11, or C(R11)2.
- In some embodiments of Formula (IIq), X4 is CR4; X5 is CR5; and X11 is C(R11)2.
- In some embodiments of Formula (IIq), X4 is CR4; X5 is N; and X11 is C(R11)2.
- In some embodiments of Formula (IIq), X4 is N; X5 is CR5; and X11 is C(R11)2.
- In some embodiments of Formula (IIq), X4 is N; X5 is N; and X11 is C(R11)2.
- In some embodiments of Formula (IIq):
- R2 is H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2,C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents;
- each R2A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkyny;
- R12 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl;
- X4 is N or CR4;
- X5 is N or CR5;
- R4 and R5 are each independently selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl;
- R10N is selected from C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl-, wherein the C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl- of R10N are each optionally substituted with 1 or 2 independently selected leNA substituents;
- each 1Z10NA is selected from H, D, halo, CN, OH, NH2, C1-6 alkyl, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl; and is selected from H, D, halo, CN, OH, NH2, and C1-6 alkyl; or, alternatively, two R11 groups together form an oxo group. In some embodiments, the compound of Formula (I) is a compound of Formula (IIu):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments of Formula (IIu): Z is CZ1 or N; Z1 and R12 are each independently selected from H, D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1,3 haloalkyl, cyano-C1-3 alkyl, HO-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, di(C1-3 alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
- R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, SRa1, NHORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, and NRc1C(O)NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
- each Ra1, Rb1, Rc1, and Rd1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra1, Rb1, Rc1 and Rd1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
- or, any Rc1 and Rd1, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
- each R1A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa11, SRa11, NHORa11, C(O)Rb11, C(O)NRc11Rd11, C(O)NRc11(ORa11), C(O)ORa11, OC(O)Rb11, OC(O)NRc11Rd11, NRc11Rd11, NRc11NRc11Rd11, NRc11C(O)Rb11, NRc11C(O)ORa11, and NRc11C(O)NRc11Rd11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra11, Rb11, Rc11, and Rd11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra111, Rb111, Rc11and Rd11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rai and Rd11, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents; each RM is independently selected from D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl,
- C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, di(C1-3 alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino; R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, c(O)-b2, C(O)NRc2Rd2,
- C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2NRc2Rd2, NRc2C(O)Rb2,
- NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents; each Ra2, Rb2, RC2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl,
- C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra2, K RC2 and Rd2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents; or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
- each R2A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa21, SRa21, NHORa21, C(O)Rb21,
- C(O)NRa1 K C(O)NRc21(ORa21), C(O)ORa21, OC(O)Rb21, OC(O)NRc21 Rd21, NRc21Rd21,
- NRc21NRc21Rd21, NRc21C(O)Rb21, IN,k
- K C(O) ORa21, and NRc21C(O)NRc21Rd21, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- R b21, -c21, each Ra21, and Rd21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl,
- C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ran, K-b21, Rc21 and Rd2l are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rai and Rd21, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or alternatively, R1 and R2, taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R1A groups;
- R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa6, SRa6, NHORa6, C(O)Rb6, C(O)NRc6Rd6, C(O)NRc6(ORa6), C(O)ORa6, OC(O)Rb6, OC(O)NRc6Rd6, NRc6Rd6, NRc6NRc6Rd6, NRc6C(O)Rb6, NRc61C(O)ORa6, NRc6C(O)NRc6Rd6, C(═NRe6)Rb6, C(═NOH)Rb6, C(═NCN)Rb6, C(═NRe6)NRc6Rd6, NRc6C(═NRe6)NRc6Rd6, NRc6C(═NOH)NRc6Rd6, NRc6C(═NCN)NRc6Rd6, NRc6C(═NRe6)Rb6, NRc6S(O)NRc6Rd6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)(═NRe6)Rb6, NRc6S(O)2NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, S(O)2NRc6Rd6, S(O)(═NRe6)Rb6, OS(O)(═NRe6)Rb6, OS(O)2Rb6, and SF5, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- each Ra6, Rb6, Rc6 and Rd6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra6, Rb6, Rc6 and Rd6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- or, any Rc6 and Rd6, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- each R6A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa61, SRa61, NHORa61, C(O)Rb61, C(O)NRc61Rd61, C(O)NRc61(ORa61), C(O)ORa61, OC(O)Rb61, OC(O)NRc61Rd61, NRc61Rd61, NRc61NRc61, Rd61, NRc61C(O)Rb61, NRc61C(O)ORa61, and NRc61C(O)NRc61Rd61, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra61, Rb61, Rc61, and Rd61 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered and heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra61, Rb61, Rc61 and Rd61 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rc61 and Rd61, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- X9 is NR9N or C(R9)2;
- X11 is NR11N or C(R11)2;
- R9N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb9N, C(O)NRc9NRd9N, C(O)ORa9N, C(═NRe9N)Rb9N, C(═NRe9N)NRc9NRd9N, C(═NCN)NRc9NRd9N, C(═NORa9N)NRc9N, S(O)2Rb9N, S(O)(═NRc9N)Rd9N, and S(O)2NRc9NRd9N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
- each Ra9N, Rb9N, Rc9N, and Rd9N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R′, Rb9N, R-c9N, and Rd9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents; or, any R′ and Rd9N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
- each R′ is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R9NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, OR a9N2, SRa9N2, NHORa9N2, C(O)Rb9N2, C(O)NRc9N2Rd9N2, C(O)NRC9N2 (ORa9N2), C(O)ORa9N2, OC(O)Rb9N2, OC(O)NRc9N2Rd9N2, NRC9N2 Rd9N2,
- NRC9N2 NRC9N2 Rd9N2, NRC9N2 C(O)Rb9N2, c9N2 c9N2Rd9N2, wherein l(O)ORa9N2, and NR C(O)iNK the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R9NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- a9N2, R b9N2, Rc9N2, each R and Rd9N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 a9N2, R b9N2, Rc9N2 and Kd9N2 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any R′2 and Rd9N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; each R9 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa91, SRa91, NHORa91, C(O)t('-'1391, C(O)NRc91Rd91, C(O)NRc91(ORa91), C(O)ORa91, OC(O)Rb91, OC(O)NRc91Rd91, NRc91Rd91, NRc91NRc91Rd91, NRc91C(O)Rb91, C(O)ORa91, and NRc91C(O)NRc91Rd91, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
- or, alternatively, two R9 groups together form an oxo group;
- R b91, - Kc91, each Ra91, and Rd91 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl,
- C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl,
- C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra91 K1391 and-, , Rc91 and Rd91 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents; or, any RM and Rd91, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
- each R9A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa92, SRa92, NHORa92, C(O)Rb62, C(O)NRc92Rd92, C(O)NRc92(ORa92), C(O)ORa92, OC(O)Rb92, OC(O)NRc92Rd92, NRc92R92, NRc92NRc92Rd92, NRc92C(O)Rb92, NRc9C(O)ORa92, and NRc92C(O)NRc92Rd92, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R9A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra92, Rb92, Rc92, and Rd92 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra92, Rb92, Rc92 and Rd92 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc92 and Rd92, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb10N, C(O)NRc10NRd10N, C(O)ORa10N, C(═NRe10N)Rb10N, C(═NRe10N)NRc10NRd10N, C(═NCN)NRc10NRd10N, C(═NORa10N)NRc10N, S(O)2Rb10N, S(O)(═NRc10N)Rd10N, S(O)2NRc10NRd10N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
- each Ra10N, Rb10N, Rc10N, and Rd10N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N, Rb10N, Rc10N, and Rd10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
- or, any Rc10N and Rd10N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
- each Re10N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R10NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6alkyl-, CN, NO2, ORa10N2, SRa10N2, NHORa10N2, C(O)Rb10N2, C(O)NRc10N2Rd10N2, C(O)NRc10N2(ORa10N2), C(O)ORa10N2, OC(O)Rb10N2, OC(O)NRc10N2Rd10N2, NRc10N2Rd10N2, NRc10N2, NRc10N2Rd10N2, NRc10N2C(O)Rb10N2, NRc10N2C(O)ORa10N2, and NRc10N2C(O)NRc10N2Rd10N2, wherein C1-6alkyl, C2-6alkenyl, C2-6alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R10NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra10N2, Rb10N2, Rc10N2, and Rd10N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N2, Rb10N2, Rc10N2 and Rd10N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc10N2 and Rd10N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- R11N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb11N, C(O)NRc11NRd11N, C(O)ORa11N, C(═NRe11N)Rb11N, C(═NRe11N)NRc11NRd11N, C(═NCN)NRc11NRd11N, C(═NORa11N)NRc11N, S(O)2Rb11N, S(O)(═NRc11N)Rd11N, and S(O)2NRc11NRd11N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
- each Ra11N, Rb11N, Rc11N, and Rd11N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra11N, Rb11N, Rc11N, and Rd11N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
- or, any Rc11N and Rd11N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
- each Re11N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R11NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6alkyl-, CN, NO2, ORa11N2, SRa11N2, NHORa11N2, C(O)Rb11N2, CO(NRc11N2Rd11N2, C(O)NRc11N2(ORa11N2), C(O)ORa11N2, OC(O)Rb11N2, OC(O)NRc11N2Rd11N2, NRc11N2Rd11N2, NRc11N2NRc11N2Rd11N2, NRc11N2C(O)Rb11N2, NRc11N2C(O)ORa11N2, and NRc11N2C(O)NRc11N2Rd11N2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R11NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra11N2, Rb11N2, Rc11N2 and Rd11N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl,
- C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C%-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 allN2 Rbl1N2, Rcl1N2 and Rd11N2 are alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; or, any Rc1' and Rd11Nz, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each le is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa111, SRa111, NHORa111, C(O)Rb111, C(O)NRc111, Rd111, C(O)NRc111(ORa111), C(O)ORa111, OC(O)Rb111, OC(O)NRc111Rd111, NRc111Rd111, NRc111, NRc111Rd111, NRc111C(O)Rb111, NRc111C(O)ORa111, and NRc111C(O)NRc111Rd111, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents;
- or, alternatively, two R11 groups together form an oxo group;
- each Ra111, Rb111, Rc111, and Rd111 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra111, Rb111, Rc111, and Rd111 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents;
- or, any Rc111 and Rd111, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents; and
- each R11A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa112, SRa112, SRa112, NHORa112, C(O)Rb112, C(O)NRc112Rd112, C(O)NRc112(ORa112), C(O)ORa112, OC(O)Rb112, OC(O)NRc112Rd112, NRc112Rd112, NRc112NRc112Rd112, NRc112C(O)Rb112, NRc112C(O)ORa112, and NRc112C(O)NRc112Rd112, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R11A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; and
- each Ra112, Rb112, Rc112, and Rd112 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra112, Rb112, Rc112 and Rd112 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc112 and Rd112, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents.
- In some embodiments of Formula (IIu):
- Z is CZ1 or N;
- Z1 and R12 are each independently selected from H, D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, di(C1-3 alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
- R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, SRa1, NHORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, and NRc1C(O)NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
- each Ra1, Rb1, Rc1, and Rd1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra1, Kb1, Rc1 Rd1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
- or, any Rc1 and Rd1, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
- each R1A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa11, SRa11, NHORa11, C(O)Rb11, C(O)NRc11Rd11, C(O)NRc11(ORa11), C(O)ORa11, OC(O)Rb11, OC(O)NRc11Rd11, NRc11Rd11, NRc11NRc11Rd11, NRc11C(O)Rb11, NRc11C(O)ORa11, and NRc11C(O)NRc11Rd11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra11, Rb11, Rc11, and Rd11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra11, Rb11, and Rc11 and Rd11 optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rc11 and Rd11, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each RM is independently selected from D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, di(C1-3 alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
- R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
- or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
- each R2A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa21, SRa21, NHORa21, C(O)Rb21, C(O)NRc21Rd21, C(O)NRc21(ORa21), C(O)ORa21, OC(O)Rb21, OC(O)NRc21Rd21, NRc21Rd21, NRc21NRc21Rd21, NRc21C(O)Rb21, NRc21C(O)ORa21, and NRc21C(O)NRc21Rd21, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra21, Rb21, Rc21, and Rd21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered and heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra21, Rb21, Rc21 and Rd21 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rc21 and Rd21, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or alternatively, R1 and R2, taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R1A groups;
- R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa6, SRa6, NHORa6, C(O)RNRc6Rd6, C(O)NRc6(ORa6), C(O)ORa6, OC(O)Rb6, OC(O)NRc6Rd6, NRc6Rd6, NRc6NRc6Rd6, NRc6C(O)Rd6, NRc6C(O)ORa6, NRc6C(O)NRc6Rd6, C(═NRe6)Rb6, C(═NOH)Rb6, C(═NCN)Rb6, C(═NRe6)NRc6Rd6, NRc6C(═NRe6)NRc6Rd6, NRc6C(═NOH)NRc6Rd6, NRc6C(═NCN)NRc6Rd6, NRc6C(═NRe6)Rb6, NRc6S(O)NRc6Rd6, NRc6S(O)Rb6, NRc6S(O)2Rb6, NRc6S(O)(═NRe6)Rb6, NRc6S(O)2NRc6Rd6, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, S(O)2NRc6Rd6, S(O)(═NRe6)Rb6, N═S(O)Ra6Rb6, OS(O)(═NRe6)Rb6, OS(O)2Rb6, and SF5, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- each Ra6, Rb6, Rc6, Rd6 and Re6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra6, Rb6, Rc6, Rd6 and Re6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- or, any Rc6 and Rd6, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
- each R6A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa61, SRa61, NHORa61, C(O)Rb61, C(O)NRc61Rd61, C(O)NRc61(ORa61), C(O)ORa61, OC(O)Rb61, OC(O)NRc61Rd61, NRc61Rd61, NRc61NRc61Rd61, NRc61C(O)Rb61, NRc61C(O)ORa61, and NRc61C(O)NRc61Rd61, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- each Ra61, Rb61, Rc61, and Rd61 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered and heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra61, Rb61, Rc61 and Rd61 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- or, any Rc61 and Rd61, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
- X9 is NR9N or C(R9)2;
- X11 is NR11N or C(R11)2;
- R9N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb9N, C(O)NRc9NRd9N, C(O)ORa9N, C(═NRe9N)Rd9N, C(═NRe9N)NRc9NRd9N, C(═NCN)NRc9N, Rd9N, C(═NORa9N)NRc9N, S(O)2Rb9N, S(O)(═NRc9N)Rd9N, and S(O)2NRc9NRd9N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
- each Ra9N, Rb9N, Rc9N, and Rd9N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra9N, Ra9N, Rb9N, Rc9N, and Rd9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
- or, any Rc9N and Rd9N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
- each Re11N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R9NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa9N2, SRa9N2, NHORa9N2, C(O)Rb9N2, C(O)NRc9N2Rd9N2, C(O)NRc9N2(ORa9N2), C(O)ORa9N2, OC(O)Rb9N2, OC(O)NRc9N2, NRc9N2Rd9N2, NRc9N2NRc9N2Rd9N2, NRc9N2C(O)Rb9N2, NRc9N2C(O)ORa9N2, and NRc9N2C(O)NRc9N2Rd9N2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R9NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra9N2, Rb9N2, Rc9N2 and Rd9N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra9N2, Rb9N2, Rc9N2 and Rd9N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc9N2 and Rd9N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each R9 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa91, SRa91, NHORa91, C(O)Rb91, C(O)NRc91Rd91, C(O)NRc91(ORa91), C(O)ORa91, OC(O)Rb91, OC(O)NRc91Rd91, NRc91Rd91, NRc91NRc91Rd91, NRc91C(O)Rb91, NRc91C(O)ORa91, and NRc91C(O)NRc91Rd91, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
- or, alternatively, two R9 groups together form an oxo group;
- each Ra91, Rb91, Rc91, and Rd91 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra91, Rb91, Rc91 and Rd91 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
- or, any Rc91 and Rd91, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
- each R9A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa92, SRa92, NHORa92, C(O)Rb92, C(O)NRc92Rd92, C(O)NRc92(ORa92), C(O)ORa92, OC(O)Rb92, OC(O)NRc92Rd92, NRc92Rd92, NRc92NRc92Rd92, NRc92C(O)Rb92, NRc92C(O)ORa92, and NRc92C(O)NRc92Rd92, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R9A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra92, Rb92, Rc92 and Rd92 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl,
- C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra92, Rb92, Rc92 and Rd92 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc92 and Rd92, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb10N, C(O)NRc10N, Rd10N, C(O)ORa10N, C(═NRe10N)Rb10N, C(═NRe10N)NRc10NRd10N, C(═NCN)NRc10NRd10N, C(═NORa10N)NRc10N, S(O)2Rb10N, S(O)(═NRc10N)Rd10N, and S(O)2NRc10NRd10N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
- each Ra10N, Rb10N, Rc10N, and Rd10N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N, Rb10N,Rc10N, and Rd10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
- or, any Rc10N and Rd10N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
- each Re10N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R10NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa10N2, SRa10N2, NHORa10N2, C(O)Rb10N2, C(O)NRc10N2Rd10N2, C(O)NRc10N2(ORa10N2), C(O)ORa10N2, OC(O)Rb10N2, OC(O)NRc10N2Rd10N2, NRc10N2Rd10N2, NRc10N2, NRc10N2Rd10N2, NRc10N2C(O)Rb10N2, NRc10N2C(O)ORa10N2, and NRc10N2C(O)NRc10N2Rd10N2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R10NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra10N2, Rb10N2, Rc10N2, and Rd10N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N2, Rb10N2, Rc10N2 and Rd10N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc10N2 and Rd10N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- R11N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 arYl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, C(O)Rb11N, C(O)NRc11NRd11N, C(O)ORa11N, C(═NRe11N)Rb11N, C(═NRe11N)NRc11NRd11N, C(═NCN)NRc11NRd11N, C(═NORa11N)NRc11N, S(O)2Rb11N, S(O)(═NRc11N)Rd11N, and S(O)2NRc11NRd11N, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
- each Ra11N, Rb11N, Rc11N, and Rd11N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra111, Rb111, Rc111, and Rd111 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
- or, any Rc11N and Rd11N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
- each Re11N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
- each R11NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa11N2, SRa11N2, NHORa11N2, C(O)Rb11N2, C(O)NRc11N2Rd11N2, C(O)NRc11N2(ORa11N2), C(O)ORa11N2, OC(O)Rb11N2, OC(O)NRc11N2, Rd11N2, NRc11N2Rd11N2, NRc11N2NRc11N2Rd11N2, NRc11N2C(O)Rb11N2, NRc11N2C(O)ORa11N2, and NRc11N2C(O)NRc11N2Rd11N2, wherein the C1-6alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R11NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each Ra11N2, Rb11N2, Rc11N2, and Rd11N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra11N2, Rb11N2, Rc11N2 and Rd11N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc11N2 and Rd11N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- each R11 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa111, SRa111, NHORa111, C(O)Rb111, C(O)NRc111Rd111, C(O)NRc111(ORa111), C(O)ORa111, OC(O)Rb111, OC(O)NRc111Rd111, NRc111Rd111, NRc111NRc111Rd111, NRc111C(O)Rb111, NRc111, C(O)ORa111, and NRc111C(O)NRc111Rd111, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents;
- or, alternatively, two R11 groups together form an oxo group;
- each Ra111, Rb111, Rc111, and Rd111 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra111, Rb111, Rc111, and Rd111 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents; or, any Rc111 and Rd111, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents; and
- each R11A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa112, SRa112, NHORa112, C(O)Rb112, C(O)NRc112Rd112, C(O)NRc112(ORa112), C(O)ORa112, OC(O)Rb112, OC(O)NRc112Rd112, NRc112Rd112, NRc112NRc112, Rd112, NRc112C(O)Rb112, NRc112C(O)ORa112, and NRc112C(O)NRc112Rd112, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R11A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; and
- eazch Ra112, Rb112, Rc112, and Rd112 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra112, Rb112, Rc112 and Rd112 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
- or, any Rc112 and Rd112, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents.
- In some embodiments of Formula (IIu):
- R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, SRa1, NHORa1, C(O)Rb1,C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, and NRc1C(O)NRc1Rd1;
- R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2,C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2 Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents;
- Z is N or CZ1;
- Z1 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl;
- R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, and S(O)2NRc6Rd6;
- each Rb6, Rc6, and Rd6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- X9 is N or C(R9)2;
- X11 is N or C(R11)2;
- each R9 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of R9 are each optionally substituted with 1, 2, 3, or 4 independently selected R9A substituents;
- or, alternatively, two R9 groups together form an oxo group;
- R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, or 4 independently selected R10NA substituents; and
- each R11 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of R11 are each optionally substituted with 1, 2, 3, or 4 independently selected R11A substituents.
- In some embodiments of Formula (IIu):
- R1 is selected from H and C1-6 alkyl;
- R2 is selected from H, C1-6 alkyl, C(O)Rb2, C(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, and 4-6 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and 4-6 membered heterocycloalkyl of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents;
- Z is CZ1;
- Z1 is selected from H, D, C1-3 alkyl, C1-3 haloalkyl, C2-3 alkenyl, and C2-3 alkynyl;
- R6 is selected from H, halo, C1-6 alkyl, S(O)Rb6, and S(O)2Rb6;
- X9 is C(R9)2;
- X11 is C(R11)2;
- each R9 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of R9 are each optionally substituted with 1, 2, 3, or 4 independently selected R9A substituents; or, alternatively, two R9 groups together form an oxo group;
- R10N is selected from C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl-, wherein the C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl- of R10N are each optionally substituted with 1 or 2 independently selected R10NA substituents; and
- each R11 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl.
- In some embodiments of Formula (IIu):
- R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, SRa1, NHORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, and NRc1C(O)NRc1Rd1;
- R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents;
- or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1 or 2 independently selected R2A substituents;
- each R2A is selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, and OH,
- Z is N or CH;
- R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, S(O)2NRc6Rd6S(O)(═NRe6)Rb6, and N═S(O)Ra6Rb6, wherein the C1-6 haloalkyl is optionally substituted with 1, 2 or 3 R6A independently selected from D, halo, CN, OH, NH2, and C1-6 alkyl;
- each Ra6, Rb6, Rc6, Rd6, and Re6 is independently selected from H and C1-6 alkyl;
- X9 is N or C(R9)2;
- X11 is N or C(R11)2;
- each R9 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of R9 are each optionally substituted with 1, 2, 3, or 4 independently selected R9A substituents;
- or, alternatively, two R9 groups together form an oxo group;
- R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, or 4 independently selected R10NA substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; and
- each R11 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of R11 are each optionally substituted with 1, 2, 3, or 4 independently selected R11A substituents.
- In some embodiments of Formula (IIu):
- R1 is selected from H and C1-6 alkyl;
- R2 is selected from H, C1-6 alkyl, C(O)Rb2, C(O)NRc2, Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl, wherein the C1-6 alkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, and OH;
- or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1 or 2 independently selected R2A substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, and OH;
- Z is N or CH;
- R6 is selected from H, halo, C1-6 alkyl, S(O)Rb6, S(O)2Rb6, S(O)(═NRe6)Rb6, and N═S(O)Ra6Rb6, wherein the C1-6 alkyl is optionally substituted with 1 or 2 OH;
- each R6, Rb6, and Re6 is independently selected from H, and C1-6 alkyl.
- X9 is C(R9)2;
- X11 is C(R11)2;
- each R9 is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, of R9 are each optionally substituted with 1, 2, 3, or 4 independently selected R9A substituents; or, alternatively, two R9 groups together form an oxo group;
- R10N is selected from C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl-, wherein the C1-6 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-6 alkyl- of R10N are each optionally substituted with 1 or 2 independently selected R10NA substituents selected from C1-6 alkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl; and each RH is independently selected from H, D, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl. In some embodiments, the disclosure provides a compound of Formula (IIw)
- or a pharmaceutically acceptable salt thereof; wherein:
- X1 is CR1 or N;
- X2 is CR2 or N;
- X3 is CR3 or N;
- wherein X1, X2, and X3 are not each simultaneously N;
- R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl- CN, NO2, OR a1, SRa1, NHORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1C(O)Rb1, NRc1C(O)ORa1, and NRc1C(O)NRc1Rd1;
- R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl of Raz, tc'.132, Roz and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents;
- or, any Roz and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1 or 2 independently selected R2A substituents;
- each R2A is selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, and OH,
- R3 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa1, SRa1, NHORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)NRc1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRC(O)Rb1, NRc1C(O)ORa1, and NRc1C(O)NRclRd1;
- Z is N or CH;
- R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, S(O)Rb6, S(O)NRc6Rd6, S(O)2Rb6, S(O)2NRc6Rd6, S(O)(═NRe6)Rb6, and N═S(O)Ra6Rb6, wherein the C1-6 haloalkyl is optionally substituted with 1, 2 or 3 R6A independently selected from D, halo, CN, OH, NH2, and C1-6 alkyl;
- each Ra6, Rb6, Rc6, Rd6, and Re6 is independently selected from H and C1-6 alkyl; and
- R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, or 4 independently selected R10NA substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl.
- In some embodiments of Formula (IIw):
- R1 is selected from H and C1-6 alkyl;
- R2 is selected from H, C1-6 alkyl, C(O)Rb2, C(O)NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2;
- each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl, wherein the C1-6 alkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1 or 2 independently selected R2A substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, and OH;
- or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1 or 2 independently selected R2A substituents selected from halo, C1-6 alkyl, C1-6 haloalkyl, CN, and OH;
- R3 is selected from H and C1-6 alkyl;
- Z is N or CH;
- R6 is selected from H, halo, C1-6 alkyl, S(O)Rb6, S(O)2Rb6, S(O)(═NRe6)Rb6, and N═S(O)Ra6Rb6, wherein the C1-6 alkyl is optionally substituted with 1 or 2 OH;
- each Ra6, Rb6, and Re6 is independently selected from H, and C1-6 alkyl; and
- R10N is selected from C1-6 alkyl, C3-6 cycloalkyl, and C3-6cycloalkyl C1-6alkyl-, wherein the C1-6 alkyl, C3-6 cycloalkyl, and C3-6cycloalkyl-C1-6alkyl- of R10N are each optionally substituted with 1 or 2 independently selected R10NA substituents independently selected from C1-6 alkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl.
- In some embodiments, the compound of Formula (I) is a compound of Formula (III):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIIb):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIIc):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIId):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (Me):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIIf):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIIg):
- or a pharmaceutically acceptable salt thereof
- In some embodiments, the compound of Formula (I) is a compound of Formula (IIIh):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IV):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IVb):
- or a pharmaceutically acceptable salt thereof
- In some embodiments, the compound of Formula (I) is a compound of Formula (IVc):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IVd):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IVe):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IVf):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula (IVg):
- or a pharmaceutically acceptable salt thereof
- In some embodiments, the compound of Formula (I) is a compound of Formula (IVh):
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound of Formula (I) is a compound of Formula 3-6 of Scheme III, a compound of Formula 5-2 of Scheme V, a compound of Formula 13-8 of Scheme XIII, a compound of Formula 14-5 of Scheme XIV, or a compound of Formula 15-5 of Scheme
- XV, or a pharmaceutically acceptable salt thereof.
- In some embodiments, the compound is the (S)-enantiomer of one of the preceding compounds, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is the (R)-enantiomer of one of the preceding compounds, or a pharmaceutically acceptable salt thereof.
- It is further appreciated that certain features of the present disclosure, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the present disclosure which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination. The present disclosure is intended to include all combinations of embodiments for each variable described hereinabove including salts thereof.
- At various places in the present specification, divalent linking substituents are described. It is specifically intended that each divalent linking substituent include both the forward and backward forms of the linking substituent. For example, —NR(CWR″).- includes both —NR(CR′R″), and —(CR′R″)NR. Where the structure clearly requires a linking group, the
- Markush variables listed for that group are understood to be linking groups.
- The term “n-membered” where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
- As used herein, the phrase “optionally substituted” means unsubstituted or substituted. The substituents are independently selected, and substitution may be at any chemically accessible position. As used herein, the term “substituted” means that a hydrogen atom is removed and replaced by a substituent. A single divalent substituent, e.g., oxo, can replace two hydrogen atoms. It is to be understood that substitution at a given atom is limited by valency.
- As used herein, the phrase “each ‘variable’ is independently selected from” means substantially the same as wherein “at each occurrence ‘variable’ is selected from.”
- Throughout the definitions, the term “C.” indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include
- C13, C1-4, C1-6, and the like.
- As used herein, the term “Calkyl”, employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched, having n to m carbons. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl (Me), ethyl (Et), n-propyl (n-Pr), isopropyl (iPr), n-butyl, teat-butyl, isobutyl, sec-butyl;
- higher homologs such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, and the like. In some embodiments, the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms.
- As used herein, “C. alkenyl” refers to an alkyl group having one or more double carbon-carbon bonds and having n to m carbons. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms. As used herein, “C_m alkynyl” refers to an alkyl group having one or more triple carbon-carbon bonds and having n to m carbons. Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
- As used herein, the term “C_m alkoxy”, employed alone or in combination with other terms, refers to a group of formula -0-alkyl, wherein the alkyl group has n to m carbons. Example alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), butoxy (e.g., n-butoxy and tent-butoxy), and the like. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “amino” refers to a group of formula —NH2. As used herein, the term “aryl,” employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or polycycliC(e.g., having 2 fused rings). The term “C.aryl” refers to an aryl group having from n to m ring carbon atoms. Aryl groups include, e.g., phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms. In some embodiments, the aryl group is phenyl or naphthyl. In some embodiments, the aryl is phenyl.
- As used herein, “halo” refers to F, Cl, Br, or I. In some embodiments, a halo is F, Cl, or Br. In some embodiments, a halo is F or Cl. In some embodiments, a halo is F. In some embodiments, a halo is Cl.
- As used herein, “C. haloalkoxy” refers to a group of formula —0-haloalkyl having n to m carbon atoms. Example haloalkoxy groups include OCF3 and OCHF2. In some embodiments, the haloalkoxy group is fluorinated only. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “C.haloalkyl”, employed alone or in combination with other terms, refers to an alkyl group having from one halogen atom to 2s+1 halogen atoms which may be the same or different, where “s” is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms. In some embodiments, the haloalkyl group is fluorinated only. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example haloalkyl groups include CF3, C2F5, CHF2, CH2F, CC13, CHC12, C2C15 and the like.
- As used herein, the term “C. alkylamino” refers to a group of formula -NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “C.alkoxycarbonyl” refers to a group of formula —C(O)O-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “C.alkylcarbonyl” refers to a group of formula -C(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. As used herein, the term “C.alkylcarbonylamino” refers to a group of formula -NHC(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “C. alkoxycarbonylamino” refers to a group of formula —NHC(O)0(C. alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “C.alkylsulfonylamino” refers to a group of formula -NHS(O)2-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “aminosulfonyl” refers to a group of formula -S(O)2NH2. As used herein, the term “C.alkylaminosulfonyl” refers to a group of formula -S(O)2NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “di(C. alkyl)aminosulfonyl” refers to a group of formula -S(O)2N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “aminosulfonylamino” refers to a group of formula —NHS(O)2NH2.
- As used herein, the term “C.alkylaminosulfonylamino” refers to a group of formula —NHS(O)2NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “di(C.alkyl)aminosulfonylamino” refers to a group of formula -NHS(O)2N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “aminocarbonylamino”, employed alone or in combination with other terms, refers to a group of formula -NHC(O)NH2.
- As used herein, the term “CHm alkylaminocarbonylamino” refers to a group of formula —NHC(O)NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “di(C.H. alkyl)aminocarbonylamino” refers to a group of formula -NHC(O)N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “Cn_malkylcarbamyl” refers to a group of formula —C(O)—NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “thio” refers to a group of formula -SH. As used herein, the term “Cn_malkylthio” refers to a group of formula -S-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “Cn_malkylsulfinyl” refers to a group of formula -S(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “Cn_malkylsulfonyl” refers to a group of formula -S(O)2-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “carbamyl” to a group of formula —C(O)NH2. As used herein, the term “carbonyl”, employed alone or in combination with other terms, refers to a -C(O)- group. As used herein, the term “cyano-C1-3 alkyl” refers to a group of formula -(C1-3 alkylene)-CN.
- As used herein, the term “HO-C1-6 alkyl” refers to a group of formula -(C1-6 alkylene)-OH.
- As used herein, the term “HO-C1-3 alkyl” refers to a group of formula -(C1-3 alkylene)-OH.
- As used herein, the term “C1-6 alkoxy-C1-6 alkyl” refers to a group of formula -(C1-6 alkylene)- 0 (C -6 alkyl).
- As used herein, the term “C1-3 alkoxy-Ci3 alkyl” refers to a group of formula -(C1-3 alkylene)-0(C1-3 alkyl).
- As used herein, the term “carboxy” refers to a group of formula -C(O)OH. As used herein, the term “di(C0-m-alkyl)amino” refers to a group of formula -N(alkyl)2, wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- As used herein, the term “di(C0-m-alkyl)carbamyl” refers to a group of formula — C(O)N(alkyl)2, wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. As used herein, the term “aminocarbonyloxy” refers to a group of formula -OC(O)NH2.
- As used herein, the term “C1-3 alkylcarbonyloxy” refers to a group of formula —OC(O)(C1— 3 alkyl).
- As used herein, the term “C1-3 alkylaminocarbonyloxy” refers to a group of formula —OC(O)NH(C1-3 alkyl). As used herein, the term “di(C1-3 alkyl)aminocarbonyloxy” refers to a group of formula —OC(O)N(C1-3 alkyl)2, wherein the two alkyl groups each has, independently, 1 to 3 carbon atoms.
- As used herein, “cycloalkyl” refers to non-aromatic cyclic hydrocarbons including cyclized alkyl and alkenyl groups. Cycloalkyl groups can include mono- or polycycliC(e.g., having 2 fused rings) groups, spirocycles, and bridged rings (e.g., a bridged bicycloalkyl group). Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo or sulfido (e.g., C(O) or C(S)). Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of cyclopentane, cyclohexane, and the like. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbons (i.e., C3_10). In some embodiments, the cycloalkyl is a C3-10 monocyclic or bicyclic cycloalkyl. In some embodiments, the cycloalkyl is a C3-10 monocyclic cycloalkyl which is optionally substituted by CH2F, CHF2, CF3, and CF2CF3. In some embodiments, the cycloalkyl is a C3-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C4-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C4_10 spirocycle or bridged cycloalkyl (e.g., a bridged bicycloalkyl group). Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, cubane, adamantane, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, and the like. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
- As used herein, “heteroaryl” refers to a monocyclic or polycycliC(e.g., having 2 fused rings) aromatic heterocycle having at least one heteroatom ring member selected from N, 0, S and B, wherein any ring forming N is optionally an N-oxide group. In some embodiments, the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from N, 0, S and B. In some embodiments, any ring-forming N in a heteroaryl moiety can be an N-oxide. In some embodiments, the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, 0, S and B. In some embodiments, the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, 0, and S. In some embodiments, the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, 0, S and B. In some embodiments, the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, 0, and S. In some embodiments, the heteroaryl is a 5-6 monocyclic heteroaryl having 1 or 2 heteroatom ring members independently selected from N, 0, S and B. In some embodiments, the heteroaryl is a 5-6 monocyclic heteroaryl ring having 1 or 2 heteroatom ring members independently selected from N, 0 or S. In some embodiments, the heteroaryl group contains 3 to 10, 4 to 10, 3 to 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to 4 ring-forming heteroatoms, 1 to 3 ring-forming heteroatoms, 1 to 2 ring-forming heteroatoms or 1 ring-forming heteroatom. When the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different. Example heteroaryl groups include, but are not limited to, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, azolyl, oxazole, isoxazole, thiophene, thiazole, isothiazole, imidazole, furan, thiophene, triazole, tetrazole, thiadiazole, quinoline, isoquinoline, indole, benzothiophene, benzofuran, benzisoxazole, imidazo[1,2-b]thiazole, purine, triazine, thieno[3,2-b]pyridine, imidazo[1,2-a]lpyridine, 1,5-naphthyridine, 1H-pyrazolo[4,3-b]pyridine, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, 1,3,4-oxadiazolyl, 1,2-dihydro-1,2-azaborine, and the like.
- As used herein, “heterocycloalkyl” refers to monocyclic or polycyclic heterocycles having at least one non-aromatic ring (saturated or partially unsaturated ring), wherein one or more of the ring-forming carbon atoms of the heterocycloalkyl is replaced by a heteroatom selected from N, 0, S and B, and wherein the ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group can be optionally substituted by one or more oxo or sulfido (e.g., C(O), S(O), C(S), or S(O)2, etc.). Heterocycloalkyl groups include monocyclic and polycycliC(e.g., having 2 fused rings) systems. Included in heterocycloalkyl are monocyclic and polycyclic 3-10-, 4-10-, 3-7-, 4-7-, and 5-6- membered heterocycloalkyl groups. Heterocycloalkyl groups can also include spirocycles and bridged rings (e.g., a 5-10 membered bridged biheterocycloalkyl ring having one or more of the ring-forming carbon atoms replaced by a heteroatom independently selected from N, 0, S and B). The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double bonds.
- Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the non-aromatic heterocyclic ring, for example, benzo or thienyl derivatives of piperidine, morpholine, azepine, etc. A heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. In some embodiments, the heterocycloalkyl group contains 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, 3 to 7 ring-forming atoms, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms or 1 heteroatom. In some embodiments, the heterocycloalkyl is a monocyclic 4-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, 0, S and B and having one or more oxidized ring members.
- Example heterocycloalkyl groups include pyrrolidin-2-one, 1,3-isoxazolidin-2-one, pyranyl, tetrahydropyran, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazapene, 1,2,3,4-tetrahydroisoquinoline, azabicyclo[3.1.0]hexanyl, diazabicyclo[3.1.0]hexanyl, oxabicyclo[2.1.1]hexanyl, azabicyclo [2.2.1]hep tanyl, diazabicyclo[2.2.1]heptanyl, azabicyclo[3.1.1]heptanyl, diazabicyclo[3.1.1]heptanyl, azabicyclo[3.2.1]octanyl, diazabicyclop.[2.11]octanyl, oxabicyclo[2.2.2]loctanyl, azabicyclo[2.2.2]loctanyl, azaadamantanyl, diazaadamantanyl, oxa-adamantanyl, azaspiro[3.3]heptanyl, diazaspiro[3.3]heptanyl, oxa-azaspiro[3.3]heptanyl (e.g. 2-oxa-6-azaspiro[3.3]heptan-6-yl), oxaspiro[3.3]heptanyl (e.g. 2-oxaspiro [3 .3] heptan-6-yl), azaspiro [3 .4] octanyl, diazaspiro [3 .4] octanyl, oxa-azaspiro [3 .4] octanyl, azaspiro[2.5]octanyl, diazaspiro[2.5]octanyl, azaspiro[4.4]nonanyl, diazaspiro[4.4]nonanyl, oxa-azaspiro[4.4]nonanyl, azaspiro[4.5]decanyl, diazaspiro[4.5]decanyl, diazaspiro[4.4]nonanyl, oxa-diazaspiro[4.4]nonanyl and the like. As used herein, “Co-p cycloalkyl-Cn_malkyl-” refers to a group of formula cycloalkyl-alkylene-, wherein the cycloalkyl has o to p carbon atoms and the alkylene linking group has n to m carbon atoms.
- As used herein “Co-p aryl-Cn_malkyl-” refers to a group of formula aryl-alkylene-, wherein the aryl has o to p carbon atoms and the alkylene linking group has n to m carbon atoms. As used herein, “heteroaryl-Cn_malkyl-” refers to a group of formula heteroaryl-alkylene-, wherein alkylene linking group has n to m carbon atoms.
- As used herein “heterocycloalkyl-Cn_m alkyl-” refers to a group of formula heterocycloalkyl-alkylene-, wherein alkylene linking group has n to m carbon atoms.
- At certain places, the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas a pyridin-3-yl ring is attached at the 3-position.
- As used herein, the term “oxo” refers to an oxygen atom (i.e., =0) as a divalent substituent, forming a carbonyl group when attached to a carbon (e.g., C=0 or C(O)), or attached to a nitrogen or sulfur heteroatom forming a nitroso, sulfinyl or sulfonyl group.
- As used herein, the term “independently selected from” means that each occurrence of a variable or substituent are independently selected at each occurrence from the applicable list.
- As used herein, a dashed bond (---) represents a single or double bond depending on the nature of the atoms in each ring and as required to complete the valencies of the atoms being linked by the bond.
- The compounds described herein can be asymmetriC(e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present disclosure that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C═N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present disclosure. Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separated isomeric forms. In some embodiments, the compound has the (R)-configuration. In some embodiments, the compound has the (S)-configuration. The Formulas (e.g., Formula (I), (II), etc.) provided herein include stereoisomers of the compounds.
- Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as (3-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of α-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.
- Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
- Compounds provided herein also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone — enol pairs, amide - imidic acid pairs, lactam — lactim pairs, enamine — imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H-isoindole, 2-hydroxypyridine and 2-pyridone, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
- All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g. hydrates and solvates) or can be isolated. In some embodiments, preparation of compounds can involve the addition of acids or bases to affect, for example, catalysis of a desired reaction or formation of salt forms such as acid addition salts.
- In some embodiments, the compounds provided herein, or salts thereof, are substantially isolated. By “substantially isolated” is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds provided herein. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds provided herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
- The term “compound” as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified.
- The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- The present application also includes pharmaceutically acceptable salts of the compounds described herein. The present disclosure also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company,
- Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety. Synthesis
- As will be appreciated by those skilled in the art, the compounds provided herein, including salts and stereoisomers thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
- Compounds of Formula (I) can be prepared as shown in Scheme 1. Appropriately substituted starting materials 1-1 wherein YB is a halogen (e.g., Cl, Br or I) can be converted to an appropriately substituted metal 1-2 (e.g., MB is B(OR)2, BF3K, Sn(R)3, or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl]palladium or [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane, and a base, such as potassium acetate). Intermediate 1-3 wherein YA is a halogen (e.g., Cl, Br or I) or pseudohalogen (e.g., OMs or OTf) and P is a suitable protecting group (e.g., trimethylsilylethoxymethyl) can be coupled with metal 1-2 under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(O), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane or bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) and a base (e.g., a carbonate base such as potassium carbonate, or cesium fluoride)) or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O)) or standard Negishi conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(O) or [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II)) to give compounds of Formula (I).
- Alternatively, compounds of Formula (I) can be prepared as shown in Scheme 2. Optionally protected intermediates such as 2-1, wherein YA is an appropriate halogen (e.g., Cl, Br, or I) or pseudohalogen (e.g., OMs or OTf), can be converted to an appropriately substituted metal MA (e.g., MA is B(OR)2, BF3K, SnR3, or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl]palladium or [1,1]-bis(diphenylphosphino)ferroceneldichloropalladium(II), complex with dichloromethane, and a base, such as potassium acetate). Intermediate 2-2 can undergo Suzuki, Stille or Negishi couplings with appropriate halo-derivatives 2-3, wherein YB is a suitable halogen (e.g., Cl, Br, or I) or pseudohalogen (e.g., OMs or OTO, to provide compounds of Formula (I). The compounds of Formula (I) can be prepared by either route depending on the compatibility of functional groups present in the intermediates.
- Compounds of Formula (I) wherein X1 is CR', X2 is CR2, and X3 is N (e.g., 3-6) can be prepared as shown in Scheme 3. Nitrile containing starting material 3-4, wherein YA is a suitable halogen (e.g., Cl, Br or I) or pseudohalogen (e.g., OMs or OTO, can be reacted with a suitable metal 3-2, wherein MB is a boronic acid, boronic ester, or an appropriately substituted metal such as Sn(Bu)4 or Zn, under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O) or 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1) and a base (e.g., a bicarbonate or carbonate base, or CsF) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O)), to give intermediate 3-5. The nitrile of intermediate 3-5 can be converted to a substituted imidazole as shown in 3-6 via several routes, some of which are outlined in Scheme 4. The order of steps can be reversed, such that imidazole formation to furnish 3-7 (by methods such as shown in Scheme 4) can precede the coupling to 3-2. In this case, the NH of the heterocycle (3-7) can be optionally protected (e.g., using SEM-Cl and base) to give a N-protected derivative (3-8), which can be coupled with 3-2 as described for the transformation from 3-4 to 3-5 above, to provide 3-9, which upon N-deprotection (e.g., reaction with a strong acid, such as TFA) will furnish compounds 3-6. The compounds of Formula (I) can be prepared by either route depending on the compatibility of functional groups present in the intermediates. Where the nitrile is not present in starting material 3-4, it can be installed from an appropriately substituted starting material 3-1, wherein Yc and YA are independently halogen (e.g., Yc is Cl or Br) or pseudohalogen (OMs or OTO, via Negishi coupling with Zn(CN)2 (e.g., in the presence of a Pd(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O)). Alternatively, a selective Suzuki, Stille or Negishi cross coupling of appropriately substituted starting material 3-1 with appropriately substituted metal 3-2 can provide intermediate 3-3, which can be converted to nitrile-containing intermediate 3-5 via Negishi coupling with Zn(CN)2 (e.g., in the presence of a Pd(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O)).
- Methods for formation of the imidazole are outlined in Scheme 4, in which both nitriles and carboxylic acids serve as useful starting materials. The imidazole formations may be carried out with RA =Cy (a bicyclic moiety shown in the intermediates 1-1, 1-2 and Formula (I) of
- Scheme 1), or alternatively with RA =XA (halo). Nitrile containing intermediate 4-1 can be converted to an imidate (e.g., by reacting with catalytic sodium methoxide in an alcohol or by reacting with HC1 in an alcohol) and the intermediate imidate can be reacted with an amino ketal or amino acetal (4-2, wherein R is an alkyl group such as methyl or ethyl) in the presence of acid (e.g., AcOH or HC1) and heat to form imidazole 4-3. Alternatively, the intermediate imidate can be reacted with NH4C1 to afford an amidine, which can be alkylated with an α-halo ketone (4-4) in the presence of base (e.g., KHCO3, or K2CO3) in a solvent such as an alcohol, or preferably, DMF, to furnish imidazole 4-3. The imidate intermediate formed by reacting nitrile 4-1 with catalytic sodium methoxide can be treated with a diamine (4-5) (e.g., a phenylenediamine derivative) and cyclized under acidic conditions and heat to afford imidazole 4-3. Alternatively, carboxylic acid 4-6 can be coupled to a diamine (4-5) in the presence of a coupling reagent (e.g., HATU) and base (e.g., Hunig's Base or triethylamine). The intermediate amide can be cyclized to imidazole 4-3 by heating in acid (e.g., AcOH). Carboxylic acid 4-6 can also be reacted with α-halo ketones (4-4) in the presence of base (e.g., K2CO3) to afford an ester intermediate that can be heated in the presence of NH4OAc to afford imidazole 4-3.
- In Scheme 4, when RA is Cy that contains a nucleophilic functional group (e.g., isoindolinone), further transformations may be carried out as shown in Scheme 5. For example, alkylation of suitably protected intermediate 5-1 with le-LG, wherein LG is a leaving group (e.g., LG =Br, I, OSO2Me, etc.), can be carried out in the presence of base (e.g.,Na2CO3,K2CO3, Cs2CO3, NaH, KO′Bu, etc.) to afford, after N-deprotection, the alkylated product 5-2. Where desired, if the alkylated product contains a manipulatable functional group, further transformations (e.g., hydrolysis, amide formation, reduction, alkylation, acylation, sulfonylation) are possible.
- Heterocycles may be installed in the compounds provided herein as shown in Schemes 6 to 9. As shown in Scheme 6, a regioselective cross-coupling can be achieved between appropriate substituted metal MB-Cy and 6-1 wherein YA and Yc are independently suitable halogens (e.g., Cl, Br or I) or pseudohalogens (e.g., OMs, OTI). This can be achieved by reacting MB-Cy, wherein MB is a boronic acid, boronic ester, or an appropriately substituted metal such as Sn(Bu)4 or Zn, under standard Suzuki conditions or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O) or 4-(di-tert-butylphosphino)-N,N-dimethylaniline-dichloropalladium (2:1) and a base (e.g., a bicarbonate or carbonate base, or CsF) or standard Negishi conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(O)), with intermediate 6-1 to give derivative 6-2. The desired heterocycle (e.g., illustrated by optionally protected imidazole isomer 6-3 wherein MD is a boronic acid, boronic ester, or an appropriately substituted metal such as Sn(Bu)4 or Zn) can be coupled with 6-2 under Suzuki, Stille or Negishi conditions as described above to afford (on subsequent N-deprotection) product 6-4.
- Compounds of Formula (I) wherein X1 is C-NHW', X2 is N, and X3 is C-R3 (e.g., 7-4 and 7-5) can be prepared, as shown in Scheme 7, by reacting an α-halo ketone (7-1) with 2-aminopyrimidine in the presence of base to form intermediate 7-2. After coupling with MB-Cy under standard Suzuki, Stille or Negishi conditions to afford 7-3, the aminoimidazole moiety can be liberated by reaction of intermediate 7-3 with hydrazine hydrate at elevated temperature (e.g., about 100° C.) to afford 7-4. The amine of 7-4 can optionally be alkylated by reaction of the amine with an aldehyde (e.g., RCHO) in the presence of a reducing agent (e.g., sodium cyanoborohydride or sodium triacetoxyborohydride) to give 7-5.
- Compounds of Formula (I) wherein X1 is C-NHW', and X2 and X3 are N (e.g., 8-6) can be prepared, as shown in Scheme 8, by reacting an ester (8-2, wherein R is an alkyl group (e.g., methyl or ethyl), prepared by Suzuki, Stille or Negishi coupling of 8-1 with MB-Cy) with hydrazine hydrate at elevated temperature to form an acyl hydrazide 8-3. Intermediate 8-3 can be reacted with an alkylated thiourea (8-5) in the presence of heat and base (e.g., 2,6-lutidine) to afford aminotriazole product 8-6. When unavailable commercially, the requisite intermediate 8-5 can be prepared by alkylating available thiourea 8-4 with methyl iodide.
- Compounds of Formula (I) wherein X1 is C-R′, and X2 and X3 are N (9-4) can be synthesized as shown in Scheme 9. Suzuki, Stille or Negishi coupling of appropriately substituted nitrile-containing intermediate 9-1 (e.g., YA =Cl, Br, I or OTf) with MB-Cy provides intermediate 9-2. Treatment of the nitrile intermediate 9-2 first with catalytic sodium methoxide, followed by an acyl hydrazide (9-3) at elevated temperature, furnishes triazole-containing product 9-4.
- Compounds provided herein that contain an imidazole can be further functionalized as shown, for example, in Schemes 10 and 11. As shown in Scheme 10, an imidazole such as 10-1, containing an unfunctionalized carbon, can be nitrated (e.g., using HNO3 in H2504) to provide nitro derivative 10-2, which can be reduced (e.g., using iron in AcOH or in aq. HC1 and alcoholic solvent) to amino derivative 10-3. If the group Cy is not anticipated to be stable to the conditions, the synthesis may alternatively be carried out with a halogen at that position, and the desired cyclic group (Cy) introduced by Suzuki, Stille, or Negishi conditions on the product of nitration or reduction (10-2, or 10-3, respectively), as appropriate. The compounds of Formula (I) can be prepared by either route depending on the compatibility of functional groups present in the intermediates.
- As shown in Scheme 11, an imidazole such as 11-1, containing an unfunctionalized carbon, can be treated with a halogenating reagent (e.g., N-iodosuccinimide or N-bromosuccinimide) to form halo-containing intermediate 11-2 (e.g., to provide a compound wherein X2 is Cl, Br or I). Subjection of an optionally protected intermediate 11-2 to a Pd-catalyzed cross-coupling reaction (e.g., Suzuki, Stille, Negishi and the like) can furnish (after N-deprotection) compounds 11-3.
- As shown in Scheme 12, appropriately substituted starting material 12-1, wherein X2 is a halogen (e.g., Cl, Br or I) or pseudohalogen (e.g., OMs or OTf) can be converted to carbonyl-containing products. Reaction of starting material 12-1 with carbon monoxide in the presence of an alcohol (e.g., R=CH3 or CH2CH3) and a Pd catalyst (e.g., [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II),complex with dichloromethane (1:1)) affords an ester (12-2). Hydrolysis of the ester in 12-2 under standard conditions (e.g., aq. NaOH in THF and an alcohol) can be carried out to afford a carboxylic acid which can be coupled with an amine, R2cR2dNH, under standard conditions (e.g., HATU in the presence of Hunig's base or triethylamine) to form amide 12-3. Amide 12-3 can also be prepared by heating ester 12-2 with amine R2cR2dNH in the presence of a suitable lewis acid (e.g., A1C13). Direct conversion of halo-containing intermediate 12-1 to amide 12-3 can also be effected by reacting 12-1 with carbon monoxide and a Pd catalyst in the presence of an amine R2cR2dNH. If the CO insertion reaction on 12-1 is carried out in the absence of alcohol and in the presence of a reducing agent (e.g., triethylsilane), aldehyde 12-4 can be prepared. The aldehyde can be converted to an amine-containing compound (12-5) by reductive amination with R2CR2dNH in the presence of a reducing agent (e.g., sodium cyanoborohydride, sodium triacetoxyborohydride). Numerous other functional group transformations can be carried out on intermediates 12-2 and 12-4, such as, but not limited to, Grignard addition, reduction, and deoxyfluorination (e.g., with Deoxo-Fluor).
- The Cy group in compounds of Formula (I) can be prepared as shown in Scheme 13. Appropriately substituted ester 13-1 (e.g., R is -CH3, -CH2CH3 and the like) wherein YB is a halo (e.g., Cl, Br, or I) or pseudohalo group (e.g., OTf or OMs), Y6 is a suitable halogen (e.g. Cl, Br or
- I), and substituent X11 is a suitable alkyl group, can be halogenated by treatment with a halogenating reagent such as an N-halosuccinimide (e.g., N-chlorosuccinimide, N-bromosuccinimide or N-iodosuccinimide) to afford intermediate 13-3 wherein LH is a halogen (e.g., Cl, Br or I). Alternatively, a suitably substituted starting material 13-2 bearing an alcohol substituent on alkyl group X11 can be halogenated by treatment with a suitable halogenating reagent (e.g., SOC12 or triphenylphosphine dibromide) to afford 13-3 wherein LH is a halogen (e.g., Cl, Br or I). Alternatively, 13-2 can be treated with a sulfonyl chloride (e.g., p-toluenesulfonyl chloride or methanesulfonyl chloride) in the presence of a base (e.g., triethylamine or Hunig's base) to afford 13-3 wherein L″ is a sulfonyl-based leaving group (e.g., OMs or OTs). Intermediate 13-3 can be converted to intermediate 13-4 via reaction with an amine
- (RioNN—ri2 ,) in the presence of base (e.g., triethylamine or N,N-diisopropylethylamine), or in the presence of acid (e.g., boric acid) and base (e.g., a carbonate base such as K2CO3, Cs2CO3 or
- Na2CO3). Intermediate 13-4 wherein Y6 is a suitable halogen (e.g., Cl, Br or I) can be converted to thioether 13-5 by heating in the presence of a suitable sulfur nucleophile Rb6SM wherein M is a suitable metal such as sodium (e.g., sodium methanethiolate). Oxidation of intermediate 13-5 with a suitable oxidizing agent (e.g., m-CPBA) provides sulfone intermediate 13-6. The YB halo (e.g., Cl, Br, or I) or pseudohalo group (e.g., OTf or OMs) of intermediate 13-6 can be converted to an appropriately substituted metal (e.g., MB is B(OH)2, Bpin, BF3K, Sn(Bu)3, or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl)]palladium or [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane, and a base, such as potassium acetate) to afford compound 13-7. Intermediates 13-4, 13-5, 13-6 and 13-7 can be used as shown in the preceding and following Schemes to prepare compounds 13-8.
- Compounds of Formula (I) can be prepared as shown in Scheme 14. A suitably substituted intermediate 14-1 wherein YB and Y6 are independently halogen (e.g., Cl, Br, or I) or pseudohalogen (e.g., OTf or OMs) can be converted to an appropriately substituted metal 14-2 (e.g., MB is B(OH)2, Bpin, BF3K, Sn(Bu)3, or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl]palladium or [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane, and a base, such as potassium acetate). Intermediate 14-2 can be transformed to 14-3 via the methods shown in preceding Schemes (e.g., Scheme 1). Compound 14-3 wherein Y6 is a suitable halogen (e.g., Cl, Br or I) can be converted to thioether 14-4 by heating in the presence of a suitable sulfur nucleophile Rb6SM wherein M is a suitable metal such as sodium (e.g., sodium methanethiolate).
- Oxidation of compound 14-4 with a suitable oxidizing agent (e.g., m-CPBA) can provide compounds 14-5.
- Compounds of Formula (I) can be prepared as shown in Scheme 15. Intermediate 15-1 wherein YB is a halogen (e.g., Cl, Br, or I) or pseudohalogen (e.g., OTf or OMs) can be converted to an appropriately substituted metal 15-2 (e.g., MB is B(OH)2, Bpin, BF3K, Sn(Bu)3, or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphorany]palladium or [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane, and a base, such as potassium acetate). In some cases, treatment of intermediate 15-2 with an alkylating agent R10 N-L, wherein L is a suitable leaving group (e.g., a halogen (e.g., Cl, Br, or I) or pseudohalo group (e.g., OTs or OMs)), in the presence of a base (e.g., sodium hydride or carbonate base (e.g., cesium carbonate)) can provide intermediate 15-3. Alternatively, the steps can be performed in reverse order (i.e., 15-1 may be alkylated with R10 N-L under conditions described above, to provide compound 15-4, which can subsequently converted to metal 15-3 under conditions described above) to afford intermediate 15-3, which can be converted to compounds of Formula (I) as outlined in preceding Schemes (e.g., Scheme 1).
- The reactions for preparing compounds described herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, (e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature). A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
- The expressions, “ambient temperature” or “room temperature” or “rt” as used herein, are understood in the art, and refer generally to a temperature, e.g., a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20° C. to about 30° C.
- Preparation of compounds described herein can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., Wiley & Sons, Inc., New York (1999).
- Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 11-1 or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LCMS), or thin layer chromatography (TLC). Compounds can be purified by those skilled in the art by a variety of methods, including high performance liquid chromatography (HPLC) and normal phase silica chromatography. Methods of Use The compounds, salts or stereoisomers thereof described herein inhibit activity of PI3Kγ kinase. Accordingly, the compounds, salts or stereoisomers described herein can be used in methods of inhibiting PI3Kγ kinase by contacting the kinase with any one or more of the compounds, salts, or compositions described herein. In some embodiments, the compounds or salts can be used in methods of inhibiting activity of PI3Kγ in an individual/patient in need of the inhibition by administering an effective amount of a compound or salt of described herein. In some embodiments, modulating is inhibiting. In some embodiments, the contacting is in vivo. In some embodiments, the contacting is ex vivo. Advantageously, the compounds as described herein demonstrate better efficacy and favorable safety and toxicity profiles in animal studies.
- In some embodiments, the PI3Kγ includes a mutation. A mutation can be a replacement of one amino acid for another, or a deletion of one or more amino acids. In such embodiments, the mutation can be present in the kinase domain of the PI3Kγ .
- In some embodiments, the compound or salt further inhibits PI3K6. The compounds or salts described herein can be selective. By “selective” is meant that the compound binds to or inhibits PI3Kγ with greater affinity or potency, respectively, compared to at least one other kinase. In some embodiments, the compounds of the disclosure are selective inhibitors of PI3Kγ over PI3K6, PI3Kα, and PI3K13. In some embodiments, the compounds of the disclosure are selective inhibitors of PI3Kγ over PI3Kα and PI3K13. In some embodiments, selectivity can be at least about 2-fold, 3-fold, 5-fold, 10-fold, at or 20-fold over PI3K6 as measured by the assays described herein. In some embodiments, selectivity can be tested at the 2 uM ATP concentration of each enzyme. In some embodiments, the selectivity of compounds of the disclosure can be determined by cellular assays associated with particular PI3K kinase activity.
- Another aspect of the present disclosure pertains to methods of treating a kinase PI3Kγ-associated disease or disorder in an individual (e.g., patient) by administering to the individual in need of such treatment a therapeutically effective amount or dose of one or more compounds of the present disclosure or a pharmaceutical composition thereof. A PI3Kγ -associated disease or disorder can include any disease, disorder or condition that is directly or indirectly linked to expression or activity of the PI3Kγ , including overexpression and/or abnormal activity levels.
- In some embodiments, the disease or disorder is an autoimmune disease or disorder, cancer, cardiovascular disease, or neurodegenerative disease.
- In some embodiments, the disease or disorder is lung cancer (e.g., non-small cell lung cancer), melanoma, pancreatic cancer, breast cancer, head and neck squamous cell carcinoma, prostate cancer, liver cancer, color cancer, endometrial cancer, bladder cancer, skin cancer, cancer of the uterus, renal cancer, gastric cancer, or sarcoma. In some embodiments, the sarcoma is Askin's tumor, sarcoma botryoides, chondrosarcoma, Ewing's sarcoma, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans, desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, or undifferentiated pleomorphic sarcoma.
- In some embodiments, the disease or disorder is mesothelioma or adrenocarcinoma. In some embodiments, the disease or disorder is mesothelioma. In some embodiments, the disease or disorder is adrenocarcinoma. In some embodiments, the disease or disorder is acute myeloid leukemia (e.g., acute monocytic leukemia), small lymphocyctic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma, T-cell actute lymphoblasic leukemia (T-ALL), cutaneous T-cell lymphoma, large granular lymphocytic leukemia, mature (peripheral) t-cell neoplasm (PTCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma. In some embodiments, the mature (peripheral) t-cell neoplasm (PTCL) is T-cell prolymphocytic leukemia, T-cell granular lymphocytic leukemia, aggressive NK-cell leukemia, mycosis fungoides/Sezary syndrome, naplastic large cell lymphoma (T-cell type), enteropathy type T-cell lymphoma, adult T-cell leukemia/lymphoma, or angioimmunoblastic T-cell lymphoma In some embodiments, the anaplastic large cell lymphoma (ALCL) is systemic ALCL or primary cutaneous ALCL.
- In some embodiments, the disease or disorder is Burkitt's lymphoma, acute myeloblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, hairy cell leukemia, Mantle cell lymphoma, small lymphocytic lymphoma, follicular lymphoma, xenoderoma pigmentosum, keratoctanthoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, myelofibrosis, mucosa-associated lymphatic tissue (MALT) lymphoma, mediastinal (thymic) large B-cell lymphoma, lymphomatoid granulomatosis, splenic marginal zone lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smouldering myeloma (aka asymptomatic myeloma), monoclonal gammopathy of undetermined significance (MGUS), or diffuse large B cell lymphoma.
- In some embodiments, the disease or disorder is Burkitt's lymphoma, acute myeloblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, hairy cell leukemia, Mantle cell lymphoma, small lymphocytic lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, myelofibrosis, mucosa-associated lymphatic tissue (MALT) lymphoma, mediastinal (thymic) large B-cell lymphoma, lymphomatoid granulomatosis, splenic marginal zone lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smouldering myeloma (aka asymptomatic myeloma), monoclonal gammopathy of undetermined significance (MGUS), or diffuse large B cell lymphoma.
- MDSC (myeloid-derived suppressor cells) are a heterogenous group of immune cells from the myeloid lineage (a family of cells that originate from bone marrow stem cells). MDSCs strongly expand in pathological situations such as chronic infections and cancer, as a result of an altered haematopoiesis. MDSCs are discriminated from other myeloid cell types in which they possess strong immunosuppressive activities rather than immunostimulatory properties. Similar to other myeloid cells, MDSCs interact with other immune cell types including T cells, dendritic cells, macrophages and natural killer cells to regulate their functions. In some embodiments, the compounds, etc. described herein can be used in methods realted to cancer tissue (e.g., tumors) with high infiltration of MDSCs, including Solid tumors with high basal level of macrophage and/or MDSC infiltration.
- In some embodiments, the non-Hodgkin's lymphoma (NHL) is relapsed NHL, refractory NHL, recucurrent follicular NHL, indolent NHL (iNHL), or aggressive NHL (aNHL).
- In some embodiments, the diffuse large B cell lymphoma is activated B-cell like (ABC) diffuse large B cell lymphoma, or germinal center B cell (GCB) diffuse large B cell lymphoma.In some embodiments, the Burkitt's lymphoma is endemic Burkitt's lymphoma, sporadic Burkitt's lymphoma, or Burkitt's-like lymphoma.
- In some embodiments, the disease or disorder is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematous, asthma, allergy (e.g, allergic rhinitis), pancreatitis, psoriasis, anaphylaxis, glomerulonephritis, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), thrombosis, meningitis, encephalitis, diabetic retinopathy, benign prostatic hypertrophy, myasthenia gravis, Sjogren's syndrome, osteoarthritis, restenosis, or atherosclerosis.
- In some embodiments, the disease or disorder is heart hypertropy, cardiac myocyte dysfunction, acute coronary syndrome, chronic obstructive pulmonary disease (COPD), chronic bronchitis, elevated blood pressure, ischemia, ischemia-reperfusion, vasoconstriction, anemia (e.g., hemolytic anemia, aplastic anemia, or pure red cell anemia), bacterial infection, viral infection, graft rejection, kidney disease, anaphylactic shock fibrosis, skeletal muscle atrophy, skeletal muscle hypertrophy, angiogenesis, sepsis, graft-versus-host disease, allogeneic or xenogeneic transplantation, glomerulosclerosis, progressive renal fibrosis, idiopathic thrombocytopenic purpura (ITP), idiopathic pulmonary fibrosis, autoimmune hemolytic anemia, vasculitis, lupus nephritis, pemphigus, or membranous nephropathy.
- In some embodiments, disease or disorder is heart hypertropy, cardiac myocyte dysfunction, chronic obstructive pulmonary disease (COPD), elevated blood pressure, ischemia, ischemia-reperfusion, vasoconstriction, anemia (e.g., hemolytic anemia, aplastic anemia, or pure red cell anemia), bacterial infection, viral infection, graft rejection, kidney disease, anaphylactic shock fibrosis, skeletal muscle atrophy, skeletal muscle hypertrophy, angiogenesis, sepsis, graft rejection, glomerulosclerosis, progressive renal fibrosis, idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, or membranous nephropathy.
- In some embodiments, the disease or disorder is Alzheimer's disease, central nervous system trauma, or stroke.
- In some embodiments, the idiopathic thrombocytopenic purpura (ITP) is relapsed ITP or refractory ITP.
- In some embodiments, the vasculitis is Behcet's disease, Cogan's syndrome, giant cell arteritis, polymyalgia rheumatica (PMR), Takayasu's arteritis, Buerger's disease (thromboangiitis obliterans), central nervous system vasculitis, Kawasaki disease, polyarteritis nodosa, Churg-Strauss syndrome, mixed cryoglobulinemia vasculitis (essential or hepatitis C virus (HCV)-induced), Henoch-Schonlein purpura (HSP), hypersensitivity vasculitis, microscopic polyangiitis,
- Wegener's granulomatosis, or anti-neutrophil cytoplasm antibody associated (ANCA) systemic vasculitis (AASV).
- The present disclosure further provides a compound described herein, or a pharmaceutically acceptable salt thereof, for use in any of the methods described herein. The present disclosure further provides use of a compound described herein, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in any of the methods described herein.
- As used herein, the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, “contacting” a PI3K with a compound of the disclosure includes the administration of a compound of the present disclosure to an individual or patient, such as a human, having a PI3K, as well as, for example, introducing a compound of the disclosure into a sample containing a cellular or purified preparation containing the PI3K.
- It is believed that compounds of provdied herein (e.g., compounds of Formula (I), or pharmaceutically acceptable salts thereof) or any of the embodiments thereof, may possess satisfactory pharmacological profile and promising biopharmaceutical properties, such as toxicological profile, metabolism and pharmacokinetic properties, solubility, and permeability. It will be understood that determination of appropriate biopharmaceutical properties is within the knowledge of a person skilled in the art, e.g., determination of cytotoxicity in cells or inhibition of certain targets or channels to determine potential toxicity.
- As used herein, the term “individual” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
- As used herein, the phrase “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician.
- As used herein, the term “treating” or “treatment” can refer to one or more of (1) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology); and (2) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
- In some embodiments, the compounds of the disclosure are useful in preventing or reducing the risk of developing any of the diseases referred to herein; e.g., preventing or reducing the risk of developing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease. Combination Therapies I. Immune-checkpoint therapies
- In some embodiments, the PI3K7 inhibitors provided herein can be used in combination with one or more immune checkpoint inhibitors for the treatment of cancer as described herein. In one embodiment, the combination with one or more immune checkpoint inhibitors as described herein can be used for the treatment of melanoma. Compounds of the present disclosure can be used in combination with one or more immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD20, CD28, CD40, CD122, CD96, CD73, CD47, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, HPK1, CD137 (also known as 4-1BB), ICOS, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, TIGIT, PD-1, PD-LI and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40,
- ICOS, OX40, GITR and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, TIGIT, and VISTA. In some embodiments, the compounds of the disclosure provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.
- In some embodiments, the PI3K7 inhibitors provided herein can be used in combination with one or more agonists of immune checkpoint molecules, e.g., OX40, CD27, OX40, GITR, and CD137 (also known as 4-1BB).
- In some embodiments, the inhibitor of an immune checkpoint molecule is anti-PD1 antibody, anti-PD-Ll antibody, or anti-CTLA-4 antibody.
- In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), durvalumab (Imfinzi®), pidilizumab, SHR-1210, PDR001, MGA012, PDR001, AB122, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD1 antibody is pembrolizumab. In some embodiments, the anti-PD-1 monoclonal antibody is MGA012. In some embodiments, the anti-PD1 antibody is SHR-1210. Other anti-cancer agent(s) include antibody therapeutics such as 4-IBB (e.g. urelumab, utomilumab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of
- PD-L1, e.g., an anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-Ll monoclonal antibody is MPDL3280A or MEDI4736. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of
- PD-1 and PD-L1, e.g., an anti-PD-1/PD-L1 monoclonal antibody. In some embodiments, the anti-PD-1/PD-L1 is MCLA-136.
- In some embodiments, the inhibitor is MCLA-145. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884, or CP-675,206.
- In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525, or INCAGN2385. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of
- TIM3, e.g., an anti-TIM3 antibody. In some embodiments, the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022.
- In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, or MEDI1873.
- In some embodiments, the inhibitor of an immune checkpoint molecule is an agonist of OX40, e.g., OX40 agonist antibody or OX4OL fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS-986178. In some embodiments, the OX4OL fusion protein is MEDI6383.
- In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.
- The compounds of the present disclosure can be used in combination with bispecific antibodies. In some embodiments, one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3 or TGFI3 receptor.
- In some embodiments, the PI3K7 inhibitors provided herein can be used in combination with one or more metabolic enzyme inhibitors. In some embodiments, the metabolic enzyme inhibitor is an inhibitor of ID01, TDO, or arginase. Examples of IDOL inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.
- As provided throughout, the additional compounds, inhibitors, agents, etc. can be combined with the present compound in a single or continuous dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.
- II. Cancer Therapies
- Cancer cell growth and survival can be impacted by multiple signaling pathways. Thus, it is useful to combine different enzyme/protein/receptor inhibitors, exhibiting different preferences in the targets which they modulate the activities of, to treat such conditions. Targeting more than one signaling pathway (or more than one biological molecule involved in a given signaling pathway) may reduce the likelihood of drug-resistance arising in a cell population, and/or reduce the toxicity of treatment.
- The compounds of the present disclosure can be used in combination with one or more other enzyme/protein/receptor inhibitors or one or more therapies for the treatment of diseases, such as cancer. Examples of diseases and indications treatable with combination therapies include those as described herein. Examples of cancers include solid tumors and liquid tumors, such as blood cancers.
- One or more additional pharmaceutical agents such as, for example, chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, immune-oncology agents, metabolic enzyme inhibitors, chemokine receptor inhibitors, and phosphatase inhibitors, as well as targeted therapies such as Bcr-Abl, Flt-3, EGFR, HER2, JAK, c-MET, VEGFR, PDGFR, c-Kit, IGF-1R, RAF, and FAK kinase inhibitors such as, for example, those described in WO 2006/056399.
- Other agents such as therapeutic antibodies can be used in combination with the compounds of the present disclosure for treatment of PI3K-associated diseases, disorders or conditions. The one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially. For example, the compounds as disclosed herein can be combined with one or more inhibitors of the following kinases for the treatment of cancer and other diseases or disorders described herein: Aktl, Akt2, Akt3, TGF-(3R, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFaR, PDGFOR, CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR/F1t2, Flt4, EphAl, EphA2,
- EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. Non-limiting examples of inhibitors that can be combined with the compounds of the present disclosure for treatment of cancer and other diseases and disorders described herein include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4, e.g., INCB54828, INCB62079 and INCB63904), a JAK inhibitor (JAK1 and/or JAK2, e.g., ruxolitinib, baricitinib or INCB39110), an IDO inhibitor (e.g., epacadostat, NLG919, or BMS-986205), an LSD1 inhibitor (e.g., INCB59872 and INCB60003), a TDO inhibitor, a PI3K-delta inhibitor (e.g., INCB50797 and INCB50465), a Pim inhibitor, a CSF1R inhibitor, a TAM receptor tyrosine kinases (Tyro-3, Axl, and Mer), a histone deacetylase inhibitor (HDAC) such as an HDAC8 inhibitor, an angiogenesis inhibitor, an interleukin receptor inhibitor, bromo and extra terminal family members inhibitors (for example, bromodomain inhibitors or BET inhibitors such as INCB54329 and INCB57643) and an adenosine receptor antagonist or combinations thereof.
- In some embodiments, the compound or salt described herein is administered with a PI3K6 inhibitor. In some embodiments, the compound or salt described herein is administered with a JAK inhibitor. In some embodiments, the compound or salt described herein is administered with a JAK1 or JAK2 inhibitor (e.g., baricitinib or ruxolitinib). In some embodiments, the compound or salt described herein is administered with a JAK1 inhibitor. In some embodiments, the compound or salt described herein is administered with a JAK1 inhibitor, which is selective over JAK2.
- Example antibodies for use in combination therapy include but are not limited to Trastuzumab (e.g. anti-HER2), Ranibizumab (e.g. anti-VEGF-A), Bevacizumab (trade name Avastin, e.g. anti-VEGF, Panitumumab (e.g. anti-EGFR), Cetuximab (e.g. anti-EGFR), Rituxan (anti-CD20) and antibodies directed to c-MET.
- One or more of the following agents may be used in combination with the compounds of the present disclosure and are presented as a non-limiting list: a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, IRESSATm(gefitinib), TARCEVA™ (erlotinib), antibodies to EGFR, intron, ara-C, adriamycin, cytoxan, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, oxaliplatin, leucovirin, ELOXATINTm (oxaliplatin), pentostatine, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, teniposide 17.alpha.-ethinylestradiol, diethylstilbestrol, testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, testolactone, megestrolacetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesteroneacetate, leuprolide, flutamide, toremifene, goserelin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, navelbene, anastrazole, letrazole, capecitabine, reloxafine, droloxafine, hexamethylmelamine, avastin, HERCEPTIN™ (trastuzumab), BEXXAR™ (tositumomab), VELCADE™ (bortezomib),
- ZEVALIN™ (ibritumomab tiuxetan), TRISENOX™ (arsenic trioxide), XELODATM (capecitabine), vinorelbine, porfimer, ERBITUX™ (cetuximab), thiotepa, altretamine, melphalan, trastuzumab, lerozole, fulvestrant, exemestane, ifosfomide, rituximab, C225 (cetuximab), Campath (alemtuzumab), clofarabine, cladribine, aphidicolon, rituxan, sunitinib, dasatinib, tezacitabine, Sml 1, fludarabine, pentostatin, triapine, didox, trimidox, amidox, 3-AP, and MDL-101,731.
- The compounds of the present disclosure can further be used in combination with other methods of treating cancers, for example by chemotherapy, irradiation therapy, tumortargeted therapy, adjuvant therapy, immunotherapy, or surgery. Examples of immunotherapy include cytokine treatment (e.g., interferons, GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccine, monoclonal antibody, adoptive T cell transfer, Toll receptor agonists, STING agonists, oncolytic virotherapy and immunomodulating small molecules, including thalidomide or JAK1/2 inhibitor and the like. The compounds can be administered in combination with one or more anti-cancer drugs, such as a chemotherapeutics. Example chemotherapeutics include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, olaparib, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, rucaparib, streptozocin, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, niraparib, veliparib, talazoparib and zoledronate.
- Additional examples of chemotherapeutics include proteosome inhibitors (e.g., bortezomib), thalidomide, revlimid, and DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.
- Example steroids include corticosteroids such as dexamethasone or prednisone. Example Bcr-Abl inhibitors include imatinib mesylate (GLEEVACTM), nilotinib, dasatinib, bosutinib, and ponatinib, and pharmaceutically acceptable salts. Other example suitable Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No. 5,521,184, WO 04/005281, and U.S. Ser. No. 60/578,491.
- Example suitable Flt-3 inhibitors include midostaurin, lestaurtinib, linifanib, sunitinib, sunitinib, maleate, sorafenib, quizartinib, crenolanib, pacritinib, tandutinib, PLX3397 and ASP2215, and their pharmaceutically acceptable salts. Other example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 03/037347, WO 03/099771, and WO 04/046120.
- Example suitable RAF inhibitors include dabrafenib, sorafenib, and vemurafenib, and their pharmaceutically acceptable salts. Other example suitable RAF inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444.
- Example suitable FAK inhibitors include VS-4718, VS-5095, VS-6062, VS-6063, BI853520, and GSK2256098,and their pharmaceutically acceptable salts. Other example suitable FAK inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595, and WO 01/014402.
- In some embodiments, the compounds of the disclosure can be used in combination with one or more other kinase inhibitors including imatinib, particularly for treating patients resistant to imatinib or other kinase inhibitors. In some embodiments, the compounds of the disclosure can be used in combination with a chemotherapeutic in the treatment of cancer, and may improve the treatment response as compared to the response to the chemotherapeutic agent alone, without exacerbation of its toxic effects. In some embodiments, the compounds of the disclosure can be used in combination with a chemotherapeutic provided herein. For example, additional pharmaceutical agents used in the treatment of multiple myeloma, can include, without limitation, melphalan, melphalan plus prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib). Further additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM). Additive or synergistic effects are desirable outcomes of combining a PI3K inhibitor of the present disclosure with an additional agent.
- In some embodiments, the compounds of the disclosure can be used in combination with an inhibitor of JAK or PI3K8. The agents can be combined with the present compound in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
- The compounds of the present disclosure can be used in combination with one or more other inhibitors or one or more therapies for the treatment of infections. Examples of infections include viral infections, bacterial infections, fungus infections or parasite infections. In some embodiments, a corticosteroid such as dexamethasone is administered to a patient in combination with the compounds of the disclosure where the dexamethasone is administered intermittently as opposed to continuously.
- The compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with another immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines. Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gp100, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-C SF. The compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be used in combination with a vaccination protocol for the treatment of cancer. In some embodiments, the tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV). In some embodiments, the compounds of the present disclosure can be used in combination with tumor specific antigen such as heat shock proteins isolated from tumor tissue itself. In some embodiments, the compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be combined with dendritic cells immunization to activate potent anti-tumor responses.
- The compounds of the present disclosure can be used in combination with bispecific macrocyclic peptides that target Fe alpha or Fe gamma receptor-expressing effectors cells to tumor cells. The compounds of the present disclosure can also be combined with macrocyclic peptides that activate host immune responsiveness.
- In some further embodiments, combinations of the compounds of the disclosure with other therapeutic agents can be administered to a patient prior to, during, and/or after a bone marrow transplant or stem cell transplant. The compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
- The compounds of Formula (I) or any of the formulas as described herein, a compound as recited in any of the claims and described herein, or salts thereof can be used in combination with vaccines, to stimulate the immune response to pathogens, toxins, and self antigens. Examples of pathogens for which this therapeutic approach may be particularly useful, include pathogens for which there is currently no effective vaccine, or pathogens for which conventional vaccines are less than completely effective. These include, but are not limited to, HIV, Hepatitis (A, B, & C), Influenza, Herpes, Giardia, Malaria, Leishmania, Staphylococcus aureus, Pseudomonas Aeruginosa.
- Viruses causing infections treatable by methods of the present disclosure include, but are not limit to human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpes simplex viruses, human cytomegalovirus, severe acute respiratory syndrome virus, ebola virus, measles virus, herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumpsvirus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.
- Pathogenic bacteria causing infections treatable by methods of the disclosure include, but are not limited to, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
- Pathogenic fungi causing infections treatable by methods of the disclosure include, but are not limited to, Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans,
- Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum. Pathogenic parasites causing infections treatable by methods of the disclosure include, but are not limited to, Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis. Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the “Physicians' Desk Reference” (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference as if set forth in its entirety.
- Pharmaceutical Formulations and Dosage Forms
- When employed as pharmaceuticals, the compounds of the disclosure can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
- Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- This disclosure also includes pharmaceutical compositions which contain, as the active ingredient, the compound of the disclosure or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical administration. In making the compositions of the disclosure, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh. The compounds of the disclosure may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the disclosure can be prepared by processes known in the art, e.g., see International App. No. WO 2002/000196.
- Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the disclosure can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
- The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1000 mg (1 g), more usually about 100 to about 500 mg, of the active ingredient. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
- In some embodiments, the compositions of the disclosure contain from about 5 to about 50 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compositions containing about 5 to about 10, about 10 to about 15, about 15 to about 20, about 20 to about 25, about 25 to about 30, about 30 to about 35, about 35 to about 40, about 40 to about 45, or about 45 to about 50 mg of the active ingredient.
- In some embodiments, the compositions of the disclosure contain from about 50 to about 500 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compositions containing about 50 to about 100, about 100 to about 150, about 150 to about 200, about 200 to about 250, about 250 to about 300, about 350 to about 400, or about 450 to about 500 mg of the active ingredient.
- In some embodiments, the compositions of the disclosure contain from about 500 to about 1000 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compositions containing about 500 to about 550, about 550 to about 600, about 600 to about 650, about 650 to about 700, about 700 to about 750, about 750 to about 800, about 800 to about 850, about 850 to about 900, about 900 to about 950, or about 950 to about 1000 mg of the active ingredient.
- Similar dosages may be used of the compounds described herein in the methods and uses of the disclosure.
- The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present disclosure. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the active ingredient of the present disclosure.
- The tablets or pills of the present disclosure can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- The liquid forms in which the compounds and compositions of the present disclosure can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
- Topical formulations can contain one or more conventional carriers. In some embodiments, ointments can contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g. glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, for example, glycerol, hydroxyethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2, or at least about 5 wt % of the compound of the disclosure. The topical formulations can be suitably packaged in tubes of, for example, 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.
- The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
- The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
- The therapeutic dosage of a compound of the present disclosure can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the disclosure in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the disclosure can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- The compositions of the disclosure can further include one or more additional pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant, examples of which are listed herein. Labeled Compounds and Assay Methods
- Another aspect of the present disclosure relates to labeled compounds of the disclosure (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating PI3K in tissue samples, including human, and for identifying PI3K ligands by inhibition binding of a labeled compound. Substitution of one or more of the atoms of the compounds of the present disclosure can also be useful in generating differentiated ADME (Adsorption, Distribution, Metabolism and Excretion). Accordingly, the present disclosure includes PI3K assays that contain such labeled or substituted compounds.
- The present disclosure further includes isotopically-labeled compounds of the disclosure. An “isotopically” or “radio-labeled” compound is a compound of the disclosure where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present disclosure include but are not limited to 2H (also written as D for deuterium), 3H (also written as
- T for tritium), 11C, 13C, 14C, 13N, 15N, 150, 170, 180, 18F, 35s, 36C1, 82—r, B 75Br, 76Br, 77Br, 1231,1241, 1251 and 1311. For example, one or more hydrogen atoms in a compound of the present disclosure can be replaced by deuterium atoms (e.g., one or more hydrogen atoms of a C1-6 alkyl group of Formula (I) can be optionally substituted with deuterium atoms, such as —CD3 being substituted for —CH3). In some embodiments,alkyl groups of the disclosed Formulas (e.g., Formula (I), (II), etc.), can be perdeuterated.
- One or more constituent atoms of the compounds presented herein can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. For example, one or more hydrogen atoms in a compound presented herein can be replaced or substituted by deuterium (e.g., one or more hydrogen atoms of a C1-6 alkyl group can be replaced by deuterium atoms, such as —CD3 being substituted for —CH3). In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, or 1-9 deuterium atoms. In some embodiments, all of the hydrogen atoms in a compound can be replaced or substituted by deuterium atoms.
- In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 hydrogen atoms, attached to carbon atoms of any alkyl, alkenyl, alkynyl, aryl, phenyl, cycloalkyl, heterocycloalkyl, or heteroaryl substituents, or -C1-6 alkyl-, alkylene, alkenylene, and alkynylene linking groups, as described herein, are each optionally replaced by a deuterium atom.
- Synthetic methods for including isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry by Alan F. Thomas (New York, N.Y., Appleton-Century-Crofts, 1971; The Renaissance of H/D Exchange by Jens Atzrodt, Volker Derdau,
- Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistry of Isotopic Labelling by James R. Hanson, Royal Society of Chemistry, 2011). Isotopically labeled compounds can be used in various studies such as NMR spectroscopy, metabolism experiments, and/or assays. Substitution with heavier isotopes, such as deuterium, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. (see e.g., A. Kerekes et.al. I Med. Chem. 2011, 54, 201-210; R. Xu et.al. I Label Compd. Radiopharm. 2015, 58, 308-312). In particular, substitution at one or more metabolism sites may afford one or more of the therapeutic advantages.
- The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro PI3K labeling and competition assays, compounds that incorporate 3H, 14C, 82Br, 1251 131=or 35S can be useful. For radio-imaging applications 11C, 18F, 125I, 123 I, 124I, 131I, 75Br, 76Br, or 77Br can be useful.
- It is understood that a “radio-labeled” or “labeled compound” is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of 3H, 14C, 125I, 35S and 82Br.
- The present disclosure can further include synthetic methods for incorporating radio-isotopes into compounds of the disclosure. Synthetic methods for incorporating radio-isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of disclosure.
- A labeled compound of the disclosure can be used in a screening assay to identify/evaluate compounds. For example, a newly synthesized or identified compound (i.e., test compound) which is labeled can be evaluated for its ability to bind a PI3K by monitoring its concentration variation when contacting with the PI3K, through tracking of the labeling. For example, a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a PI3K (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the PI3K directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
- Kits
- The present disclosure also includes pharmaceutical kits useful, for example, in the treatment or prevention of PI3K-associated diseases or disorders, such as cancer, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the disclosure. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
- The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples have been found to be PI3Kγ inhibitors according to at least one assay described herein.
- Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature (see e.g.
- “Two-Pump At Column Dilution Configuration for Preparative LC-MS”, K. Blom, J. Combi. Chem., 4, 295 (2002); “Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification”, K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Hague, A. Combs, J. Combi. Chem., 5, 670 (2003); and “Preparative LC-MS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004)).
- The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity analysis under the following conditions: Instrument =Agilent 1100 series, LC/MSD; Column: Waters SunfireTM C18 5μm, 2.1×50 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient 2% to 80% B in 3 minutes with flow rate 2.0 mL/minute.
- Some of the compounds prepared were also separated on a preparative scale by reverse-phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse-phase high performance liquid chromatography (RP-HPLC) column conditions are as follows:
- pH=2 purifications: Waters Sunfire™ C18 5 μm, 30×100 mm or Waters XBridge™ C18 5 μm, 30×100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 60 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature (see e.g., “Preparative LCMS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, I Comb. Chem., 6, 874-883 (2004)). pH =6.5 purifications: Waters XBridge™ C18 5μm, 30×100 mm column, eluting with mobile phase A: 100 mM ammonium acetate (NH4OAc) in water and mobile phase B: acetonitrile; the flow rate was 60 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature (see e.g. “Preparative LCMS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, I Comb. Chem., 6, 874-883 (2004)).
- pH =10 purifications: Waters XBridge™ C18 5μm, 30×100 mm column, eluting with mobile phase A: 0.1% NH4OH in water and mobile phase B: acetonitrile; the flow rate was 60 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature (see e.g., “Preparative LCMS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R.
- Sparks, A. Combs, I Comb. Chem., 6, 874-883 (2004)). Stereochemical Rationale
- The Sharpless asymmetric dihydroxylation of olefins has been studied extensively, and its basis as a model for enantioselectivity is well established (Sharpless, K.B.; Amberg, W.; Bennani, Y.L.; Crispino, G.A.; Hartung, J.; Jeong, K.-S.; Kwong, H.-L.; Morikawa, K.; Wang,
- Z.-M.; Xu, D.; Zhang, X.-L. I Org. Chem., 1992, 57, 2768-2771; and Kolb, H.C.; VanNieuwenhze, M.S.; Sharpless, K.B. Chem. Rev., 1994, 94, 2483-2547). Briefly, the application of AD-mix-a (containing (DHQ)2-PHAL) in the dihydroxylation of prop-1-en-2-ylbenzene affords (S)-2-phenylpropane-1,2-diol. Application of AD-mix-I3 (containing (DHQD)2-PHAL) in the dihydroxylation of prop-1-en-2-ylbenzene affords (R)-2-phenylpropane-1,2-diol
- (Sharpless and Kolb, supra). Moreno-Dorado et al. extended the method to the trifluoromethyl case (e.g., (3,3,3-trifluoroprop-1-en-2-yl)benzene affords (S)-3,3,3-trifluoro-2-phenylpropane-1,2-diol when treated with AD-mix-a and affords (R)-3,3,3-trifluoro-2-phenylpropane-1,2-diol when treated with AD-mix-(3), and the stereochemical outcome was verified by subsequent conversion to well known compounds whose specific rotations were found to be in agreement with the literature values (Moreno-Dorado, F.J.; Guerra, F.M.; Ortega, M.J.; Zubia, E.; Massanet, G.M. Tetrahedron: Asymmetry, 2003, 14, 503-510). While not wishing to be bound by any one theory, in the dihydroxylations performed on vinyl arenes in the examples, we expect to obtain the (S)-configuration with AD-mix-a and the (R)-configuration with AD-mix-I3.
-
- Step 1. 4-Bromo-2-(4,5-dimethyl-11-1-imidazol-2-Apyridine
- 4-Bromopyridine-2-carbonitrile (1.0 g, 5.5 mmol, Synthonix) in MeOH (10 mL) was treated with sodium methoxide (25 wt% in methanol (MeOH), 0.095 mL, 0.47 mmol) and the reaction mixture was stirred for 1 hour. Ammonium chloride (0.37 g, 6.9 mmol) was added, and the reaction mixture was stirred for 4 days. Solvent was then removed in vacuo. Water (4.0 mL) and ethyl acetate (EtOAc) (6.0 mL) were added, the mixture was saturated with solid NaCl, and the mixture was stirred overnight. The solid product was isolated by filtration and dried at 40° C. under vacuum overnight. The product was used below without further purification.
- To 4-bromopyridine-2-carboximidamide (0.50 g, 2.5 mmol) in DMF (5.0 mL) was added K2CO3 (0.52 g, 3.7 mmol) and 3-bromo-2-butanone (0.24 mL, 3.2 mmol). The reaction mixture was stirred for 4 days. The reaction mixture was partitioned between EtOAc and H2O, and the layers were separated. The aqueous layer was extracted with two further portions of EtOAc. The combined organic extracts were washed sequentially with water and saturated NaCl solution. The organic solution was dried over Na2SO4, filtered, and concentrated. The crude product was slurried in methyl tert-butyl ether (MTBE, 2.0 mL) and the solid product was isolated by filtration and dried under vacuum at 40° C. for 3 hours to afford the title compound (370 mg, 59%). LCMS for CiothiBrN3 (M+H)±: calculated monoisotopic m/z =252.0; found 252.0. Step 2. Methyl 4-bromo-2-(bromomethyl)-6-chlorobenzoate
- To methyl 4-bromo-2-chloro-6-methylbenzoate (1.5 g, 5.7 mmol, Astatech) in CC14 (28 mL) was added N-bromosuccinimide (1.1 g, 6.3 mmol) and benzoyl peroxide (0.028 g, 0.11 mmol) and the reaction was heated to reflux for 1.5 hours, then stirred at room temperature overnight. A further portion of benzoyl peroxide (0.050 g, 0.20 mmol) was added, and heating at reflux was continued for 3 hours. The reaction mixture was washed with a solution of Na2S2O3 and the aqueous layer was extracted twice with EtOAc. The combined organic extracts were dried over Na2SO4, filtered, and concentrated. Flash chromatography, eluting with a gradient from 0-50% EtOAc in hexanes, afforded the title compound (0.15 g, 67%). Step 3. (S)-5-Bromo-7-chloro-2-(1-cyclopropylethyl)isoindolin-1-one
- To a flask containing methyl 4-bromo-2-(bromomethyl)-6-chlorobenzoate (1.9 g, 5.6 mmol) in acetonitrile (19 mL) was added (S)-1-cyclopropylethan-1-amine (0.48 g, 5.6 mmol,
- Aldrich), followed by boric acid (0.35 g, 5.6 mmol). Potassium carbonate (1.5 g, 11 mmol) was added portionwise over 2 min, and the reaction was stirred overnight. The reaction mixture was filtered and solids were washed with acetonitrile. The filtrate was concentrated in vacuo. Flash chromatography, eluting with a gradient from 0-30% EtOAc in hexanes, afforded the title compound (1.1 g, 62%). LCMS for C131-114BrC1NO (M+H)±: calculated monoisotopic m/z =314.0; found 314.0. Step 4. (5)-7-Chloro-2-(1-cyclopropylethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
- A degassed mixture of (S)-5-bromo-7-chloro-2-(1-cyclopropylethyl)isoindolin-1-one (0.25 g, 0.80 mmol), bis(pinacolato)diboron (0.30 g, 1.2 mmol), potassium acetate (0.47 g, 4.78 mmol) and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.039 g, 0.048 mmol) in dioxane (4.0 mL) was heated to 80° C. overnight. Upon cooling to room temperature, water was added and the mixture was extracted with EtOAC(3x). The combined organic extracts were dried over Na2SO4, filtered and concentrated. Flash chromatography, eluting with a gradient from 0-100% EtOAc in hexanes, afforded the title compound (0.25 g, 87%). LCMS for CI9H26BC1NO3 (M+H)±: calculated monoisotopic mlz =362.1; found 362.1. Step 5. (S)-7-Chloro-2-(1-cyclopropylethyl)-5-(2-(4,5-dimethyl-11-1-imidazol-2-yl)pyridin-4-yl)isoindolin-1-one
- A mixture of (S)-7-chloro-2-(1-cyclopropylethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (0.13 g, 0.36 mmol), 4-bromo-2-(4,5-dimethyl-1H-imidazol-2-yl)pyridine (0.091 g, 0.36 mmol) and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.059 g, 0.072 mmol) in
- THF (2.4 mL) and aq. K2CO3 solution (1.0 M, 1.1 ml, 1.1 mmol) was sparged with N2 for 10 min, and was heated in the microwave reactor for 60 min at 120° C., then in an oil bath at 80° C. over 3 nights. Upon cooling to room temperature, the reaction mixture was diluted with MeCN and MeOH, filtered and purified via preparative HPLC-MS (pH =10) to afford the title compound (36 mg, 25%). LCMS for C23H24C1N40 (M+H)±: calculated monoisotopic mlz =407.2; found 407.1. iH NMR (400 MHz, DMSO-d6) 6 12.43 (s, 1H), 8.65 (d, J=5.2 Hz, 1H), 8.23 (d, J=1.8 Hz, 1H), 8.06 (d, J=1.5 Hz, 1H), 7.92 (d, J=1.5 Hz, 1H), 7.69 (dd, J=5.2, 1.9 Hz, 1H), 4.63 (s, 2H), 3.70-3.48 (m, 1H), 2.19 (s, 3H), 2.12 (s, 3H), 1.31 (d, J=6.9 Hz, 3H), 1.21-1.09 (m, 1H), 0.66-0.54 (m, 1H), 0.50-0.35 (m, 2H), 0.32-0.20 (m, 1H).
-
- Step 1. (S)-5-Bromo-2-(1-cyclopropylethyl)-7-(methylthio)isoindolin-1-one
- Sodium methanethiolate (0.30 g, 4.3 mmol) was added to (S)-5-bromo-7-chloro-2-(1-cyclopropylethyl)isoindolin-1-one (0.45 g, 1.4 mmol) in acetonitrile (6.0 mL) and the mixture was heated to 120° C. overnight. Upon cooling to room temperature, the reaction mixture was filtered through Celite®, and the Celite® was washed with EtOAc. The organic solution was washed with water (2x), and brine, dried over MgSO4, fitered and concentrated to afford the title compound as a yellow solid (250 mg, 53%). LCMS for Ci4Hi7BrNOS (M+H)±: calculated monisotopic m/z =326.0; found 326.1.
- Step 2. (S)-5-Bromo-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one
- To (S)-5-bromo-2-(1-cyclopropylethyl)-7-(methylthio)isoindolin-1-one (0.10 g, 0.31 mmol) in DCM (2.0 mL) at 0° C. was added m-CPBA (130 mg, 0.77 mmol). After stirring for 2 hours, the reaction mixture was diluted with DCM and washed with saturated NaHCO3 solution and brine. The organic layer was dried over MgSO4, filtered and concentrated. Purification via flash chromatography, eluting with a gradient from 0-80% EtOAc in hexanes, provided the title compound as a yellow solid (0.080 g, 72%). LCMS for CI4H17BrNO3S (M+H)±: calculated monoisotopic m/z =358.0; found 358.1. Step 3. (S)-2-(1-Cyclopropylethyl)-7-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
- A mixture of (S)-5-bromo-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (0.10 g, 0.28 mmol), bis(pinacolato)diboron (0.11 g, 0.42 mmol), potassium acetate (0.082 g, 0.84 mmol) and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.060 g, 0.017 mmol) in dioxane (3 mL) was degassed by sparging with N2 for 10 min. The reaction was then heated at 80° C. for 2 hours. Upon cooling to room temperature, the reaction mixture was diluted with water and extracted with EtOAc. The combined organic extracts were dried over Na2SO4, filtered and concentrated. Flash chromatography, eluting with a gradient from 0-100% EtOAc in hexanes, afforded the title compound (0.080 g, 80%). Step 4. (S)-2-(1-Cyclopropylethyl)-5-(2-(4,5-dimethyl-11-1-imidazol-2-yl)pyridin-4-y0-7-(methylsulfonyl)isoindolin-1-one, trifluoroacetate salt
- A mixture of (S)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (0.020 g, 0.049 mmol), 4-bromo-2-(4,5-dimethyl-1H-imidazol-2-yl)pyridine (12 mg, 0.049 mmol), and dichloro[1,1-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (8.1 mg, 9.9 μmol) in THF (0.33 mL) and aq. K2CO3 solution (1.0 M, 0.15 mL, 0.15 mmol) was degassed by sparging with N2, and was heated to 120° C. in a microwave reactor for 1 hour. Upon cooling to room temperature, the reaction mixture was diluted with MeCN and MeOH, filtered and purified via preparative HPLC-MS (pH =10) to afford the title compound (3.0 mg, 11%). LCMS for C24H27N403S (M+H)±: calculated m/z =451.2; found 451.1. 1H NMR (400 MHz, DMSO) 6 14.79 (br s, 1H), 8.95 (d, J=5.2 Hz, 1H), 8.56 (s, 1H), 8.48 (d, J=1.6 Hz, 1H), 8.44 (d, J=1.6 Hz, 1H), 8.05 (dd, J=5.0, 1.3 Hz, 1H), 4.78 (s, 2H), 3.69 (s, 3H), 3.68-3.62 (m, 1H), 2.33 (s, 6H), 1.36 (d, J=6.8 Hz, 3H), 1.30-1.09 (m, 1H), 0.70-0.54 (m, 1H), 0.54-0.37 (m, 2H), 0.37-0.12 (m, 1H).
-
- Step 1. (S)-5-Bromo-2-(1-cyclopropylethyl)isoindolin-1-one
- A mixture of methyl 4-bromo-2-(bromomethyl)benzoate (1.00 g, 3.25 mmol, Ark Pharm, AK-26333), (S)-1-cyclopropylethan-1-amine (0.304 g, 3.57 mmol, Aldrich 727245), and K2CO3 (0.898 g, 6.49 mmol) in acetonitrile (8.1 mL) in a microwave vial was sealed and heated at 120 ° C. in a microwave oven for 30 min. The reaction mixture was filtered and solvent was removed in vacuo. The product was purified via flash chromatography, eluting with a gradient of 0-25%
- EtOAc in hexanes, to afford product as a white solid (0.42 g, 46%). LCMS for Ci3Hi5BrNO (M+H)±: calculated monoisotopic mlz =280.0; found 280.0. Step 2. (S)-2-(1-Cyclopropylethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-Aisoindolin-1-one
- (S)-5-Bromo-2-(1-cyclopropylethyl)isoindolin-1-one (0.421 g, 1.50 mmol) was combined with bis(pinacolato)diboron (0.572 g, 2.25 mmol), potassium acetate (0.885 g, 9.02 mmol) and dichloro[1,1″-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.074 g, 0.090 mmol) in dioxane (7.5 mL), and the mixture was degassed. The reaction was heated to 80° C. for 3 hours. Upon cooling to room temperature, the mixture was diluted with EtOAc, filtered over Celite®, and concentrated. The product was purified via flash chromatography, eluting with a gradient from 0-20% EtOAc in hexanes, to afford product as a light yellow solid (theoretical yield assumed). LCMS for Ci9H27BNO3 (M+H)±: calculated mlz =328.2; found 328.2. Step 3. 4-Bromo-2-(4-methyl-1H-imidazol-2-yl)pyridine
- To 4-bromopyridine-2-carbonitrile (0.50 g, 2.7 mmol, Synthonix) in methanol (3.0 mL) was added sodium methoxide in methanol (25 wt %, 69 pL, 0.30 mmol), and the reaction mixture was heated to 40° C. for 1 hour. The mixture was cooled to room temperature, and 1,1-diethoxypropan-2-amine (0.40 g, 2.7 mmol) and then acetic acid (0.30 mL, 5.2 mmol) were added dropwise. The reaction mixture was heated at 100° C. for 30 min. After the reaction mixture was cooled to room temperature, methanol (1.5 mL) and 6.0 M HC1 in water (7.5 mmol) were added, and the mixture was heated at 70° C. for 5 hours. Heating was discontinued, and the reaction mixture was stirred overnight. The reaction mixture was concentrated. Aqueous K2CO3 solution (saturated) was added slowly to the crude residue until the solution reached pH 10, and the slurry was stirred for 1 hour. The resulting tan precipitate was isolated by filtration and washed with aq. K2CO3 solution (sat.) and then cold water. The resulting solid was air dried to afford a tan solid (0.57 g, 88%). LCMS for C9H9BrN3 (M+H)±: calculated monoisotopic mlz =238.0; found 238.0. 1H NMR (400 MHz, DMSO-d6) 6 12.65 (br s, 1H), 8.45 (d, J =5.3 Hz, 1H), 8.11 (d, J =1.6 Hz, 1H), 7.58 (dd, J =5.3, 1.9 Hz, 1H), 6.88 (s, 1H), 2.21 (s, 3H).
- Step 4. 4-Bromo-2-(4-methyl-14(2-(trimethylsilyl)ethoxy)methyl)-111-imidazol-2-yl)pyridine (mixture of regioisomers prepared - single regioisomer isolated)
- To a solution of 4-bromo-2-(5-methyl-1H-imidazol-2-yl)pyridine (120 mg, 0.50 mmol) in THF (6.0 mL) at 0° C. was added potassium tert-butoxide (1.0 M, 0.71 mL, 0.71 mmol). The reaction mixture was stirred for 30 min, and 2-(trimethylsilyl)ethoxymethyl chloride (0.125 mL, 0.71 mmol) was added. After stirring for 30 min at 0° C., aq. NH4C1 (sat.) solution was added. After stirring for an additional 30 min, the aqueous mixture was extracted with EtOAC(3x). The combined organic extracts were washed with water, followed by brine. The organic solution was dried over MgSO4, filtered and concentrated. Flash chromatography, eluting with a gradient from 0-10% EtOAc in hexanes, afforded the title compound (85 mg, 46%). The major isomer (first to elute) was collected. LCMS for CI5H23BrN30Si (M+H)±: calculated monoisotopic mlz =368.1; found 368.0. Step 5. (S)-2-0-Cyclopropylethyl)-5-(2-(4-methyl-1-((2-(trimethylsily0ethoxy)methyl)-11-1-imidazol-2-yl)pyridin-4-yl)isoindolin-1-one
- To a solution of 4-bromo-2-(5-methyl-1-42-(trimethylsilypethoxy)methyl)-11-1-imidazol-2-yl)pyridine (0.020 g, 0.054 mmol) and (S)-2-(1-cyclopropylethyl)-5-(4,4,5,5-tetramethyl-1,3,2-doxaborolan-2-ylisoindolin-1-one (0.020 g, 0.060 mmol) in THF (1.0 mL) was added sodium carbonate (12 mg, 0.11 mmol) in water (0.5 mL). The reaction mixture was degassed by sparging with N2 for 10 min, at which time PdC12(dppf)-CH2C12 adduct (8.9 mg, 11 umol) was added. The mixture was again sparged with N2 for 1 min, and the reaction mixture was then heated at 100° C. for 1 hour. Upon cooling to room temperature, the reaction mixture was diluted with water and EtOAc. The layers were separated, and the organic layer was washed with brine, dried over MgSO4, filtered and concentrated. Flash chromatography, eluting with a gradient from 0-80%
- EtOAc in hexanes, afforded the title compound (0.020 g, 75%). LCMS for C28H37N4O2Si (M+H)±: calculated monoisotopic mlz =489.3; found 489.2. Step 6. (S)-2-(1-Cyclopropylethyl)-5-(2-(5-iodo-4-methyl-14(2-(trimethylsily0ethoxy)methyl)-11-1-imidazol-2-yl)pyridin-4-Aisoindolin-1-one
- To a mixture of (S)-2-(1-cyclopropylethyl)-5-(2-(5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyridin-4-ypisoindolin-1-one (0.080 g, 0.16 mmol) in DMF (6.0 mL) was added NIS (43 mg, 0.19 mmol). The mixture was stirred for 20 min at room temperature, and then at 50° C. for 2 hours. Upon cooling to room temperature, the reaction mixture was diluted with water and extracted with EtOAC(3x). The combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated to afford the title compound (0.10 g, 99%). LCMS for C28E137IN402Si (M+H)±: calculated m/z =615.2; found 615.1. Step 7. Methyl (S)-2-(4-(2-(1-cyclopropylethyl)-1-oxoisoindohn-5-Apyridin-2-y0-4-methyl-1-((2-(trimethylsilyothoxy)methyl)-11-1-imidazole-5-carboxylate
- A solution of (S)-2-(1-cyclopropylethyl)-5-(2-(4-iodo-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyridin-4-ylisoindolin-1-one (0.10 g, 0.16 mmol) in methanol (3.0 mL) was treated with triethylamine (0.091 mL, 0.65 mmol) and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (27 mg, 0.033 mmol). Carbon monoxide was bubbled through the solution for 10 min. The reaction mixture was heated at 60° C. under 1 atm of CO overnight. Solvent was removed in vacuo. Flash chromatography, eluting with a gradient from 0-80% EtOAc in hexanes, afforded the title compound (0.060 g, 67%). LCMS for C3oH39N4O4Si (M+H)±: calculated mlz =547.3; found 547.1. Step 8. (S)-2-(4-(2-(1-Cyclopropylethyl)-1-oxoisoindolin-5-yl)pyridin-2-yl)-4-methyl-1-((2-(trimethylsilyoethoxy)methyl)-111-imidazole-5-carboxylic acid
- To a solution of methyl (S)-2-(4-(2-(1-cyclopropylethyl)-1-oxoisoindolin-5-yl)pyridin-2-yl)-5-methyl-1-42-(trimethylsilypethoxy)methyl)-1H-imidazole-4-carboxylate (45 mg, 0.082 mmol) in methanol (2.0 mL) was added lithium hydroxide (5.9 mg, 0.25 mmol) in water (2.0 mL). The reaction mixture was stirred for 2 hours. Solvent was removed in vacuo. 1.0 N HC1 solution was added to adjust to pH =2, and the aqueous mixture was extracted with EtOAC(2x). The combined organic extracts were dried over MgSO4, filtered and concentrated, to afford the title compound which was used without further purification (0.040 g, 92%). LCMS for C29H37N4O4Si (M+H)±: calculated mlz =533.3; found 533.2. Step 9. (S)-2-(4-(2-(1-Cyclopropylethyl)-1-oxoisoindolin-5-yl)pyridin-2-yl)-N-isopropyl-5-methyl-1H-imidazole-4-carboxamide trifluoroacetate salt To a solution of (S)-2-(4-(2-(1-cyclopropylethyl)-1-oxoisoindolin-5-yl)pyridin-2-yl)-N-isopropyl-5-methyl-1-42-(trimethylsilypethoxy)methyl)-1H-imidazole-4-carboxamide (8.0 mg, 0.015 mmol) in DMF (1.0 mL) was added N,N-diisopropylethylamine (7 uL, 0.04 mmol) and HATU (6.9 mg, 0.018 mmol). After stirring for 5 min, propan-2-amine (1.1 mg, 0.018 mmol) was added. The reaction mixture was stirred for 1 hour. Water was added and the mixture was extracted with EtOAc. The organic layer was dried over MgSO4, filtered and concentrated. The residue was dissolved in DCM (0.5 mL) and trifluoroacetic acid (TFA) (0.035 mL, 0.45 mmol) was added. After stirring for 1 hour, volatiles were removed in vacuo, the residue was reconstituted in acetonitrile and methanol, and the product was purified via preparative HPLC-MS (pH =2) to afford the title compound (4 mg, 40%). LCMS for C26H3oN502 (M+H)±:
- calculated m/z =444.2; found 444.2. 1H NMR (400 MHz, DMSO-d6) 6 8.73 (d, J=5.2 Hz, 1H), 8.43 (d, J=1.7 Hz, 1H), 8.12 (d, J=1.4 Hz, 1H), 7.97 (dd, J=7.9, 1.3 Hz, 1H), 7.85 (d, J=7.9 Hz, 1H), 7.79 (dd, J=5.3, 1.8 Hz, 1H), 4.67 (s, 2H), 4.18-3.99 (m, 1H), 3.71-3.55 (m, 1H), 2.53 (s, 3H), 1.33 (d, J=6.9 Hz, 3H), 1.19 (d, J=6.6 Hz, 6H), 1.23-1.10 (m, 1H), 0.66-0.50 (m, 1H), 0.48-0.33 (m, 2H), 0.30-0.16 (m, 1H).
- Compounds in Table 1 were prepared by the procedure of Example 3, substituting the appropriate amine for propan-2-amine in Step 9.
-
TABLE 1 Example Compound Name R LCMS No. 1H NMR 4 (S)-2-(4-(2-(1-Cyclopropylethyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)-5- methyl-N-(tetrahydro-2H-pyran-4-yl)- 1H-imidazole-4-carboxamide trifluoroacetate salt Calculated for C28H32N5O3 (M + H)+: m/z = 486.2, found: 486.2 1H NMR (400 MHz, DMSO-d6) δ 8.73 (d, J = 5.2 Hz, 1H), 8.44 (d, J = 1.8 Hz, 1H), 8.11 (d, J = 1.4 Hz, 1H), 7.97 (dd, J =7.9, 1.6 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.79 (dd, J = 5.2, 1.9 Hz, 1H), 7.76 (br, 1H), 4.67 (s, 2H), 4.02- 3.93 (m, 1H), 3.92-3.83 (m, 2H), 3.68-3.57 (m, 1H), 3.39 (td, J = 11.7, 2.3 Hz, 2H), 2.53 (s, 3H), 1.80-1.72 (m, 2H), 1.66 (qd, J = 12.0, 4.3 Hz, 2H), 1.33 (d, J = 6.8 Hz, 3H), 1.24-1.12 (m, 1H), 0.66-0.52 (m, 1H), 0.50- 0.36 (m, 2H), 0.31-0.20 (m, 1H). 5 (S)-2-(4-(2-(1-Cyclopropylethyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- N,N,5-trimethyl-1H-imidazole-4- carboxamide trifluoroacetate salt Calculated for C25H28N5O2 (M + H)+: m/z = 430.2, found: 430.2 1H NMR (400 MHz, DMSO-d6) δ 8.74 (d, J = 5.2 Hz, 1H), 8.34 (d, J = 1.9 Hz, 1H), 8.10 (d, J = 1.4 Hz, 1H), 7.96 (dd, J = 7.9, 1.6 Hz, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.79 (dd, J = 5.2, 1.9 Hz, 1H), 4.66 (s, 2H), 3.68-3.58 (m, 1H), 3.33 (s, 3H), 2.98 (s, 3H), 2.40 (s, 3H), 1.33 (d, J = 6.8 Hz, 3H), 1.22-1.10 (m, 1H), 0.67-0.53 (m, 1H), 0.49-0.35 (m, 2H), 0.31-0.20 (m, 1H). 6 (S)-2-(4-(2-(1-Cyclopropylethyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)-N,5- dimethyl-1H-imidazole-4- carboxamide trifluoroacetate salt Calculated for C24H26N5O2 (M + H)+: m/z = 416.2, found: 416.2 1H NMR (400 MHz, DMSO-d6) δ 8.73 (d, J = 5.2 Hz, 1H), 8.43 (d, J = 1.7 Hz, 1H), 8.10 (d, J = 1.3 Hz, 1H), 7.96 (dd, J =7.9, 1.6 Hz, 1H), 7.94-7.88 (m, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.78 (dd, J = 5.2, 1.9 Hz, 1H), 4.66 (s, 2H), 3.68-3.59 (m, 1H), 2.78 (d, J = 4.7 Hz, 3H), 2.53 (s, 3H), 1.33 (d, J = 6.8 Hz, 3H), 1.23-1.10 (m, 1H), 0.65-0.56 (m, 1H), 0.49-0.33 (m, 2H), 0.33- 0.19 (m, 1H). - The compounds in Table 2 were prepared by the procedure of Example 3, Steps 5-9, using (S)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one instead of (S)-2-(1-cyclopropylethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one in Step 5, and using the appropriate amine instead of isopropylamine in Step 9.
-
TABLE 2 Example Compound Name R LCMS No. 1H NMR 7 (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- N,4-dimethyl-1H-imidazole-5- Calculated for C25H28N5O4S (M + H)+: m/z = 494.2, found: 494.1 carboxamide, trifluoroacetate salt 1H NMR (500 MHz, DMSO-d6) δ 8.79 (d, J = 5.1 Hz, 1H), 8.45 (s, 1H), 8.40- 8.37 (m, 1H), 8.33 (d, J = 1.5 Hz, 1H), 7.89 (q, J = 4.5 Hz, 1H), 7.80 (dd, J = 5.2, 1.9 Hz, 1H), 4.77 (s, 2H), 3.68 (s, 3H), 3.68-3.61 (m, 1H), 2.77 (d, J = 4.7 Hz, 3H), 2.53 (s, 3H), 1.35 (d, J = 6.8 Hz, 3H), 1.28-1.16 (m, 1H), 0.71- 0.57 (m, 1H), 0.51-0.38 (m, 2H), 0.36-0.24 (m, 1H). 7a (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- N-isopropyl-4-methyl-1H- Calculated for C27H32N5O4S (M + H)+: m/z = 522.2, found: 522.2 imidazole-5-carboxamide, trifluoroacetate salt 7b (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- 4-methyl-N-(tetrahydro-2H- pyran-4-yl)-1H-imidazole-5- Calculated for C29H34N5O5S (M + H)+: m/z = 564.2, found: 564.2 carboxamide, trifluoroacetate salt 7c (S)-N-(Bicyclo[1.1.1]pentan-1- yl)-2-(4-(2-(1-cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- 4-methyl-1H-imidazole-5- Calculated for C29H32N5O4S (M + H)+: m/z = 546.2, found: 546.2 carboxamide, trifluoroacetate salt 7d (S)-2-(1-Cyclopropylethyl)-5-(2- (5-(3,3-difluoroazetidine-1- carbonyl)-4-methyl-1H-imidazol- 2-yl)pyridin-4-yl)-7- (methylsulfonyl)isoindolin-1-one, trifluoroacetate salt Calculated for C27H28F2N5O4S (M + H)+: m/z = 556.2, found: 556.2 7e (S)-2-(1-Cyclopropylethyl)-5-(2- (5-(3-hydroxyazetidine-1- carbonyl)-4-methyl-1H-imidazol- 2-yl)pyridin-4-yl)-7- (methylsulfonyl)isoindolin-1-one, Calculated for C27H30N5O5S (M + H)+: m/z = 536.2, found: 536.2 trifluoroacetate salt 7f (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- N-(3-hydroxycyclobutyl)-4- methyl-1H-imidazole-5- Calculated for C28H32N5O5S (M + H)+: m/z = 550.2, found: 550.2 carboxamide, trifluoroacetate salt (mixture of two diastereomers) 7g 2-(4-(2-((S)-1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- 4-methyl-N-(1,1,1- trifluoropropan-2-yl)-1H- Calculated for C27H29F3N5O4S (M + H)+: m/z = 576.2, found: 576.2 imidazole-5-carboxamide, trifluoroacetate salt (mixture of two diastereomers) 7h (S)-N-(4- Cyanobicyclo[2.1.l]hexan-1-yl)- 2-(4-(2-(1-cyclopropylethyl)-7- (methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- Calculated for C31H33N6O4S (M + H)+: m/z = 585.2, found: 585.2 4-methyl-1H-imidazole-5- carboxamide, trifluoroacetate salt 7i (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- 4-methyl-N-(2- oxaspiro[3.3]heptan-6-yl)-1H- imidazole-5-carboxamide, Calculated for C30H34N5O5S (M + H)+: m/z = 576.2, found: 576.3 trifluoroacetate salt 7j (S)-5-(2-(5-(Azetidine-1- carbonyl)-4-methyl-1H-imidazol- 2-yl)pyridin-4-yl)-2-(1- cyclopropylethyl)-7- (methylsulfonyl)isoindolin-1-one, Calculated for C27H30N5O4S (M + H)+: m/z = 520.2, found: 520.2 trifluoroacetate salt 7k (S)-N-Cyclobutyl-2-(4-(2-(1- cyclopropylethyl)-7- (methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- 4-methyl-1H-imidazole-5- Calculated for C28H32N5O4S (M + H)+: m/z = 534.2, found: 534.2 carboxamide, trifluoroacetate salt 7l N-(sec-Butyl)-2-(4-(2-((S)-1- cyclopropylethyl)-7- (methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- 4-methyl-1H-imidazole-5- Calculated for C28H34N5O4S (M + H)+: m/z = 536.2, found: 536.2 carboxamide, trifluoroacetate salt (mixture of two diastereomers) 7m (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- 4-methyl-N-(1-methylazetidin-3- yl)-1H-imidazole-5-carboxamide, Calculated for C28H33N6O4S (M + H)+: m/z = 549.2, found: 549.2 trifluoroacetate salt 7n 2-(4-(2-((S)-1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- 4-methyl-N-(tetrahydrofuran-3- yl)-1H-imidazole-5-carboxamide, Calculated for C28H32N5O5S (M + H)+: m/z = 550.2, found: 550.2 trifluoroacetate salt (mixture of two diastereomers) 7o (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- N,4-dimethyl-N-(tetrahydro-2H- pyran-4-yl)-1H-imidazole-5- carboxamide, trifluoroacetate salt Calculated for C30H36N5O5S (M + H)+: m/z = 578.2, found: 578.2 7p (S)-2-(1-Cyclopropylethyl)-5-(2- (4-methyl-5-(2-oxa-6- azaspiro[3.3]heptane-6-carbonyl)- 1H-imidazol-2-yl)pyridin-4-yl)-7- (methylsulfonyl)isoindolin-1-one, trifluoroacetate salt Calculated for C29H32N5O5S (M + H)+: m/z = 562.2, found: 562.2 7q (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- 4-methyl-1H-imidazole-5- Calculated for C24H26N5O4S (M + H)+: m/z = 480.2, found: 480.2 carboxamide, trifluoroacetate salt 7r (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- N-ethyl-4-methyl-1H-imidazole- 5-carboxamide, trifluoroacetate Calculated for C26H30N5O4S (M + H)+: m/z = 508.2, found: 508.2 salt 7s (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- N-ethyl-N,4-dimethyl-1H- imidazole-5-carboxamide, Calculated for C27H32N5O4S (M + H)+: m/z = 522.2, found: 522.2 trifluoroacetate salt 7t (S)-2-(4-(2-(1-Cyclopropylethyl)- 7-(methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- N-isopropyl-N,4-dimethyl-1H- imidazole-5-carboxamide, Calculated for C28H34N5O4S (M + H)+: m/z = 536.2, found: 536.2 trifluoroacetate salt 7u (S)-N-Cyclobutyl-2-(4-(2-(1- cyclopropylethyl)-7- (methylsulfonyl)-1- oxoisoindolin-5-yl)pyridin-2-yl)- N,4-dimethyl-1H-imidazole-5- Calculated for C29H34N5O4S (M + H)+: m/z = 548.2, found: 548.2 carboxamide, trifluoroacetate salt -
- Step 1. (S)-5-(6-Chloropyridazin-4-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonylfisoindolin-1-one
- A mixture of (S)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (0.57 g, 1.4 mmol, from Example 2, Step 3), 3,5-dichloropyridazine (0.21 g, 1.4 mmol, Aldrich MN0000179), palladium(II) acetate (0.031 g, 0.14 mmol), 1,2,3,4,5-pentaphenyl-1″-(di-teat-butylphosphino)ferrocene (0.099 g, 0.14 mmol), and cesium carbonate (1.4 g, 4.2 mmol) in water (1.4 mL) and 1,4-dioxane (5.6 mL) was degassed by sparging with N2, and was heated at 70° C. for 18 hours. Upon cooling to room temperature, the reaction mixture was diluted with water, and was extracted with EtOAC(3x). The combined organic extracts were dried over Na2SO4, filtered and concentrated. Flash chromatography, eluting with a gradient from 0-100% EtOAc in hexanes, afforded the title compound (0.13 g, 24%). 1H NMR (400 MHz, CD3OD) 6 9.63 (d, J=2.0 Hz, 1H), 8.51 (d, J=1.6 Hz, 1H), 8.42 (d, J=1.7 Hz, 1H), 8.30 (d, J=2.0 Hz, 1H), 4.86 (d, J=18.7 Hz, 1H), 4.79 (d, J=18.9 Hz, 1H), 3.81-3.68 (m, 1H), 3.62 (s, 3H), 1.44 (d, J=6.8 Hz, 3H), 1.27-1.16 (m, 1H), 0.78-0.67 (m, 1H), 0.60-0.50 (m, 1H), 0.50-0.42 (m, 1H), 0.42-0.34 (m, 1H). LCMS for Ci8Hl9C1N3O3S (M+H)±: calculated monoisotopic miz =392.1; found 392.0.
- Step 2. (S)-5-(2-(1-Cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-Apyridazine-3-carbonitrile
- A degassed mixture of (S)-5-(6-chloropyridazin-4-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (0.065 g, 0.17 mmol), zinc cyanide (0.058 g, 0.50 mmol), zinc powder (2.2 mg, 0.033 mmol), palladium(II) trifluoroacetate (5.5 mg, 0.017 mmol) and 2-(di-tert-butylphosphino)biphenyl (9.9 mg, 0.033 mmol) in N,N-dimethylacetamide (1.7 mL) was heated at 95° C. overnight. Upon cooling to room temperature, the reaction mixture was diluted with water and extracted with EtOAC(3x). The reaction mixture was filtered through Celite®. The combined organic extracts were dried over Na2SO4, filtered and concentrated. Flash chromatography, eluting with a gradient from 0-10% MeOH/DCM, afforded the title compound (38 mg, 60%). LCMS for C19EI19N403S (M+H)±: calculated monoisotopic m/z =383.1; found 383.1.
- Step 3. (S)-5-(2-(1-Cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-yl)pyridazine-3-carboximidamide
- To a degassed solution of (5)-5-(2-(1-cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-yl)pyridazine-3-carbonitrile (0.038 g, 0.099 mmol) in MeOH (1.0 mL) and THF (1.0 mL) was added sodium methoxide (1.7 mg, 8.0 mg, 25 wt% in MeOH). The reaction mixture was heated to reflux for 2 hours. Ammonium chloride (8.0 mg, 0.15 mmol) was added, and the reaction was stirred overnight. Solvent was removed in vacuo, and the product was used without further purification (theoretical yield assumed). LCMS for CI9H22N503S (M+H)±: calculated monoisotopic m/z =400.1; found 400.1.
- Step 4. (S)-2-(1-Cyclopropylethyl)-5-(6-(4,5-dimethyl-11-1-imidazol-2-yl)pyridazin-4-y0-7-(methylsulfonyl)isoindolin-1-one trifluoroacetate salt
- To (S)-5-(2-(1-cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-yl)pyridazine-3-carboximidamide (0.040 g, 0.10 mmol) in DMF (1.0 mL) was added 3-bromobutan-2-one (0.016 ml, 0.15 mmol, Alfa Aesar A10186) and K2CO3 (0.021 g, 0.15 mmol). The reaction was stirred overnight, then was diluted with water and MeOH, filtered and purified via preparative HPLC-MS (pH =2). 1H NMR (400 MHz, CD3OD) 6 9.82 (s, 1H), 8.71 (s, 1H), 8.63 (s, 1H), 8.52 (s, 1H), 4.95 — 4.77 (m, 2H), 3.81 — 3.69 (m, 1H), 3.64 (s, 3H), 2.44 (s, 6H), 1.45 (d, J=6.8 Hz, 3H), 1.29 — 1.10 (m, 1H), 0.80 — 0.69 (m, 1H), 0.61 — 0.51 (m, 1H), 0.51 — 0.43 (m, 1H), 0.43 — 0.32 (m, 1H). LCMS for C23H26N503S (M+H)±: calculated monoisotopic m/z =452.2; found 452.1.
-
- A degassed mixture of (S)-5-(6-chloropyridazin-4-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (10 mg, 0.026 mmol, from Example 8, Step 1), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (5.9 mg, 0.031 mmol, Combi-Blocks #PN-8344), Cs2CO3 (17 mg, 0.051 mmol), and dichloro[1,1″-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (2.1 mg, 2.6 limo') in dioxane (0.50 mL) and water (0.13 mL) was heated to 100° C. for 2h. Upon cooling to room temperature, the reaction mixture was diluted with acetonitrile and methanol and was filtered. The product was purified via preparative HPLC-MS (pH =2) to afford the title compound (3.0 mg, 21%). 1H NMR (400 MHz, DMSO-d6) 6 9.63 (d, J=2.3 Hz, 1H), 8.58 (d, J=1.6 Hz, 1H), 8.49 (d, J=2.3 Hz, 1H), 8.41 (d, J=1.6 Hz, 1H), 7.93 (d, J=2.5 Hz, 1H), 7.14 (d, J=2.3 Hz, 1H), 4.78 (s, 2H), 3.70 — 3.62 (m, 1H), 3.67 (s, 3H), 1.35 (d, J=6.8 Hz, 3H), 1.29 — 1.09 (m, 1H), 0.70 — 0.56 (m, 1H), 0.56 — 0.37 (m, 2H), 0.37 — 0.16 (m, 1H). LCMS for C211-122N5O3S (M+H)±: calculated m/z =424.1; found 424.1.
- The compound in Table 3 was prepared by the procedure of Example 9, using 5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (6.4 mg, 0.031 mmol, Astatech #P18160) instead of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
-
TABLE 3 Example Compound Name R LCMS No. 1H NMR 10 (S)-2-(1-Cyclopropylethyl)-5-(6-(3- methyl-1H-pyrazol-5-yl)pyridazin-4- yl)-7-(methylsulfonyl)isoindolin-1- one, trifluoroacetate salt Calculated for C22H24N5O3S (M + H)+: m/z = 438.2, found: 438.2 1H NMR (400 MHz, DMSO-d6) δ 9.61 (d, J = 2.3 Hz, 1H), 8.57 (d, J = 1.6 Hz, 1H), 8.44 (d, J = 2.3 Hz, 1H), 8.40 (d, J = 1.6 Hz, 1H), 6.87 (s, 1H), 4.77 (s, 2H), 3.71-3.61 (m, 1H), 3.66 (s, 3H), 2.35 (s, 3H), 1.35 (d, J = 6.8 Hz, 3H), 1.27-1.09 (m, 1H), 0.68-0.54 (m, 1H), 0.54-0.36 (m, 2H), 0.36- 0.14 (m, 1H). -
- Step 1. 5-Chloro-3-(3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyridazine
- A degassed mixture of 3-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.080 g, 0.27 mmol, Combi Block #PN-4298), 3,5-dichloropyridazine (41 mg, 0.27 mmol, Aldrich #MN0000179), dichloro[1, F-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (11 mg, 0.014 mmol) and Cs2CO3 (220 mg, 0.680 mmol) in dioxane (1.0 mL) and water (0.25 mL) was heated to 70° C. for 3h. Upon cooling to room temperature, the reaction mixture was diluted with EtOAC(6.0 mL), filtered through Celite® and concentrated. The product was initially purified via flash column chromatography, eluting with a gradient of 0-70% EtOAc/hexanes. The product was further purified via preparative HPLC-MS (pH =10) to afford the title compound (12 mg, 16%).
- The major isomer was the desired product. 1H NMR (400 MHz, CDC13) 6 9.16 (d, J=2.4 Hz, 1H), 7.77 (d, J=2.3 Hz, 1H), 6.53 (s, 1H), 6.20 (dd, J=10.3, 2.1 Hz, 1H), 4.11-3.98 (m, 1H), 3.63 (td, J=11.6, 2.6 Hz, 1H), 2.38 (s, 3H), 2.18-2.05 (m, 2H), 1.83-1.49 (m, 4H). LCMS for CI3H16C1N40 (M+H)±: calculated monoisotopic m/z =279.1; found 279.1. Step 2. (S)-2-0-Cyclopropylethyl)-5-(6-(3-methyl-11-1-pyrazol-5-yl)pyridazin-4-Aisoindolin-1-one trifluoroacetate salt
- A degassed mixture of (S)-2-(1-cyclopropylethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (14 mg, 0.043 mmol, from Example 3, Step 2), 5-chloro-3-(3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyridazine (12 mg, 0.043 mmol, from Step 1), dichloro[1,1″-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (7.0 mg, 8.6 umol) and Cs2CO3 (42 mg, 0.13 mmol) in dioxane (0.50 mL) and water (0.13 mL) was heated to 95° C. for 5.5 hours. Upon cooling to room temperature, the reaction mixture was diluted with MeOH and MeCN and was filtered. Solvent was removed in vacuo and the residue was stirred with 1.0 N HC1 (1.0 mL) in MeCN and MeOH (1.0 mL each) overnight. The product was purified via preparative HPLC-MS (pH =2) to afford the title compound (3.6 mg, 18%).
- NMR (400 MHz, DMSO-d6) 6 9.59 (d, J=2.3 Hz, 1H), 8.41 (d, J=2.3 Hz, 1H), 8.22 (s, 1H), 8.07 (dd, J=8.0, 1.6 Hz, 1H), 7.85 (d, J=7.9 Hz, 1H), 6.86 (s, 1H), 4.66 (s, 2H), 3.70-3.54 (m, 1H), 2.35 (s, 3H), 1.33 (d, J=6.8 Hz, 3H), 1.23-1.09 (m, 1H), 0.70-0.53 (m, 1H), 0.51-0.33 (m, 2H), 0.33 — 0.16 (m, 1H). LCMS for C21H22N50 (M+H)±: calculated mlz =360.2; found 360.1.
-
- Step 1. (S)-4-(2-(1-Cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-Apicolinonitrile
- A degassed mixture of 4-bromopicolinonitrile (0.050 g, 0.27 mmol, Synthonix #B0041), (S)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (110 mg, 0.27 mmol, from Example 2, Step 3), cesium fluoride (120 mg, 0.80 mmol) and 4-(di-tert-butylphosphino)-N,N-dimethylaniline - dichloropalladium (2:1) (19 mg, 0.027 mmol) in dioxane (1.0 mL) and water (0.25 mL) was was heated to 100° C. for 2 h. Upon cooling to room temperature, the reaction mixture was diluted with water and extracted with EtOAC(2x). The combined organic extracts were dried over Na2SO4, filtered and concentrated.
- The product was purified via flash column chromatography, eluting with a gradient of 0-80% EtOAc in hexanes to afford the title compound (55 mg, 54%). LCMS for C201-120N303S (M+H)±: calculated m/z =382.1; found 382.1.
- Step 2. (S)-2-0-Cyclopropylethyl)-5-(2-(5-methyl-41-1-1,2,4-triazol-3-Apyridin-4-y0-7-(methylstdfonyl)isoindolin-1-one
- Sodium methoxide (25 wt% in MeOH, 33 uL, 0.14 mmol) was added to a suspension of (S)-4-(2-(1-cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-yl)picolinonitrile (55 mg, 0.14 mmol, from Step 1) in MeOH (1.0 mL), and the reaction mixture was stirred for one hour.
- An aliquot of 1/3 of the reaction mixture was removed and acetohydrazide (7.2 mg, 0.097 mmol) was added. The reaction mixture was heated to reflux overnight. Upon cooling to room temperature, the reaction mixture was diluted with MeOH, filtered and purified via preparative HPLC-MS (pH =10) to afford the title compound (1.2 mg, 2%). NMR (400 MHz, DMSO-d6) 6 8.83 (d, J=5.1 Hz, 1H), 8.49 (d, J=1.6 Hz, 1H), 8.39 (d, J=1.7 Hz, 1H), 8.34 (d, J=1.6 Hz, 1H), 7.89 (d, J=5.1 Hz, 1H), 4.77 (s, 2H), 3.69-3.63 (m, 1H), 3.67 (s, 3H), 3.30 (s, 3H), 1.35 (d, J=6.8 Hz, 3H), 1.25-1.14 (m, 1H), 0.66-0.57 (m, 1H), 0.53-0.35 (m, 2H), 0.34-0.25 (m, 1H). LCMS for C22H24N503S (M+H)±: calculated m/z =438.2; found 438.2.
- The compound in Table 4 was prepared by the procedure of Example 12, using (5)-241-cyclopropylethy0-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (from Example 3, Step 2) instead of (S)-2-(1-cyclopropylethy0-7-(methylsulfony0-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one in Step 1.
-
TABLE 4 Example Compound Name R LCMS No. 1H NMR 13 (S)-2-(1-Cyclopropylethyl)-5-(2-(5- methyl-4H-1,2,4-triazol-3-yl) pyridin-4-yl)isoindolin-1-one Calculated for C21H22N5O (M + H)+: m/z = 360.2, found: 360.2 1H NMR (400 MHz, DMSO-d6) δ 8.77 (d, J = 5.2 Hz, 1H), 8.35 (d, J = 1.8 Hz, 1H), 8.11 (s, 1H), 7.96 (dd, J = 8.1, 1.6 Hz, 1H), 7.85-7.80 (m, 2H), 4.65 (s, 2H), 3.69-3.57 (m, 1H), 2.40 (s, 3H), 1.32 (d, J = 6.8 Hz, 3H), 1.21-1.11 (m, 1H), 0.65-0.52 (m, 1H), 0.48-0.36 (m, 2H), 0.33-0.19 (m, 1H). -
- Step 1. ((S)-5-(2-Chloropyridin-4-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonylfisoindolin-1-one
- Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (38 mg, 0.046 mmol) was added to a degassed mixture of (S)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ypisoindolin-1-one (190 mg, 0.46 mmol, from Example 2, Step 3), 2-chloro-4-iodopyridine (110 mg, 0.459 mmol, Matrix #009790) and K2CO3 (190 mg, 1.378 mmol) in THF (3.0 mL) and water (1.0 mL). The reaction was then heated to 66° C. for 3h. Upon cooling to room temperature, the reaction mixture was diluted with water and extracted with EtOAC(3x). The combined organic extracts were dried over Na2SO4, filtered and concentrated. The product was purified via flash column chromatography, eluting with a gradient from 0-100% EtOAc in hexanes to afford the title compound (0.060 g, 33%). LCMS for CI9H20C1N203S (M+H)±: calculated monoisotopic m/z =391.1; found 391.0.
- Step 2. (S)-2-0-Cyclopropylethyl)-5-(2-(3-inethyl-11-1-pyrazol-5-yl)pyridin-4-y0-7-(inethylsulfonyl)isoindolin-1-one, trifluoroacetate salt Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (3.1 mg, 3.84 umol) was added to a degassed mixture of (S)-5-(2-chloropyridin-4-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonypisoindolin-1-one (15 mg, 0.038 mmol, from Step 1), 3-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (13 mg, 0.046 mmol, Combi Block PN-4298) and Cs2CO3 (25 mg, 0.077 mmol) in dioxane (2.0 mL) and water (1.0 mL). The reaction mixture was then heated to 100° C. for 3h.
- Upon cooling to room temperature, the reaction mixture was partitioned between EtOAc and water. The organic layer was dried over MgSO4, filtered and concentrated. LCMS for C28H33N404S (M+H)±: calculated m/z =521.2; found 521.1. The crude product was stirred with TFA (0.090 mL, 1.2 mmol) in DCM (1.0 mL) for 12 hours. Volatiles were removed in vacuo and the product was dissolved in MeCN and purified via HPLC-MS (pH =2) to afford the title compound (8.0 mg, 38%). 1H NMR (400 MHz, DMSO-d6) 6 8.74 (d, J=5.3 Hz, 1H), 8.46 (d, J=1.6 Hz, 1H), 8.34 (d, J=1.6 Hz, 1H), 8.31 (d, J=1.7 Hz, 1H), 7.75 (dd, J=5.5, 1.9 Hz, 1H), 6.74 (s, 1H), 4.77 (s, 2H), 3.70-3.61 (m, 1H), 3.67 (s, 3H), 2.32 (s, 3H), 1.34 (d, J=6.8 Hz, 3H), 1.26-1.13 (m, 1H), 0.67-0.55 (m, 1H), 0.54-0.34 (m, 2H), 0.34-0.25 (m, 1H). LCMS for C23H25N403S (M+H)±: calculated m/z =437.2; found 437.1.
- The compound in Table 5 was prepared by the procedure of Example 14, using 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3 ,2-dioxaborolan-2-yl)-1H-pyrazole (Combi Blocks #PN-8344) instead of 3-methyl-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole in Step 2, and performing the deprotection by stirring with HC1 (1.0 N in water, 0.21 mL, 0.21 mmol) in MeCN (1.0 mL) for 20 min instead of with TFA in DCM.
-
TABLE 5 Example Compound Name R LCMS No. 1H NMR 15 (S)-5-(2-(1H-Pyrazol-5-yl)pyridin- 4-yl)-2-(1-cyclopropylethyl)-7- (methylsulfonyl)isoindolin-1-one, trifluoroacetate salt Calculated for C22H23N4O3S (M + H)+: m/z = 423.1, found: 423.1 1H NMR (400 MHz, DMSO-d6) δ 8.76 (d, J = 5.3 Hz, 1H), 8.47 (s, 1H), 8.37- 8.31 (m, 2H), 7.82 (s, 1H), 7.75 (d, J = 4.6 Hz, 1H), 6.97 (s, 1H), 4.77 (s, 2H), 3.71-3.61 (m, 1H), 3.67 (s, 3H), 1.35 (d, J = 6.8 Hz, 3H), 1.28-1.13 (m, 1H), 0.67-0.57 (m, 1H), 0.52-0.38 (m, 2H), 0.34-0.25 (m, 1H). -
- To a suspension of (S)-4-(2-(1-cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-yl)picolinonitrile (18 mg, 0.047 mmol, from Example 12, Step 1) in MeOH (0.30 mL) was added NaOMe (25 wt% in MeOH, 11 μL, 0.047 mmol), and the reaction mixture was stirred for lh. To the mixture was then added 1,1-diethoxypropan-2-amine (8.0 μL, 0.047 mmol, Astatech #84948) and acetic acid (7.0 μL 0.12 mmol). The mixture was sealed and heated at 100° C. for 2.5 hours.
- The mixture was cooled to rt, and c.HC1 (0.012 mL, 0.19 mmol) was added and the mixture was heated to 85° C. for 2 h. Upon cooling to rt, the reaction mixture was diluted with MeOH, and the product was purified via prepartive HPLC-MS (pH=2) to afford the title compound (0.010 g, 38%). iH NMR (400 MHz, DMSO-d6) 6 8.95 (d, J=5.2 Hz, 1H), 8.62 (d, J=1.8 Hz, 1H), 8.48 (d, J=1.7 Hz, 1H), 8.44 (d, J=1.6 Hz, 1H), 8.06 (dd, J=5.2, 1.8 Hz, 1H), 7.57 (s, 1H), 4.78 (s, 2H), 3.69 (s, 3H), 3.67 — 3.62 (m, 1H), 2.39 (s, 3H), 1.36 (d, J=6.8 Hz, 3H), 1.28 — 1.14 (m, 1H), 0.68 — 0.55 (m, 1H), 0.51 — 0.39 (m, 2H), 0.35 — 0.24 (m, 1H). LCMS for C23H25N403S (M+H)±: calculated m/z =437.2; found 437.1.
- The compound in Table 6 was prepared by the procedure of Example 16, using 2,2-diethoxyethan-1-amine (6.3 mg, 0.047 mmol, Aldrich #A37200) instead of 1,1-diethoxypropan-2-amine.
-
TABLE 6 Example Compound Name R LCMS No. 1H NMR 17 (S)-5-(2-(1H-Imidazol-2-yl) pyridin-4-yl)-2-(1-cyclopropylethyl)- 7-(methylsulfonyl)isoindolin-1- one, trifluoroacetate salt Calculated for C22H23N4O3S (M + H)+: m/z = 423.1, found: 423.1 1H NMR (400 MHz, DMSO-d6) δ 8.95 (d, J = 5.1 Hz, 1H), 8.66 (s, 1H), 8.49 (d, J = 1.6 Hz, 1H), 8.45 (d, J = 1.6 Hz, 1H), 8.06 (dd, J = 5.3, 1.7 Hz, 1H), 7.80 (s, 2H), 4.78 (s, 2H), 3.69 (s, 3H), 3.68-3.61 (m, 1H), 1.36 (d, J = 6.8 Hz, 3H), 1.29-1.15 (m, 1H), 0.69-0.56 (m, 1H), 0.50-0.40 (m, 2H), 0.35-0.25 (m, 1H). -
- Step 1. (S)-5-Chloro-2-(1-cyclopropylethyl)-7-iodoisoindolin-1-one
- The title compound was prepared as described in Example 1, Steps 2 and 3, using methyl 4-chloro-2-iodo-6-methylbenzoate (6.9 g, 22 mmol, prepared as described in WO 2011006794) instead of methyl 4-bromo-2-chloro-6-methylbenzoate in Step 2 (3.7 g, 52% over 2 steps). LCMS for C131-114C1INO (M+H)±: calculated monoisotopic mlz =362.0; found 361.9.
- Step 2. (S)-5-Chloro-2-(1-cyclopropylethyl)-7-vinylisoindolin-1-one
- A degassed mixture of (5)-5-chl oro-2-(1-cycl opropyl ethyl)-7-iodois oindolin-1-one (0.50 g, 1.4 mmol, from Step 2), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (260 mg, 1.7 mmol, Combi Blocks #PN-8602), and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (56 mg, 0.069 mmol) in dioxane (8.5 mL) and aq.K2CO3 solution (1.0 M, 4.2 mL, 4.2 mmol) was heated to 80° C. for 2h. Upon cooling to room temperature, the reaction mixture was diluted with water and extracted with EtOAC(2x). The combined organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated. The product was purified via flash column chromatography, eluting with a gradient of 0-20% EtOAc in hexanes to afford the title compound (0.31 g, 86%). LCMS for CI5I-117C1N0 (M+H)±: calculated monoisotopic m/z =262.1; found 262.1.
- Step 3. 5-Chloro-24(S)-1-cyclopropylethyl)-7-(1,2-dihydroxyethyl)isoindolin-1-one (mixture of two diastereomers)
- To a solution of (S)-5-chloro-2-(1-cyclopropylethyl)-7-vinylisoindolin-1-one (0.31 g, 1.2 mmol, a mixture of two diastereomers from Step 2) in acetone (15 mL) and water (5.0 mL) was added NMO (0.18 g, 1.5 mmol) and 0s04 (4% w/v in water, 0.45 mL, 0.071 mmol). The mixture was stirred for lh, followed by the addition of sodium sulfite (0.30 g, 2.4 mmol). After stirring for 10 min, the reaction mixture was filtered. The filtrate was diluted with EtOAc and brine. The layers were shaken and separated and the aqueous layer was extracted with EtOAC(2x). The combined organic extracts were dried over Na2SO4, filtered and concentrated. The product was purified via flash column chromatography, eluting with a gradient of 0-100% EtOAc in hexanes to afford the title compound (0.31 g, 88%). LCMS for CI5I-119C1NO3 (M+H)+: calculated monoisotopic m/z=296.1; found 296.1.
- Step 4. 24(S)-1-Cyclopropylethyl)-7-(1,2-dihydroxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (mixture of two diastereomers)
- A degassed mixture of 5-chloro-2-((S)-1-cyclopropylethyl)-7-(1,2-dihydroxyethyl)isoindolin-1-one (0.31 g, 1.0 mmol, a mixture of two diastereomers from Step 3), bis(pinacolato)diboron (0.80 g, 3.1 mmol), potassium acetate (0.62 g, 6.3 mmol), Pd2(dba)3 (0.048 g, 0.052 mmol) and 2-dicyclohexylphosphino-2′,4′,6′-tri-iso-propyl-1,1′-biphenyl (0.10 g, 0.21 mmol) in dioxane (8.0 mL) was heated in a sealed vial to 120° C. for 45 min. Upon cooling to room temperature, the reaction mixture was diluted with EtOAc, filtered through Celite® and concentrated. The product was purified via flash column chromatography, eluting with a gradient of 0-100% EtOAc in hexanes to afford the title compound (0.23 g, 57%). LCMS for C211-131BNO5 (M+H)±: calculated mlz =388.2; found 388.2.
- Step 5. 4-Bromo-2-(4,5-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyridine
- To a solution of 4-bromo-2-(4,5-dimethyl-1H-imidazol-2-yl)pyridine (0.60 g, 2.4 mmol, prepared as in Example 1, Step 1) in THF (26 mL) at 0° C. was added potassium tert-butoxide (1.0 M in THF, 3.3 mL, 3.3 mmol). After stirring for 30 min, 2-(trimethylsilyl)ethoxymethyl chloride, stabilized, tech. (0.59 mL, 3.3 mmol) was added, and the reaction was stirred for 30 min at 0° C. The reaction was quenched by the addition of NH4C1 solution and was stirred for 30 min. The mixture was extracted with EtOAc, and the organic extract was washed with water, followed by brine. The organic solution was dried over Na2SO4, filtered and concentrated. Purification via flash column chromatography, eluting with a gradient from 0-20% EtOAc in hexanes, provided the title compound (0.63 g, 69%). LCMS for Ci6H25BrN3OSi (M+H)±: calculated monoisotopic m/z =382.1; found 382.0.
- Step 6. 24(S)-1-Cyclopropylethyl)-7-(1,2-dihydroxyethyl)-5-(2-(4,5-dimethyl-14(2-(trimethylsilyoethoxy)methyl)-1H-imidazol-2-yl)pyridin-4-yl)isoindolin-1-one (mixture of two diastereomers)
- A degassed mixture of 2-((S)-1-cyclopropylethyl)-7-(1,2-dihydroxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (31 mg, 0.080 mmol, a mixture of two diastereomers from Step 4) , 4-bromo-2-(4,5-dimethyl-1-42-(trimethylsilypethoxy)methyl)-111-imidazol-2-yl)pyridine (37 mg, 0.096 mmol, from Step 5) and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (13 mg, 0.016 mmol) in THF (1.0 mL) and aq. Na2CO3 (1.0 M, 0.24 mL, 0.24 mmol) was heated in a sealed vial at 95° C. for lh. Upon cooling to room temperature, the reaction mixture was diluted with water and extracted with EtOAC(3x). The combined organic extracts were dried over Na2SO4, filtered and concentrated. The product was purified via flash column chromatography, eluting with a gradient of 0-100% EtOAc in hexanes, followed by 5% MeOH in EtOAc to afford the title compound (29 mg, 64%). LCMS for C3,H43N4O4Si (M+H)±: calculated mlz =563.3; found 563.3.
- Step 7. 24(S)-1-Cyclopropylethyl)-7-(1,2-dihydroxyethyl)-5-(2-(4,5-dimethyl-1H-imidazol-2-yl)pyridin-4-yl)isoindolin-1-one (mixture of two diastereomers)
- A solution of 2-((S)-1-cyclopropylethyl)-7-(1,2-dihydroxyethyl)-5-(2-(4,5-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyridin-4-ypisoindolin-1-one (29 mg, 0.052 mmol, from Step 6) in DCM (1.0 mL) and TFA (0.1 mL) was stirred overnight. Volatiles were removed in vacuo and the residue was dissolved MeOH (1.0 mL). Concentrated aq. NH4OH (25 pi) was added, and the mixture was stirred for 20 min and then evaporated. The residue was dissolved in a mixture of MeOH and MeCN and was purified via preparative HPLC-MS (pH =10) to afford the title compound (0.010 g, 45%). 1H NMR (400 MHz, DMSO-d6, diastereomers) 6 12.41 (s, 1H), 8.65 (d, J=5.2 Hz, 1H), 8.28 — 8.20 (m, 1H), 7.96 (s, 1H), 7.94 (s, 1H), 7.63 (dd, J =5.2, 1.8 Hz, 1H), 5.77 (d, J=6.8 Hz, 1H), 5.54 — 5.45 (m, 1H), 4.73 — 4.67 (m, 1H), 4.65 (s, 2H), 3.66 — 3.57 (m, 2H), 3.56 — 3.49 (m, 1H), 2.19 (s, 3H), 2.12 (s, 3H), 1.32 (d, J=6.8 Hz, 1.5H), 1.31 (d, J=6.8 Hz, 1.5H), 1.22 — 1.10 (m, 1H), 0.64 — 0.55 (m, 1H), 0.50 — 0.35 (m, 2H), 0.31 — 0.21 (m, 1H). LCMS for C25H29N403 (M+H)±: calculated m/z =433.2; found 433.3.
-
- The procedure of Example 8, Steps 1 through 4 were followed, using 24(S)-1-cyclopropylethyl)-7-(1,2-dihydroxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (a mixture of two diastereomers from Example 18, Step 4) instead of (S)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one in Step 1. 1H NMR (400 MHz, DMSO-d6, diastereomers) 6 9.78 (s, 1H), 8.64 (s, 1H), 8.11 (s, 2H), 5.63 — 5.57 (m, 1H), 4.68 (s, 2H), 3.67 — 3.49 (m, 3H), 2.33 (s, 6H), 1.34 (d, J=6.8 Hz, 1.5H), 1.33 (d, J=6.9 Hz, 1.5H), 1.26 — 1.14 (m, 1H), 0.65 — 0.55 (m, 1H), 0.48 — 0.36 (m, 2H), 0.31 — 0.22 (m, 1H). LCMS for C24H28N503 (M+H)±: calculated m/z =434.2; found 434.2.
-
- Step 1. (S)-2-(1-Cyclopropylethyl)-7-(methylthio)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
- The procedure of Example 2, Step 3 was followed, using (S)-5-bromo-2-(1-cyclopropylethyl)-7-(methylthio)isoindolin-1-one (0.10 g, 0.31 mmol, from Example 2, Step 1) instead of (S)-5-bromo-2-(1-cyclopropylethyl)-7-(methylsulfonypisoindolin-1-one as starting material, to afford the title compound which was used without further purification (theoretical yield assumed). LCMS for C201-129BNO3S (M+H)±: calculated mlz =374.2; found 374.2. Step 2. (S)-2-(1-Cyclopropylethyl)-5-(2-(4,5-dimethyl-1-((2-(trimethylsilyl)ethoxy)methyl)-11-1-imidazol-2-Apyridin-4-yl)-7-(methylthio)isoindolin-1-one
- The procedure of Example 18, Step 6 was followed, using (S)-2-(1-cyclopropylethyl)-7-(methylthio)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one (110 mg, 0.31 mmol) instead of 2-((S)-1-cyclopropylethyl)-7-(1,2-dihydroxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one as starting material, to afford the title compound (0.080 g, 48%). LCMS for C30H4,N4O2SSi (M+H)±: calculated m/z =549.3; found 549.2.
- Step 3. (S)-2-0-Cyclopropylethyl)-5-(2-(4,5-dimethyl-11-1-imidazol-2-yl)pyridin-4-y0-7-(methylthio)isoindolin-1-one
- A solution of (S)-2-(1-cyclopropylethyl)-5-(2-(4,5-dimethyl-1-42-(trimethylsilypethoxy)methyl)-1H-imidazol-2-yl)pyridin-4-yl)-7-(methylthio)isoindolin-1-one (0.040 g, 0.073 mmol) in TFA (3.3 mL) and DCM (1.2 mL) was stirred for 3h. Volatiles were removed in vacuo. The residue was partitioned between EtOAc and saturated aq. NaHCO3, and the layers were separated. The aqueous layer was extracted with two further portions of EtOAc. The combined organic extracts were dried over Na2SO4, filtered and concentrated and used without further purification (theoretical yield assumed). LCMS for C24H27N4OS (M+H)±:
- calculated m/z =419.2; found 419.2. Step 4. 24(S)-1-Cyclopropylethyl)-5-(2-(4,5-dimethyl-1H-imidazol-2-yl)pyridin-4-y0-7-(S-methylsulfonimidoylisoindolin-1-one, trifluoroacetate salt (mixture of two diastereomers)
- To (S)-2-(1-cyclopropylethyl)-5-(2-(4,5-dimethyl-1H-imidazol-2-yl)pyridin-4-yl)-7-(methylthio)isoindolin-1-one (0.030 g, 0.072 mmol) in MeOH (0.14 mL) was added aq. NH4OH (28%, 10. IA, 0.14 mmol), followed by (diacetoxyiodo)benzene (0.046 g, 0.14 mmol). The reaction was stirred for 45 minutes, then was diluted with MeOH and purified via preparative HPLC-MS (pH=2) to afford the title compound (6.0 mg, 15%). 1H NMR (400 MHz, DMSO-d6, diastereomers) 6 8.96 (d, J=5.2 Hz, 1H), 8.55 (s, 1H), 8.43 (d, J=1.6 Hz, 1H), 8.37 (s, 1H), 8.07 (dd, J=5.1, 1.7 Hz, 1H), 4.78 (s, 2H), 3.70 — 3.62 (m, 1H), 3.56 (s, 3H), 2.33 (s, 6H), 1.36 (d, J=6.8 Hz, 1.5H), 1.36 (d, J=6.8 Hz, 1.5H), 1.28 — 1.14 (m, 1H), 0.68 — 0.55 (m, 1H), 0.55 — 0.38 (m, 2H), 0.37 — 0.19 (m, 1H). LCMS for C24H28N502S (M+H)±: calculated m/z =450.2; found 450.2.
-
- To (S)-2-(1-cyclopropylethyl)-5-(2-(4,5-dimethyl-1H-imidazol-2-yl)pyridin-4-yl)-7-(methylthio)isoindolin-1-one (0.22 g, 0.52 mmol, prepared as in Example 20, Step 3) in MeOH (1.7 mL) and DCM (0.90 mL) was added aq. NH4OH (28%, 0.071 mL, 1.0 mmol), followed by (diacetoxyiodo)benzene (0.34 g, 1.0 mmol). After stirring for 2 hours, volatiles were removed in vacuo and the mixture was dissolved in DCM and purified via flash column chromatography, eluting with a gradient from 0-10% MeOH in DCM to obtain a mixture of diastereomers (37 mg, 16%). The diastereomers were separated via chiral HPLC (Phenomenex Lux Cellulose-1, 21.2×250 mm, 5 μm, loading: 2.5 mg in 250 μL EtOH and eluting with 45% EtOH in hexanes at 20 mL/min over 15 min).
- Peak 1 (Example 21) (retention time 6.8 min): LCMS for C24H28N502S (M+H)±: calculated m/z =450.2; found 450.2.
- Peak 2 (Example 22) (retention time 10.2 min): LCMS for C24H28N502S (M+H)±: calculated m/z =450.2; found 450.2.
-
- 2-((S)-1-Cyclopropylethyl)-5-(2-(4,5-dimethyl-1H-imidazol-2-yl)pyridin-4-yl)-7-(S-methylsulfonimidoypisoindolin-1-one (0.076 g, 0.17 mmol, mixture of two diastereomers prepared as in Example 20) and paraformaldehyde (0.011 g, 0.37 mmol) were dissolved in formic acid (0.5 mL, 13 mmol) and the mixture was heated to reflux for 36 hours. The reaction was diluted with MeOH and purified via preparative HPLC-MS (pH =6.5) to afford the title compound (0.010 g, 13%). NMR (500 MHz, DMSO-d6, diastereomers) 6 8.69 (d, J=5.2 Hz, 1H), 8.38 (d, J =1.6 Hz, 1H), 8.31 (d, J =1.5 Hz, 1H), 8.26 (d, J =1.7 Hz, 1H), 7.68 (dd, J =5.2, 1.9 Hz, 1H), 4.73 (s, 2H), 3.69-3.64 (m, 1H), 3.63 (s, 1.5H), 3.62 (s, 1.5H), 2.16 (s, 6H), 1.88 (s, 3H), 1.33 (d, J=6.1 Hz, 1.5H), 1.32 (d, J=6.3 Hz, 1.5H) 1.23-1.11 (m, 1H), 0.68-0.56 (m, 1H), 0.50-0.38 (m, 2H), 0.33-0.24 (m, 1H). LCMS for C25H30N502S (M+H)±: calculated m/z =464.2; found 464.1.
-
- The diastereomers of Example 23 were separated via chiral HPLC (Phenomenex Lux Cellulose-1, 21.2x250mm, 5μm, loading 3.3 mg in 500 p.L EtOH and eluting with 15% EtOH in hexanes at 20 mL/min over 25 min).
- Peak 1 (Example 24) (retention time 16.8 min): LCMS for C25H30N502S (M+H)±: calculated m/z =464.2; found 464.2.
- Peak 2 (Example 25) (retention time 19.7 min): LCMS for C25H30N502S (M+H)±: calculated m/z =464.2; found 464.1.
-
- Step 1. (S)-5-Chloro-2-(1-cyclopropylethyl)-7-((dimethyl(oxo)-)r-sulfanylidene)aminofisoindolin-1-one
- A degassed mixture of (S)-5-chloro-2-(1-cyclopropylethyl)-7-iodoisoindolin-1-one (0.10 g, 0.28 mmol, from Example 18, Step 1), dimethylsulfoximine (0.026 g, 0.28 mmol, Astatech #F31251), Pd2(dba)3 (0.013 g, 0.014 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.016 g, 0.028 mmol) and Cs2CO3 (0.14 g, 0.42 mmol) in dioxane (0.46 mL) was heated to reflux for 3 hours. The reaction mixture was cooled to room temperature and was partitioned between water and EtOAc. The aqueous layer was extracted with two further portions of EtOAc.
- The combined organic extracts were dried over Na2SO4, filtered and concentrated. The product was used without further purification (theoretical yield assumed). LCMS for CI5H20C1N202S (M+H)±: calculated monoisotopic m/z =327.1; found 327.1. Step 2. (S)-2-(1-cyclopropylethyl)-7-((dimethyl(oxo)-)-sulfanylidene)amino)-5-(4,4,5,5-tetramethyl-1 , 3, 2-dioxab orolan-2-yl)isoindolin- 1-one
- A degassed mixture of (S)-5-chloro-2-(1-cyclopropylethyl)-7-((dimethyl(oxo)-X6-sulfanylidene)amino)isoindolin-1-one (0.090 g, 0.28 mmol), bis(pinacolato)diboron (210 mg, 0.83 mmol), KOAC(160 mg, 1.6 mmol), Pd2(dba)3 (13 mg, 0.014 mmol) and 2-dicyclohexylphosphino-2″,4′,6′-tri-iso-propyl-1,1′-biphenyl (26 mg, 0.055 mmol) in dioxane (2.7 mL) was heated in a sealed vial at 120° C. for 1.5 hours. The reaction mixture was filtered and solvent was removed in vacuo. The product was purified via flash column chromatography, eluting with a gradient from 0-10% MeOH in DCM to afford the title compound (96 mg, 83%). LCMS for C21-132BN204S (M+H)±: calculated m/z =419.2; found 419.2. Step 3. (S)-2-(1-Cyclopropylethyl)-7-((dimethyl(oxo)-A6-sulfanylidene)amino)-5-(2-(5-methyl-1H-imidazol-2-yl)pyridin-4-yl)isoindolin-1-one (single enantiomer prepared)
- A degassed mixture of (S)-2-(1-cyclopropylethyl)-7-((dimethyl(oxo)-X6-sulfanylidene)amino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ylisoindolin-1-one (0.030 g, 0.072 mmol), 4-bromo-2-(4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyridine (0.026 g, 0.072 mmol, from Example 3, Step 4) and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (0.080 g, 0.098 mmol), in dioxane (2.0 mL) and aq. Na2CO3 (1.0 M, 0.42 mL, 0.42 mmol) was heated in the microwave at 140° C. for 30 min. Upon cooling to room temperature, the reaction mixture was diluted with water, brine, EtOAc and was filtered. The layers were separated and the aqueous layer was extracted with EtOAC(2x). The combined organic extracts were dried over Na2SO4, filtered and concentrated. The product was purified via flash column chromatography, eluting with a gradient from 0-100% EtOAc in hexanes, followed by 0-10% MeOH in DCM, to afford the SEM protected intermediate. The protected intermediate was deprotected by stirring with TFA in DCM (1:1, 4.0 mL) for 1 hour. Volatiles were removed in vacuo and the residue was reconstituted in
- MeOH and purified via preparative HPLC-MS (pH =6.5) to afford the title compound as the free base. LCMS for C24H28N502S (M+H)±: calculated m/z =450.2; found 450.1.
- To measure the Phosphorylated Ribosomal Protein S6 (RPS6) in cell lysates, THP-1 cells
- (Human Acute Monocytic Leukemia) are purchased from ATCC (Manassas, VA) and maintained in RPMI with 10% FBS (Gibco/Life Technologies, Carlsbad, CA). For the assay, THP-1 cells are serum starved overnight in RPMI, then plated in RPMI (2x105 cells/well in 90 μL) into 96-well flat-bottom tissue culture treated plates (Corning, Corning, NY), in the presence or absence of a concentration range of test compounds. Covered plates are incubated for 2 hours at 37° C., 5%
- CO2 then treated with or without 10 nM MCP-1(MYBioSource, San Diego, CA) for 15 minutes at 37° C., 5% CO2. Plates are centrifuged at 1600 RPM and supernatants are removed. Cells are lysed in Lysis Buffer (Cell Signaling, Danvers, MA) with Protease Inhibitor (Calbiochem/EMD, Germany), PMSF (Sigma, St Louis MO), HALTS (Thermo Fisher, Rockford, IL) for 30 min on wet ice. Cell lysates are frozen at -80° C. before testing. The lysates are tested in the
- Human/Mouse/Rat Phospho-RPS6 ELISA (R&D Systems, Inc. Minn, MN). The plate is measured using a microplate reader (SpectraMax M5 — Molecular Devices, LLC Sunnyvale, CA) set to 450 nm with a wavelength correction of 540. IC50 determination is performed by fitting the curve of inhibitor percent inhibition versus the log of the inhibitor concentration using the GraphPad Prism 5.0 software.
- Materials: [y-3313]ATP (10 mCi/mL) and Wheat Germ Agglutinin (WGA) YSi SPA Scintillation Beads was purchased from Perkin Elmer (Waltham, MA). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2)D (+)-sn-1,2-di-O-octanoylglyceryl, 3-0-phospho linked (PIP2), CAS 204858-53-7, was purchased from Echelon Biosciences (Salt
- Lake City, UT). PI3Kγ (p110y) Recombinant Human Protein was purchased from Life technology (Grand Island, NY). ATP, MgC12, DTT, EDTA, MOPS and CHAPS were purchased from Sigma Aldrich (St. Louis, MO).
- The kinase reaction was conducted in polystyrene 384-well Greiner Bio-one white plate from Thermo Fisher Scientific in a final volume of 25 μL. Inhibitors were first diluted serially in
- DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 2%. The PI3Kγ assay was carried out at room temperature in 20 mM MOPS, pH 6.7, 10 mM MgC12, 5 mM DTT and CHAPS 0.03%. Reactions were initiated by the addition of ATP, the final reaction mixture consisted of 20 μM PIP2, 2 μM ATP, 0.5 μCi [γ-33P] ATP, 13 nM PI3Kγ . Reactions were incubated for 120 min and terminated by the addition of 40 μL SPA beads suspended in quench buffer: 163 mM potassium phosphate pH 7.8, 20% glycerol, 25 mM EDTA. The final concentration of SPA beads is 1.0 mg/mL. After the plate sealing, plates were shaken overnight at room temperature and centrifuged at 1500 rpm for 10 min, the radioactivity of the product was determined by scintillation counting on Topcount (Perkin—Elmer). ICso determination was performed by fitting the curve of percent of the solvent control activity versus the log of the inhibitor concentration using the GraphPad Prism 6.0 software.
- Materials: [7-33P]ATP (10 mCi/mL) and Wheat Germ Agglutinin (WGA) YSi SPA Scintillation Beads was purchased from Perkin Elmer (Waltham, MA). Lipid kinase substrate, D-myo-Phosphatidylinositol 4,5-bisphosphate (Ptdlns(4,5)P2)D (+)-sn-1,2-di-O-octanoylglyceryl, 3-0-phospho linked (PIP2), CAS 204858-53-7, was purchased from Echelon Biosciences (Salt Lake City, UT). PI3K6 (p1106/p85a) Recombinant Human Protein was purchased from Eurofins
- (St Charles, MO). ATP, MgC12, DTT, EDTA, MOPS and CHAPS were purchased from Sigma Aldrich (St. Louis, Mo.).
- The kinase reaction was conducted in polystyrene 384-well Greiner Bio-one white plate from Thermo Fisher Scientific in a final volume of 25 μL. Inhibitors were first diluted serially in DMSO and added to the plate wells before the addition of other reaction components. The final concentration of DMSO in the assay was 2%. The PI3K6 assay was carried out at room temperature in 20 mM MOPS, pH 6.7, 10 mM MgC12, 5 mM DTT and CHAPS 0.03%. Reactions were initiated by the addition of ATP, the final reaction mixture consisted of 20 μM PIP2, 2 μM ATP, 0.5 μCi [γ-33P] ATP, 3.4 nM PI3K6. Reactions were incubated for 120 min and terminated by the addition of 40 μL SPA beads suspended in quench buffer: 163 mM potassium phosphate pH 7.8, 20% glycerol, 25 mM EDTA. The final concentration of SPA beads is 1.0 mg/mL. After the plate sealing, plates were shaken overnight at room temperature and centrifuged at 1500 rpm for 10 min, the radioactivity of the product was determined by scintillation counting on Topcount (PerkinElmer). ICso determination was performed by fitting the curve of percent of the solvent control activity versus the log of the inhibitor concentration using the GraphPad Prism 6.0 software.
- The compounds of the Examples were tested in the assays described in Examples A, B and C and found to have the ICsos are shown in Table A.
-
TABLE A PI3Kγ_THP1_ Ex. PI3Kγ PI3Kδ RPS6_ELISA No. IC50 (nM) IC50 (nM) IC50 (nM) 1 + ++ ### 2 + ++ ### 3 + +++ #### 4 + +++ #### 5 + ++++ #### 6 + ++++ #### 7 + +++ ## 7a + ++ # 7b + ++ ### 7c + ++ #### 7d + ++ ## 7e + ++ #### 7f + ++ #### 7g + ++ #### 7h + + ## 7i + + ## 7j + ++ ## 7k + ++ ## 7l + ++ ## 7m + +++ ### 7n + ++ ## 7o + ++ ## 7p + +++ ## 7q + +++ #### 7r + +++ ## 7s + +++ ### 7t + +++ ## 7u + +++ ## 8 + ++++ NA 9 ++ ++++ #### 10 ++ ++++ #### 11 +++ ++++ NA 12 + ++++ #### 13 + ++++ NA 14 + ++++ #### 15 + ++++ #### 16 + +++ # 17 + ++++ ### 18 + ++++ ## 19 + ++++ NA 20 + ++++ ## 21 + ++++ ### 22 + +++ ### 23 + +++ ## 24 + +++ ## 25 + +++ ### 26 + ++++ #### + refers to IC50 of ≤100 nM; ++ refers to IC50 of ≤500 nM; +++ refers to an IC50 of <2000 nM; ++++ refers to an IC50 of ≥2000 nM. # refers to IC50 of ≤100 nM; ## refers to IC50 of ≤500 nM; ### refers to IC50 of <1000 nM; #### refers to an IC50 of ≥1000 nM. - Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.
Claims (24)
1-35. (canceled)
36. A method of inhibiting an activity of PI3Kγ kinase, comprising contacting the kinase with a compound of Formula (IIu):
or a pharmaceutically acceptable salt thereof, wherein:
Z is CZ1 or N;
Z1 and R12 are each independently selected from H, D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, di (C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
R1 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa1, —SRa1, —C(O)Rb1, —C(O)NRc1Rd1, —C(O)NRc1(ORa1), —C(O)ORa1, —OC(O)Rb1, —OC(O)NRc1Rd1, —NRc1Rd1, —NRc1NRc1Rd1, —NRc1C(O)Rb1, —NRc1C(O)ORa1, and —NRc1C(O)NRc1Rd1, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
each Ra1, Rb1, Rc1, and Rd1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra1, Rb1, Rc1 and Rd1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
or, any Rc1 and Rd1, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
each R1A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa11, —SRa11, —NHORa11, —C(O)Rb11, —C(O)NRc11Rd11, —C(O)NRc11(ORa11), —C(O)ORa11, —OC(O)Rb11, —OC(O)NRc11Rd11, —NRc11Rd11, —NRc11Rc11Rd11, —NRc11C(O)Rb11, —NRa11, and —NRc11C(O)NRc11R11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each Ra11, Rb11, Ra11, and Rd11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra11, Rb11, Ra11and Rd11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
or, any Rc11 and Rd11, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each RM is independently selected from D, OH, NO2, CN, halo, alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO—C1-3 alkyl, alkoxy-C1-3 alkyl, C3-6 cycloalkyl, alkoxy, C1-3 haloalkoxy, amino, alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa2, —SRa2, —NHORa2, —C(O)Rb2, —C(O)NRC2Rd2, —C(O)NRc2(ORa2), C(O)ORa2, —OC(O)Rb2, —OC(O)NRc2Rd2, —NRc2Rd2, —NRc2NRc2Rd2, —NRc2C(O)Rb2, —NRc2C(O)ORa2, and —NRc2C(O)NRc2Rd2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
each Ra2, Rb2, Rc2, Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-Ch6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra2, Rb2, Rc2 and R d2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
each R2A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa21, —SRa21, —NHORa21, —C(O)Rb21, —C(O)NRc21Rd21, —C(O)NRc21(ORa21), —C(O)ORa21, —OC(O)Rb21, —OC(O)NRc21Rd21, —NRc21Rd21, NRc21NRc21Rd21, —NRc21C(O)Rb21, —NRc21 C(O)ORa21, and —NRc21C(O)NRc21Rd21, alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each Ra21, Rb21, Rc21, and Rd21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-Ch6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra21, Rb21, Rc21 and Rd21 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
or, any Rc21 and Rd21, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
or alternatively, R1 and R2, taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R1A groups;
R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa6, —SRa6, —NHORa6, —C(O)Rb6, —C(O)NRc6Rd6, —C(O)NRc6(ORa6), —C(O)ORa6, —OC(O)Rb6, —OC(O)NRc6Rd6NRC6Rd6, —NRc6NRc6Rd6, —NRc6C(O)Rb6, —NRc6C(O)ORa6, —NRc6C(O)NRc6Rd6, —C(═NRe6)Rb6, —C(═NOH)Rd6, —C(═NCN)Rb6, —C(═NRe6)NRc6Rd6, —NRc6C(═NRe6)NRc6Rd6, —NRc6C(═NOH)NRc6Rd6, —NRc6C(═NCN)NRc6Rd6, —NRc6C(═NRe6)Rb6, —NRc6S(O)NRc6Rd6, —NRc6S(O)Rb6, —NRc6S(O)2Rb6, —NRc6S(O)(═NRe6)Rb6, —NRc6S(O)2NRc6Rd6, —S(O)Rb6, —S(O)NRc6Rd6, —S(O)2Rb6, —S(O)2NRc6Rd6, —S(O)(═NRe6)Rb6, —N═S(O)Ra6Rb6, —OS(O)(═NRe6)Rb6, —OS(O)2Rb6, and —SF5, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C 6 alkyl- of R6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
each Ra6, and Rb6, Rc6, Rd6, and Re6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra6, Rb6, Rc6, Rd6, and Re6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
or, any Rc6 and Rd6, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
each R6A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa61, —SRa61, —NHORa61, —C(O)Rb61, —C(O)NRc61Rd61, —C(O)NRc61(ORa61), —C(O)ORa61, —OC(O)Rb61, —OC(O)NRc61Rd61, —NRc61Rd61, —NRc61NRc61Rd61, —NRc61C(O)Rb61, —NRc61C(O)ORa61, and —NRc61C(O)NRc61Rd61, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each Ra61, Rb61, Rc61, and Rd61 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-Ch6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra61, Rb61, Rc61 and Rd61 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
or, any Rc61 and Rd61, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
X9 is —NR9N or —C(R9)2;
X11 is —NR11N or —C(R11)2:,
R9N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, —C(O)Rb9N, —C(O)NRc9NRd9N, —C(O)ORa9N. —C(═NRe9N)Rb9N, C(═NRe9N)NRc9NRd9N, —C(═NCN)NRc9NRd9N, —C(═NORa9N)NRc9N, —S(O)2Rb9N, —S(O)(═NRc9N)Rd9N, (and —S(O)2NRc9N-Rd9N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
each Ra9N, Rb9N, Rc9N, and Rd9N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra9N, Rb9N, Rc9N, and Rd9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
or, any Rc9N and Rd9N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
each Re9N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
each R9NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa9N2, —SRa9N2, —NHORa9N2, —C(O)Rb9N2, —C(O)NRc9N2Rd9N2, —C(O)NRc9N2(ORa9N2), —C(O)ORa9N2, —OC(O)Rb9N2, —OC(O)NRc9NRd9N2, NRc9N2Rd9N2, —NRC9N2 NRC9N2 Rd9N2, —NRC9N2C(O)Rb9N2, —NRC9N2 C(O)ORa9N2, —NRc9N2C(O)NR c9N2Rd9N2; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1, 6 alkyl- of R9NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Ra9N2, Rb9N2, Rc9N2, and Rd9N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2,6 alkenyl, C2,6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2,6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra9N2, Rb9N2, Rc9N2 and Rd9N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, any Rc9N2 and Rd9N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each R9 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2,6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa91, -SRa91, —NHORa91, —C(O)Rb91, —C(O)NRc91Rd91, —C(O)NRc91(ORa91), C(O)ORa91, —OC(O)Rb91, —OC(O)NRc91Rd91, —NRc91Rd91, —NRc91NRc91Rd91, —NRc91C(O)Rb91, —NRc91 C(O)OR a91, and —NRc91C(O)NRc91Rd91, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
or, alternatively, two R9 groups together form an oxo group;
each Ra91, Rb91, Rc91, and Rd91 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra91, Rb91, Rc91 and Rd91 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
or, any Rc91 and Rd91, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
each R9A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroa 1 4-7 membered heteroc cloalk 1 phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa92, —SRa92, —NHORa92, —C(O)Rb92, —C(O)NRc92Rd92, —C(O)NRc92(ORa92), —C(O)ORa92, —OC(O)Rb92, —OC(O)NRc92Rd92, —NRc92Rd92, —NRc92NRc92Rd92, —NRc92C(O)Rb92, —NRc92C(O)ORa92, and —NRc92C(O)NRc92Rd92, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R9A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Ra92, Rb92, Rc92, and Rd92 is independently selected from H, C1-6 alkyl, C16 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra92, Rb92, Rc92 and Rd92 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, any Rc92 and Rd92, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, —C(O)Rb10N, —C(O)NRc10NRd10N, —C(O)ORa10N, —C(═NRe10N)Rb10N, —C (═NRe10N)NRc10NRd10N, —C(═NCN)NRc10NRd10N, —C(NORa10N)NRc10N, —S(O)2Rb10N, —S(O)(═NRc10N)Rd10N, and —S(O)2NRc10NRd10N wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
each Ra10N, Rb10N, Rc10N, and Rd10N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N, Rb10N, Rc10N, and Rd10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
or, any Rc10N and Rd10N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents; each Re10N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
each R10NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa10N2, —SRa10N2, —NHORa10N2, —C(O)Rb10N2, —C(O)NRc10N2Rd10N2, —C(O)NRc10N2(ORa10N2), —C(O)ORa10N2, —OC(O)Rb10N2, OC(O)NRc10N2Rd10N2, —NRc10N2Rd10N2, —NRc10N2NRc10N2Rd10N2, —NRc10N2C(O)Rb10N2, —NRc10N2C(O)ORa10N2 and —NRc10N2C(O)NRc10N2Rd10N2 wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R10NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Ra10N2, Rb10N2, Rc10N2, and Rd10N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N2, Nb10N2, Rc10N2 and Rd10N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, any Rc10N2 and Rd10N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R11N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, —C(O)Rb11N, —C(O)NR c11NRd11N, —C(O)ORa11N, —C(═NRe11N)Rb11N, —C(═NRe11N)NRc11NRd11N, —C(═NCN)NRc11NRd11N, —C(═NORa11N)NRc11N, —S(O)2Rb11N, —S(O)(═NRc11N)Rd11N, and —S(O)2NRc11NRd11N wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 1 5-10 membered heteroaryl,4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
each RallN, Rb11N, Rc11N, and Rd11N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra11N, Rb11N, Rc11N, and Rd11N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
or, any Rc11Nand Rd11N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
each Re11N is independently selected from H, OH, CN, Cu-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
each R11NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa11N2, —SRa11N2, —NHORa11N2, —C(O)Rb11N2, —C(O)NRc11N2Rd11N, —C(O)NRc11N2(ORa11N2), —C(O)ORa11N2, —OC(O)Rb11N2, —OC(O)NRc11N2Rd11N2, —NRc11N2Rd11N2, —NRc11N2NRc11N2Rd11N2, —NRc11N2C(O)Rb11N2, —NRc11N2C(O)ORa11N2, and —NRc11N2C(O)NR c11N2Rd11N2; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R11NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Ra11N2, Rb11N2, Rc11N2 and Rd11N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra11N2, Rb11N2, Rc11N2, and Rd11N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, any Rc11N2 and Rd11N2 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each R11 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa111, —SRa111, —NHORa111, —C(O)Rb111, —C(O)NRc111Rd111) —C(O)NRc111(ORa111), —C(O)ORa111, —OC(O)Rb111, OC(O)NRc111Rd111, —NRc111Rd111, —NRc111NRc111Rd111, —NRc111C(O)Rb111, —NRc111C(O)ORa111, and —NRc111C(O)NRc111Rd111, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents;
or, alternatively, two R11 groups together form an oxo group;
each Ra11, Rb111, and Rc111, is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra111, Rb111, Rc111, and Rd111 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents;
or, any Ra11 and Rd111, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents; and
each R11A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa112, —SRa112, —NHORa112, —C(O)Rb112, —C(O)NRc112Rd112, —C(O)NRc112(ORa112), —C(O)ORa112, —OC(O)Rb112, —OC(O)NRc112Rd112, —NRc112 R d112, —NRc112, —NRc112Rd112, —NRc112C(O)Rb112, —NRc112C(O)ORa112, and —NRc112C(O)NRc112Rd112, wherein the C1-6 alkylm C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1.6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R11A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; and
each Ra112, Rb112, Rc112, and Rd112 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra112, Rb112, Rc112 and Rd112 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, any Rc112 and Rd112, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents.
37. The method of claim 36 , wherein the compound of Formula (IIu), or pharmaceutically acceptable salt thereof, is a selective inhibitor for PI3Kγ over one or more of PI3Kα, PI3Kβ, and PI3Kδ.
38. A method of treating a disease or disorder in a patient, wherein the disease or disorder is associated with abnormal expression or activity of PI3Kγ kinase, comprising administering to the patient a therapeutically effective amount of a compound of Formula (IIu):
or a pharmaceutically acceptable salt thereof, wherein:
Z is CZ1 or N;
Z1 and R12 are each independently selected from H, D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO—C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkvl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, alkyl)amino, thio, C1-3 alkylthio, alkylsulfinyl, alkylsulfonyl, carbamyl, alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, C1-4 alkoxycarbonyl, alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alklaminosulfon 1 di(C1-3 alk aminosulfon 1 aminosulfon lamino C1-3 alkylaminosulfonylamino, alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
Ri is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa1, —SRa1, —NHORa1, —C(O)Rb1, —C(O)NR c1Rd1, —C(O)NRc1(ORa1), —C(O)ORa1, —OC(O)Rb1, —OC(O)NRc1Rd1, —NRc1Rd1, —NRc1NRc1Rd1, —NRc1C(O)Rb1, —NRc1C(O)ORa1, and —NRc1C(O)NRc1Rd1, wherein the C1-6 alkyl, C2-6alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
each Ra1, Rb1, Rc1, and Rd1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra1, Rb1, Rc1 and Rd1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
or, any Rc1 and Rd1, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R1A substituents;
each R1A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa111, —SRa11, —NHORa11, —C(O)Rb11, —C(O)NRc11Rd11, —C(O)NRc11(ORa11), —C(O)ORa11, —OC(O)Rb11, —OC(O)NRc11Rd11, —NRc11Rd11, —NRc11NRc11Rd11, —NRc11C(O)Rb11, —NRc11C(O)ORa11, and —NRc11C(O)NRc11Rd11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each Ra11, Rb11, Rc11, and Rd11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-Ch6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra11, Rb11, Rc11 and Rd11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
or, any Rc11 and Rd11, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each RM is independently selected from D, OH, NO2, CN, halo, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 haloalkyl, cyano-C1-3 alkyl, HO—C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, amino, C1-3 alkylamino, di(C1-3 alkyl)amino, thio, C1-3 alkylthio, C1-3 alkylsulfinyl, C1-3 alkylsulfonyl, carbamyl, C1-3 alkylcarbamyl, di(C1-3 alkyl)carbamyl, carboxy, C1-3 alkylcarbonyl, alkoxycarbonyl, C1-3 alkylcarbonylamino, C1-3 alkoxycarbonylamino, C1-3 alkylcarbonyloxy, aminocarbonyloxy, C1-3 alkylaminocarbonyloxy, di(C1-3 alkyl)aminocarbonyloxy, C1-3 alkylsulfonylamino, aminosulfonyl, C1-3 alkylaminosulfonyl, alkyl)aminosulfonyl, aminosulfonylamino, C1-3 alkylaminosulfonylamino, alkyl)aminosulfonylamino, aminocarbonylamino, C1-3 alkylaminocarbonylamino, and di(C1-3 alkyl)aminocarbonylamino;
R2 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa2, —SRa2, —NHORa2, —C(O)Rb2, —C(O)NR c2Rd2, —C(O)NRc2(ORa2), —C(O)ORa2, —OC(O)Rb2, —OC(O)NRc2Rd2, —NRc2Rd2, —NRc2NRc2Rd2, —NRc2C(O)Rb2, —NRc2(O)ORa2, and —NRc2C(O)NRc2Rd2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra2, Rb2, Rc2 and Rd2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
or, any Rc2 and Rd2, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
each R2A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-11) cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa21, —SRa21, —NHORa21, —C(O)Rb21, —C(O)NRc21Rd21, —C(O)NRc21(ORa21), —C(O)ORa21, —OC(O)Rb21, —OC(O)NRc21Rd21, —NRc21Rd21, —NRc21NRc21Rd21, —NRc21C(O)Rb21, —NRc21C(O)ORa21, and —NRc21C(O)NRc21Rd21, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-11) aryl-C1-6 alkyl-, C3-11) cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each Ra21, Rb21, Rc21, and Rd21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra21, Rb21, Rc21 and Rd21 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
or, any Rc21 and Rd21, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
or alternatively, R1 and R2, taken together with the carbon atoms to which they are attached form a monocyclic 4-7 membered cycloalkyl ring, a phenyl ring, a monocyclic 4-7 membered heterocycloalkyl ring, or a monocyclic 5-6 membered heteroaryl ring, each of which is optionally substituted by 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R1A groups;
R6 is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-11) aryl-C1-3 6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa6, —SRa6, —NHORa6, —C(O)Rb6, —C(O)NRc6 R d6, —C(O)NRc6(ORa6), —C(O)ORa6, —OC(O)Rb6, —OC(O)NRc6Rd6, —NRc6Rd6, —NRc6NRc6Rd6, —NRc6C(O)Rb6, NRc6C(O)ORa6, —NRc6C(O)NRc6Rd6, —C(═NOH)Rb6, —C(═NCN)Rb6, —C(═NRe6)NRc6Rd6, —NRc6C(═NRe6)NRc6Rd6, —NRc6C(═NOH)Rb6, —NRc6C(═NCN)NRc6Rd6, —NRc6C(═NRe6)Rb6, —NRc6 S(O)NRc6Rd6, —NRc6S(O)2Rb6, —NRc6S(O)(═NRe6)Rb6, —NRc6S(O)2NRc6Rd6, S(O)Rb6, —S(O)NRc6Rd6, —S(O)2Rb6, —S(O)2NRc6Rd6, —S(O)(═NRe6)Rb6, —N═S(O)Ra6Rb6, —OS(O)(═OS(O)2Rb6 and —SF5, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-11) aryl-C1-6 alkyl-, C3-11) cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
each Ra6, Rb6, Rc6, Rd6, and Re6, is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra6, Rb6, Rc6, Rd6, and Re6 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
or, any Rcb and Rd6, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R6A substituents;
each R6A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa61, —NHORa61, —C(O)Rb61, C(O)NRc61Rd61, —C(O)NRc61(ORa61), —C(O)ORa61, —OC(O)Rb61, —OC(O)NRc61Rd61NRc61Rd61, —NRc61NRc61Rd61, —NRc61C(O)Rb61, —NRc61C(O)ORa61and —NRc61C(O)NRc61Rd61, alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R6A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each Ra61, Rb61, Rc61, and Rd61 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra61, Rb61, Rc61 and Rd61 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
or, any Rc61 and Rd61, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
X9 is —NR9N or —C(R9)2;
X11 is —NR11N or —C(R11)2;
R9N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, —C(O)Rb9N, —C(O)NRc9NRd9N, —C(O)ORa9N, —C(═NRe9N)Rb9N, —C(═NRe9N)NRc9NRd9N, —C(═NCN)NRc9NRd9N, —C(═NORa9N)NRc9N, S(O)2Rb9N, —S(O)(═Rc9N)Rd9N, and —S(O)2NRc9NRs9N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
each Ra9N, Rb9N, Rc9N, and Rd9N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6alkyl- of Ra9N, Rb9N, Rc9N, and Rd9N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
or, any Rc9N and Rd9N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9NA substituents;
each Re9N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl; each R9NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa9N2, —SRa9N2, —NHORa9N2 —C(O)Rb9N2, C(O)NRC9N2 Rd9N2, —C(O)NRC9N2 (ORa9N2), —C(O)ORa9N2, —OC(O)Rb9N2, —OC(O)NRc9N2Rd9N2, NRC9N2 Rd9N2, —NRC9N2NRC9N2Rd9N2, —NRC9N2C(O)Rb9N2, —NRC9N2C(O)ORa9N2, and —NRc9N2C(O)NR c9N2Rd9N2; wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R9NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Ra9N2, Rb9N2, Rc9N2, and Rd9N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra9N2, Rb9N2, Rc9N2 and Rd9N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, any Rc9N2 and Rd9N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each R9 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa91, —SRa91, —NHORa91, —C(O)Rb91, —C(O)NRc91Rd91, —C(O)NRc91(ORa91), —C(O)ORa91, and —NRc91C(O)NRc91Rd91, NRc91Rd91, —NRc91NRc91Rd91, —NRc91C(O)Rb91, —NRc91C(O)ORa91, and —NRc91C(O)NRc91Rd91, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
or, alternatively, two R9 groups together form an oxo group;
each Ra91, Rb91, Rc91, and Rd91 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-Ch6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra91, Rb91, Rc91 and Rd91 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
or, any Rc91 and Rd91, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R9A substituents;
each R9A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa92, —SRa92, —NHORa92, —C(O)Rb92, —C(O)NRc92Rd92, —C(O)NRc92(ORa92), —C(O)ORa92, —OC(O)Rb92, —OC(O)NRc92Rd92NRc92Rd92, —NRc92NRc92Rd92, —NRc92C(O)Rb92, —NRc92C(O)ORa92, and —NRc92C(O)NRc92Rd92, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R9A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Ra92, Rb92, Rc92, and Rd92 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra92, Rb92, Rc92 and Rd92 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, any Rc92 and Rd92, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R10N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, —C(O)Rb10N, —C(O)NRc10NRd10N, —C(O)ORa10N, —C(═NRe10N)Rb10N, C(═NRe10N)NRc10NRd10N, —C(═NCN)NRc10NRd10N(═NORa10N)NRc10N, —S(O)2Rb10N, S(O)(═NRc10N)Rd10N, and —S(O)2NRc10NRd10N wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
each Ra10N, Rb10N, Rc10N, and Rd10N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N, Rb10N, Rc10N, and Rd10N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
or, any Rc10N and Rd10N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R10NA substituents;
each Re10N is independently selected from H, OH, CN, C1-6 alkyl, Ci-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
each R10NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa10N2, —SRa10N2, —NHORa10N2, —C(O)Rb10N2 —C(O)NRc10N2Rd10N2, —C(O)NRc10N2(OR a10N2), —C(O)ORa10N2, —OC(O)Rb10N2, —OC(O)NRc10N2Rd10N2, —NRc10N2Rd10N2, —NRc10NRNRc10N2Rd10N2, —NRc10N2C(O)Rb10N2, —NRc10N2C(O)ORa10N2, and —NRc10N2C(O)NRc10N2Rd10N2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R10NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Ra10N2, Rb10N2, Rc10N2, and Rd10N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra10N2, Rb10N2, Rc10N2 and Rd10N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, any Rc10N2 and Rd10N2, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R11N is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, —C(O)Rb11N, —C(O)NRc11NRd11N, —C(O)ORa11N, —C(═NRe11N)Rb11N, C(═NRe11N)NRc11NRd11N, —C(═NCN)NRc11NRd11N, —C(═NORa11N)NRc11N, —S(O)2Rb11N, —S(O)(═NRc11N)Rd11N, and —S(O)2NRc11NRd11N, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl- and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
each Ra11N, Rb11N, Rc11N, and Rd11N is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra11N, Rb11N, Rc11N, and Rd11N are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
or, any Rc11N and Rd11N, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11NA substituents;
each Re11N is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
each R11NA is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa11N2, —OC(O)Rb11N2, ——C(O)NRc11N2Rd11N2, —C(O)NRc11N2(ORa11N2), —C(O)ORa11N2, —OC(O)Rb11N2, —OC(O)NRc11N2Rd11N2, —NRc11NRRd11N2, —NRc11N2NRc11N2Rd11N2, —NRc11N2C(O)Rb11N2, —NRc11N2C(O)ORa11N2, and —NRc11N2C(O)NRc11N2Rd11N2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R11NA are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Ra11N2, Rb11N2, Rc11N2 and Rd11N2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra11N2, Rb11N2, Rc11N2 and Rd11N2 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, any Rc11N2 and Rd11N2 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each R11 is independently selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa111, —SRa111, NHORa111, —C(O)Rb111, —C(O)NRc111Rd111, —C(O)NRc111(ORa111), —C(O)ORa111, —OC(O)NRc111Rd111, —NRc111Rd111, —NRc111Rd111, —NRc111C(O)Rb111, —NRc111C(O)ORa111, and —NRc111C(O)NRc111Rd111, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents;
or, alternatively, two R11 groups together form an oxo group;
each Ra111, Rb111, Rc111, and Rd111 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra111, Rb111, Rc111, and Rd111 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents;
or, any Rc111 and Rd111, attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl group or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl group or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R11A substituents; and
each R11A is selected from H, D, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, —ORa112, —SRa112, —NHORa112, —C(O)Rb112, —C(O)NRc112Rd112, —C(O)NRc112(ORa112) —C(O)ORa112, —OC(O)Rb112, —OC(O)NRc112Rb112, —NRc112Rd112, —NRc112NRc112, Rd112, —NRc112C(O)Rb112NRc112C(O)ORa112, and —NRc112C(O)NRc112Rd112, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1.6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R11A are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; and
each Ra112, Rb112, Rc112, and Rd112 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra112, Rb112, Rc112 and Rd112 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents; or, any Rc112 and Rd112, attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl group or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl group or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents.
39. The method of claim 38 , wherein the disease or disorder is an autoimmune disease or disorder, cancer, cardiovascular disease, or neurodegenerative disease.
40. The method of claim 38 , wherein the disease or disorder is lung cancer, melanoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, color cancer, endometrial cancer, bladder cancer, skin cancer, cancer of the uterus, renal cancer, gastric cancer, seminoma, teratocarcinoma, astrocytoma, neuroblastoma, glioma, or sarcoma.
41. The method of claim 40 , wherein the sarcoma is Askin's tumor, sarcoma botryoides, chondrosarcoma, Ewing's sarcoma, malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans, desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, or undifferentiated pleomorphic sarcoma.
42. The method of claim 38 , wherein the disease or disorder is acute myeloid leukemia, acute monocytic leukemia, small lymphocyctic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma, T-cell actute lymphoblasic leukemia (T-ALL), cutaneous T-cell lymphoma, large granular lymphocytic leukemia, mature (peripheral) t-cell neoplasm (PTCL), anaplastic large cell lymphoma (ALCL), or lymphoblastic lymphoma.
43. The method of claim 42 , wherein the mature (peripheral) t-cell neoplasm (PTCL) is T-cell prolymphocytic leukemia, T-cell granular lymphocytic leukemia, aggressive NK-cell leukemia, mycosis fungoides/Sezary syndrome, naplastic large cell lymphoma (T-cell type), enteropathy type T-cell lymphoma, adult T-cell leukemia/lymphoma, or angioimmunoblastic T-cell lymphoma.
44. The method of claim 42 , wherein the anaplastic large cell lymphoma (ALCL) is systemic ALCL or primary cutaneous ALCL.
45. The method of claim 38 , wherein the disease or disorder is Burkitt's lymphoma, acute myeloblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, hairy cell leukemia, Mantle cell lymphoma, small lymphocytic lymphoma, follicular lymphoma, xenoderoma pigmentosum, keratoctanthoma, lymphoplasmacytic lymphoma, extranodal marginal zone lymphoma, Waldenstrom's macroglobulinemia, prolymphocytic leukemia, acute lymphoblastic leukemia, myelofibrosis, mucosa-associated lymphatic tissue (MALT) lymphoma, mediastinal (thymic) large B-cell lymphoma, lymphomatoid granulomatosis, splenic marginal zone lymphoma, primary effusion lymphoma, intravascular large B-cell lymphoma, plasma cell leukemia, extramedullary plasmacytoma, smouldering myeloma, monoclonal gammopathy of undetermined significance (MGUS), or diffuse large B cell lymphoma.
46. The method of claim 45 , wherein the non-Hodgkin's lymphoma (NHL) is relapsed NHL, refractory NHL, recucurrent follicular NHL, indolent NHL (iNHL), or aggressive NHL (aNHL).
47. The method of claim 45 , wherein the diffuse large B cell lymphoma is activated B-cell like (ABC) diffuse large B cell lymphoma, or germinal center B cell (GCB) diffuse large B cell lymphoma.
48. The method of claim 45 , wherein the Burkitt's lymphoma is endemic Burkitt's lymphoma, sporadic Burkitt's lymphoma, or Burkitt's-like lymphoma.
49. The method of claim 38 , wherein the disease or disorder is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematous, asthma, allergy, allergic rhinitis, pancreatitis, psoriasis, anaphylaxis, glomerulonephritis, inflammatory bowel disease, thrombosis, meningitis, encephalitis, diabetic retinopathy, benign prostatic hypertrophy, myasthenia gravis, Sjogren's syndrome, osteoarthritis, restenosis, or atherosclerosis.
50. The method of claim 38 , wherein the disease or disorder is heart hypertropy, cardiac myocyte dysfunction, acute coronary syndrome, chronic obstructive pulmonary disease (COPD), chronic bronchitis, elevated blood pressure, ischemia, ischemia-reperfusion, vasoconstriction, anemia, bacterial infection, viral infection, graft rejection, kidney disease, anaphylactic shock fibrosis, skeletal muscle atrophy, skeletal muscle hypertrophy, angiogenesis, sepsis, graft-versus-host disease, allogeneic or xenogeneic transplantation, glomerulosclerosis, progressive renal fibrosis, idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, vasculitis, systemic lupus erythematosus, lupus nephritis, pemphigus, or membranous nephropathy.
51. The method of claim 50 , wherein the idiopathic thrombocytopenic purpura (ITP) is relapsed ITP or refractory ITP.
52. The method of claim 50 , wherein the vasculitis is Behcet's disease, Cogan's syndrome, giant cell arteritis, polymyalgia rheumatica (PMR), Takayasu's arteritis, Buerger's disease, central nervous system vasculitis, Kawasaki disease, polyarteritis nodosa, Churg-Strauss syndrome, mixed cryoglobulinemia vasculitis (essential or hepatitis C virus (HCV)-induced), Henoch-Schönlein purpura (HSP), hypersensitivity vasculitis, microscopic polyangiitis, Wegener's granulomatosis, or anti-neutrophil cytoplasm antibody associated (ANCA) systemic vasculitis (AASV).
53. The method of claim 38 , wherein the disease or disorder is Alzheimer's disease, central nervous system trauma, or stroke.
54. A compound selected from:
(S)-5-(6-(1H-Pyrazol-5-yl)pyridazin-4-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one;
(S)-2-(1-Cyclopropylethyl)-5-(6-(3-methyl-1H-pyrazol-5-yl)pyridazin-4-yl)-7-(methylsulfonyl)isoindolin-1-one;
(S)-2-(1-Cyclopropylethyl)-5-(6-(3-methyl-1H-pyrazol-5-yl)pyridazin-4-yl)isoindolin-1-one;
(S)-2-(1-Cyclopropylethyl)-5-(2-(5-methyl-4H-1,2,4-triazol-3-yl)pyridin-4-yl)-7-(methylsulfonyl)isoindolin-1-one;
(S)-2-(1-Cyclopropylethyl)-5-(2-(5-methyl-4H-1,2,4-triazol-3-yl)pyridin-4-yl)isoindolin-1-one;
(S)-2-(1-Cyclopropylethyl)-5-(2-(3-methyl-1H-pyrazol-5-yl)pyridin-4-yl)-7-(methylsulfonyl)isoindolin-1-one; and
(5)-5-(2-(1H-Pyrazol-5-yl)pyridin-4-yl)-2- (1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one;
or a pharmaceutically acceptable salt thereof
55. A pharmaceutical composition comprising a compound of claim 54 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
56. A method of inhibiting an activity of PI3Kγ kinase, comprising contacting the kinase with a compound of claim 54 , or a pharmaceutically acceptable salt thereof
57. The method of claim 56 , wherein the compound, or pharmaceutically acceptable salt thereof, is a selective inhibitor for PI3Kγ over one or more of PI3Kα, PI3Kβ, and PI3Kδ.
58. A method of treating a disease or disorder in a patient, wherein the disease or disorder is associated with abnormal expression or activity of PI3Kγ kinase, comprising administering to the patient a therapeutically effective amount of a compound of claim 54 , or a pharmaceutically acceptable salt thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/846,799 US20220340544A1 (en) | 2018-11-13 | 2022-06-22 | Substituted heterocyclic derivatives as pi3k inhibitors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862760479P | 2018-11-13 | 2018-11-13 | |
US16/681,267 US11396502B2 (en) | 2018-11-13 | 2019-11-12 | Substituted heterocyclic derivatives as PI3K inhibitors |
US17/846,799 US20220340544A1 (en) | 2018-11-13 | 2022-06-22 | Substituted heterocyclic derivatives as pi3k inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/681,267 Division US11396502B2 (en) | 2018-11-13 | 2019-11-12 | Substituted heterocyclic derivatives as PI3K inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220340544A1 true US20220340544A1 (en) | 2022-10-27 |
Family
ID=69160226
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/681,267 Active 2040-04-24 US11396502B2 (en) | 2018-11-13 | 2019-11-12 | Substituted heterocyclic derivatives as PI3K inhibitors |
US17/846,799 Pending US20220340544A1 (en) | 2018-11-13 | 2022-06-22 | Substituted heterocyclic derivatives as pi3k inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/681,267 Active 2040-04-24 US11396502B2 (en) | 2018-11-13 | 2019-11-12 | Substituted heterocyclic derivatives as PI3K inhibitors |
Country Status (2)
Country | Link |
---|---|
US (2) | US11396502B2 (en) |
WO (1) | WO2020102216A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12006320B2 (en) | 2021-06-24 | 2024-06-11 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020102150A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
WO2023165551A1 (en) * | 2022-03-02 | 2023-09-07 | 上海海雁医药科技有限公司 | Six-membered aromatic ring-pyrrolidone derivative, and pharmaceutical composition thereof and use thereof |
WO2024104441A1 (en) * | 2022-11-17 | 2024-05-23 | Insilico Medicine Ip Limited | Salt-inducible kinases (sik) inhibitors and methods of uses thereof |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
JP4516690B2 (en) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | Isoquinoline derivatives having angiogenesis inhibitory activity |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
PT1294358E (en) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | MOORING PROCESS BY HUMIDITY |
EP1436291B1 (en) | 2001-09-19 | 2009-01-14 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
CN1582150B (en) | 2001-10-30 | 2011-09-07 | 诺瓦提斯公司 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
CL2003002353A1 (en) | 2002-11-15 | 2005-02-04 | Vertex Pharma | COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
AR045944A1 (en) | 2003-09-24 | 2005-11-16 | Novartis Ag | ISOQUINOLINE DERIVATIVES 1.4-DISPOSED |
WO2005047280A1 (en) | 2003-11-10 | 2005-05-26 | Merck Sharp & Dohme Limited | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
EP1758892B1 (en) | 2004-06-10 | 2012-10-17 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
WO2006038041A1 (en) | 2004-10-08 | 2006-04-13 | Merck Sharp & Dohme Limited | Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
EP1919895A2 (en) | 2005-08-02 | 2008-05-14 | Lexicon Pharmaceuticals, Inc. | 2-aminoaryl pyridines as protein kinases inhibitors |
WO2007021309A1 (en) | 2005-08-12 | 2007-02-22 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
JP2009515882A (en) | 2005-11-10 | 2009-04-16 | シェーリング コーポレイション | Methods for inhibiting protein kinases |
TW200804281A (en) | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
WO2008047831A1 (en) | 2006-10-17 | 2008-04-24 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
WO2008130853A1 (en) | 2007-04-17 | 2008-10-30 | Astrazeneca Ab | Hydrazides and their use as metabotropic glutamate receptor potentiators - 681 |
TWI417100B (en) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842 |
TW200911255A (en) | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
WO2009100130A1 (en) | 2008-02-04 | 2009-08-13 | Mercury Therapeutics, Inc. | Ampk modulators |
US7790760B2 (en) | 2008-06-06 | 2010-09-07 | Astrazeneca Ab | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 |
UY32049A (en) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | CMET INHIBITORS |
FR2946140B1 (en) | 2009-05-29 | 2011-12-09 | Ixsea | BRAGG NETWORK FIBER HYDROPHONE WITH MEMBRANE AMPLIFIER |
WO2010148074A1 (en) | 2009-06-19 | 2010-12-23 | Astrazeneca Pharmaceuticals | The use of metabotropic glutamate receptor potentiators for reducing nicotine dependence |
NZ597050A (en) | 2009-06-29 | 2014-02-28 | Incyte Corp | Pyrimidinones as pi3k inhibitors |
ES2759751T3 (en) | 2009-07-14 | 2020-05-12 | Nerviano Medical Sciences Srl | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
US8680108B2 (en) | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
MX350761B (en) | 2009-12-22 | 2017-09-18 | Vertex Pharma | Isoindolinone inhibitors of phosphatidylinositol 3-kinase. |
JP2013516402A (en) | 2009-12-31 | 2013-05-13 | ピラマル エンタープライジーズ リミテッド | Diacylglycerol acyltransferase inhibitors |
AU2011203993A1 (en) | 2010-01-07 | 2012-08-02 | Astrazeneca Ab | Process for making a metabotropic glutamate receptor positive allosteric modulator - 874 |
US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
MX2012013130A (en) | 2010-05-13 | 2013-04-11 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors. |
US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
BR122019020716B1 (en) | 2011-09-02 | 2021-02-17 | Incyte Holdings Corporation | heterocyclylamines as pi3k inhibitors and pharmaceutical composition comprising them |
US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
AU2013305475B2 (en) | 2012-08-21 | 2017-10-12 | Peter Maccallum Cancer Institute | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof |
CN103804358B (en) | 2012-11-14 | 2016-06-29 | 上海医药集团股份有限公司 | One class Diarylhydantoin derivant, its preparation method, pharmaceutical composition and application |
WO2014154760A1 (en) | 2013-03-27 | 2014-10-02 | Boehringer Ingelheim International Gmbh | Indolinone analogues as brd4 inhibitors |
WO2016012930A1 (en) | 2014-07-22 | 2016-01-28 | Viiv Healthcare Uk Limited | Isoindolinone derivatives useful as antiviral agents |
US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
WO2016168633A1 (en) * | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
BR112017023038A2 (en) | 2015-04-29 | 2018-07-03 | Janssen Pharmaceutica Nv | imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators |
GB201517263D0 (en) | 2015-09-30 | 2015-11-11 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
US20170145002A1 (en) | 2015-11-25 | 2017-05-25 | Astrazeneca Ab | Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators |
EP3426652B1 (en) | 2016-03-10 | 2021-12-01 | Astrazeneca AB | Novel inhibitors of phosphatidylinositol 3-kinase gamma |
WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
JOP20190052A1 (en) | 2016-09-22 | 2019-03-21 | Astrazeneca Ab | 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma |
CN107417738A (en) | 2017-08-30 | 2017-12-01 | 烟台显华光电材料研究院有限公司 | One kind is used as transient metal complex, its preparation method and the application of phosphor material |
WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
WO2020102150A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
-
2019
- 2019-11-12 WO PCT/US2019/060955 patent/WO2020102216A1/en active Application Filing
- 2019-11-12 US US16/681,267 patent/US11396502B2/en active Active
-
2022
- 2022-06-22 US US17/846,799 patent/US20220340544A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12006320B2 (en) | 2021-06-24 | 2024-06-11 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
Also Published As
Publication number | Publication date |
---|---|
WO2020102216A1 (en) | 2020-05-22 |
US11396502B2 (en) | 2022-07-26 |
US20200148667A1 (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10975088B2 (en) | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | |
US11926616B2 (en) | Aminopyrazine diol compounds as PI3K-γ inhibitors | |
US11396502B2 (en) | Substituted heterocyclic derivatives as PI3K inhibitors | |
US11926630B2 (en) | Tertiary alcohols as PI3K-γ inhibitors | |
US11161838B2 (en) | Heterocyclic derivatives as PI3K inhibitors | |
US11046658B2 (en) | Aminopyrazine derivatives as PI3K-γ inhibitors | |
US11306079B2 (en) | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors | |
US11078204B2 (en) | Heterocyclic derivatives as PI3K inhibitors | |
US12006320B2 (en) | Heterocyclic derivatives as PI3K inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: INCYTE CORPORATION, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHEPARD, STACEY;COMBS, ANDREW P.;SIGNING DATES FROM 20200929 TO 20201104;REEL/FRAME:062644/0519 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |